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ABSTRACT
The polyhydroxylated alkaloids are natural heterocycles that contain one or more basic
nitrogen atoms and several hydroxy substituents. The hyacinthacine alkaloids are
polyhydroxylated 3-hydroxylmethylpyrrolizidines which were named after the plant
family, Hyacinthaceae, or bluebell family from which they were isolated. Since the
structure of first hyacinthacine alkaloid was published in 1999, nineteen hyacinthacines
have been reported, these are hyacinthacines A1-A7, B1-B7, C1-C5, two hyacinthacine
A1 derivatives and one hyacinthacine A2 derivative. The hyacinthacine alkaloids show
weak to moderate activity against glycosidases. Up to the end of 2013, twelve different
hyacinthacine alkaloids, A1, A2, A3, A6, A7, B1, B2, B3, B7, C1, C3 and C5, have been
synthesized. These syntheses confirmed the structures of seven of these alkaloids but
showed that the original structures assigned to hyacinthacines B7, C3 and C5 were
incorrect.

The main aims of this PhD project were to synthesize 5-epi-hyacinthacine B5 and to
compare its NMR spectroscopic data with those of natural hyacinthacine B7 and to
synthesize hyacinthacine B5 to confirm its structure and absolute configuration.
The total syntheses of 5-epi-hyacinthacine B5 and hyacinthacine B5 were designed to
start with commercially available (S)-4-penten-2-ol. In Chapter 2, the preparation of the
1,2-anti amino alcohol 155 using the Petasis boronic acid Mannich reaction is
described using a modification of the previous synthetic method that was developed in
our group. The new synthetic route, involving the Sharpless ADH of the terminal
alkene 151, followed by the regioselective oxidation of the resulting diol 190, and then
the Petasis boronic acid Mannich reaction gave 155 in 72% yield over 3 steps. This was
a significant improvement over the previous method that proceeded in 24% overall
yield over 3 steps.

The base induced E2-elimination-SN2-cyclization of the N-Boc mesylate 176, that was
designed to be employed to invert the configuration of the pro-C7 centre, worked
efficiently in a model study. Unfortunately, the steric hindrance caused by the -methyl
group of 155 prevented its N-Boc protection. Consequently our synthetic route was

xxi

changed to follow our previous work on the total synthesis of hyacinthacine B3 with the
aim of inverting the stereochemistry at the pro-C7 centre after the pyrrolizidine ring
was formed.

The total synthesis of 5-epi-hyacinthacine B5 was accomplished in 15 steps and in
5.58% overall yield form commercially available (S)-4-pentan-2-ol. The 1H and

13

C

NMR data of 5-epi-hyacinthacine B5 were markedly different to those of natural
hyacinthacine B7. In addition, the specific rotation of the natural product ([ ] D - 4.4,
c 0.20, H2O) and synthetic compound ([] 25
D + 18.5, c 0.14, H2O) were different in
magnitude and opposite in sign. This synthesis confirmed that the structure and
absolute configuration of natural hyacinthacine B7 did not match with that of 5-epihyacinthacine B5.
The total synthesis of hyacinthacine B5 is described in Chapter 3 starting with the
bicyclic oxazolidinone intermediate 160 used in the total synthesis of 5-epihyacinthacine B5. This synthesis was accomplished in 14 steps and in 2.21% overall
yield form commercially available (S)-4-pentan-2-ol. This total synthesis also
produced, hyacinthacine B4 in 15 synthetic steps and in 1.11% overall yield, and
7a-epi-hyacinthacine B3 in 14 synthetic steps and in 2.03% overall yield, as side
products. The 1H and 13C NMR chemical shifts of these compounds were in very close
agreement with those of natural hyacinthacines B5 and B4, respectively as well as the
specific rotation results. These comparisons indicated that the proposed structures and
absolute configurations of hyacinthacine B5 and B4, that were published, were the
correct ones.

A study of the relationship between the configurations of the methyl group at C5 and
the hydroxy group at C7 on the 13C NMR chemical shifts of natural hyachithacine B3,
natural hyachithacine B5, synthetic 5-epi-hyacinthacine B5, synthetic hyacinthacine B7
and natural hyacinthacine B7 was made. This comparison showed that the configuration
at C5 affected the 13C NMR chemical shifts of C3, C5 and C9. While the configuration
at C7 affected the 13C NMR chemical shifts of C7 and C7a. Using this information we
suggested that natural hyacinthacine B7 should have an -methyl group at C5 and an
-hydroxy group at C7, similar to that of natural hyacinthacine B5. We concluded that

xxii

natural hyacinthacine B7 is most likely to be hyacinthacine B5, however without access
to the authentic samples we cannot make an unequivocal conclusion.

In Chapter 4, an attempted synthesis of hyacinthacine B4, starting from 3,5-di-Obenzyl-,-L-xylofuranose, is described. Due to time constraints only the first four
steps of this synthesis were achieved.

xxiii
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Chapter 1
Introduction
This thesis reports on the total synthesis of 5-epi-hyacinthacine B5 and hyacinthacine B5
and our progress towards the synthesis of hyacinthacine B4. Before a more detailed
discussion of the aims of this project, it seems appropriate to first briefly review
glycosidases, the polyhydroxylated alkaloids, the structure and biological activities of
the hyacinthacine alkaloids and their total synthesis.

1.1 Glycosidases

Glycosidases, that are commonly found in biological systems, are involved in a wide
range of important biological processes, such as the intestinal digestion of
carbohydrates, the post-translational processing of glycoproteins and the lysosomal
catabolism of glycoconjugates.1 Glycosidases are also involved in the biosynthesis of
oligosaccharide chains and quality control mechanisms in the endoplasmic reticulum of
N-linked glycoproteins.2 Compounds that show inhibitory activities against these
enzymes should effect; (i) quality control machanisms; (ii) maturation, transport, and
secretion of glycoproteins; and (iii) cell-cell and cell-virus recognition processes.2

1.2 The polyhydroxylated alkaloids

The polyhydroxylated alkaloids are natural heterocycles that contain one or more basic
nitrogen atoms and several hydroxy substituents. Based on their different ring
structures, they can be classified as polyhydroxylated pyrrolidines, piperidines,
pyrrolizidines, indolizidines and nortropanes (Figure 1.1).3 The polyhydroxylated
alkaloids are also known as iminosugars or aza-sugar because their structures are
related to those of sugars.3
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Figure 1.1 Examples of polyhydroxylated alkaloids

The polyhydroxylated alkaloids show potent activity against glycosidases and thus
have a wide range of potential utility as antiviral (HIV-1, herpes simplex virus, bovine
viral diarrhea virus [BVDV] and hepatitis C virus [HCV]), anticancer, antitumor,
antidiabetic and antiobesity drugs and also in the treatment of lysosomal storage
disorders (Gaucher’s and Niemann-Pick type C disease). They can also act as immune
modulators.3,4 1-Deoxynojirimycin (DNJ, Figure 1.2) is one of the first examples of the
development of a drug from a natural polyhydroxylated alkaloid. DNJ is a derivative of
the first isolated natural iminosugar, nojirimycin (Figure 1.2), which was isolated from
Streptomyces in 1966. It showed potent activity against - and -glucosidases from
various sources.5 Because of its instability, its derivative DNJ was prepared by removal
of the anomeric hydroxyl group by a reduction reaction.6 Ten years later it was
discovered that DNJ was also a naturally occurring polyhydroxylated alkaloid. It was
isolated from the roots of mulberry trees (Morus spp.)7,8 and many strains of the genera
Bacillus and Streptomyces.9-11 DNJ was found to be a strong inhibitor of digestive
α-glycosidases in vitro, however it showed only moderate activity against
α-glycosidases in vivo.12-14 Medicinal chemists tried to develop derivatives of DNJ to
use as an antidiabetic drug. Their research found that N-hydroxylethyl-DNJ (Migitol)
(Figure 1.2) had potent activity and was successfully developed as an antidiabetic
drug.12,13 Migitol was employed to reduce the rate of carbohydrate digestion and also to
control the rate of glucose absorption after meals and thus prevent hyperglycemia.3
Migitol was the first iminosugar drug to reach the market with the commercial name of
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Glyset which was used for the oral treatment of non-insulin-dependent diabetes
mellitus (NIDDM, type 2 diabetes).3 Glyset was introduced onto the market in 1999
and was later found to have an adverse gastrointestinal effect in some patients.2,3

Figure 1.2 Nojirimycin, 1-deoxynojirimycin (DNJ) and DNJ derivatives

N-Butyl-1-deoxynojirimycin or N-butyl-DNJ (Zavesca) (Figure 1.2) was developed by
Oxford University and Oxford Glycoscience for use in the treatment of type I
Gaucher’s disease, Niemann-Pick type C disease and lysosomal storage disorders.3,15
N-Butyl-DNJ was shown to be a specific inhibitor of the glucosyltransferase-catalyzed
biosynthesis of glucosylceramide16,17 without effecting the maturation of N-linked
oligosaccharides or lysosomal glucocerebrosidase.2 Oxford Glycoscience did not
provide sufficient support for the safety efficacy of Zavesca which impacted on its
clinical development.2,18 Moreover, N-butyl-DNJ also showed potent activity against
HIV-1 infectivity by blocking the development of viral glycoside trimming.3 In phase II
clinical trials, this compound showed an inhibitory effect towards HIV-1 but also had
the side-effect of a high prevalence for gastrointestinal tract complications.15

Swainsonine (Figure 1.3) is an example of an indolizidine polyhydroxylated alkaloid
which has potent activity against glycosidases. It was isolated from both plants and
microorganisms and showed potent activities against -mannosidases, including
-mannosidase II in the N-glycan biosynthetic pathway.3,19 Moreover, swainsonine also
showed other useful biological activities including anti-tumor activity, cancer cell
metastasis inhibition, decreasing the toxicity of chemotherapeutic drugs and
immunomodulation.3 This compound however, showed adverse side effects due to its
inhibition of lysosomal mannosidase.19,20
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Figure 1.3 Swainsonine

It was found that the number, position and the configuration of the hydroxy groups of
these polyhydroxylated alkaloids were the main features for their specific activity
against glycosidases.19 Moreover, the conformation and the electrostatic properties of
these molecules is an important factor for glycosidase inhibition.19 Their mechanism of
action is thought to involve their competitive binding to the active site of the
glycosidase. The protonation of these compounds at physiological pH leads them to
form an ion pair to the carboxylated anion in the active site of the enzyme.21 Moreover,
their protonated structures mimic that of the oxonium ion intermediate that is generated
at the active site of the glycosidase during the processing of polysaccharides and
glycoprotein resulting in highly potent and specific inhibitors.8,19,22 For example, the
two possible half-chair conformers, galacto-form B and manno-form C, of 2,5-dideoxy2,5-imino-D-altritol A show similarity to the galactose oxonium ion D and mannose
oxonium ion E, respectively (Figure 1.4). These conformers can be used to explain why
2,5-dideoxy-2,5-imino-D-altritol

is

a

potent

galactrosyltransferase and -mannosidase.23

inhibitor

against

both

-1,4-
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Figure 1.4 Mechanism of glycosidase inhibition

1.3 The hyacinthacine alkaloids

The hyacinthacine alkaloids are polyhydroxylated 3-hydroxymethylpyrrolizidines
which were named from the plant family, Hyacinthaceae or bluebell family, from
which they were isolated. They have been classified as hyacinthacines A, B and C
based on the number of hydroxy and hydroxymethyl substituents on the B ring (Figure
1.5).24 Since the structure of the first hyacinthacine alkaloid was published in 1999,
nineteen hyacinthacines have been reported (Figures 1.6-1.9), these are hyacinthacines
A1-A7 (1-7) (Figure 1.6), B1-B7 (8-14) (Figure 1.7), C1-C5 (15-19) (Figure 1.8), three
hyacinthacine A1 derivatives (20-22) and one of hyacinthacine A2 derivative (23)
(Figure 1.9). The structures and relative configurations of these new alkaloids were
determined by NMR spectroscopic analysis. Their relative configurations were
determined by NOESY experiments and from the analysis of their 1H NMR vicinal
coupling constants. There is no single crystal X-ray structure reported for these natural
products.

Chapter 1 | 6

Hyacinthacine
A
B
C

Number of hydroxy (-OH) and hydroxymethyl
(-CH2OH) groups on the B-ring
0
1
2

Figure 1.5 Classification of hyacinthacine alkaloids according to the number of
hydroxy and hydroxymethyl groups

Figure 1.6 Hyacinthacine alkaloids of type A
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Figure 1.7 Hyacinthacine alkaloids of type B

Figure 1.8 Hyacinthacine alkaloids of type C (Note: hyacinthacines C1 and C4 were
assigned the same structures)
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Figure 1.9 The derivatives of hyacinthacine alkaloids of type A

1.3.1

Isolation and biological activities

In 1999, Asano and co-workers published the isolation and structures of hyacinthacines
B1 8 and B2 9 from the immature fruits and stalks of Hyacinthoides non-scripta (Figure
1.10), while hyacinthacine C1 15 was isolated from the bulbs of Scilla campanulata
(Hyacinthaceae) (Figure 1.11).24 Hyacinthacines B1 and B2 showed weak inhibitory
activity against almond β-glucosidase with IC50 values of 320 and 100 M, respectively
and bovine liver β-galactosidase with IC50 values of 110 and 160 M, respectively.
Hyacinthacine B2 was much more potent against β-galactosidase (from rat intestinal
lactase) (IC50 = 3.6 μM) than hyacinthacine B1 (IC50 = 270 μM). Hyacinthacine C1
showed weak inhibitory activity against amyloglucosidase (from A. niger) with an IC50
value of 84 μM.
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Figure 1.10 Hyacinthoides non-scripta 25

Figure 1.11 Scilla campanulata 26

In 2000, Asano and co-workers published the structures of four new hyacinthacine
alkaloids, A1 1, A2 2, A3 3 and B3 4, which were isolated from the fresh bulbs of
Muscari armeniacum (Hyacinthaceae) (Figure 1.12).27 These alkaloids showed
moderate active against amyloglucosidase (from Aspergillus niger) with IC50 values of
25, 8.6, 17 and 51 μM, respectively. Hyacinthacine A3 had a weaker activity against
β-galactosidase (from rat intestinal lactase) (IC50 = 160 μM) than hyacinthacine A2
(IC50 = 73 μM), possibly because of the effect of the extra -methyl group at C5. While
the -hydroxy group at C1 of hyacinthacine A1 was possibly responsible for the better
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activity of this compound against the same enzyme, with an IC50 value of 4.4 μM.
Morover, hyacinthacine A1 showed moderate activity against rat epidermis
-L-fucosidase with an IC50 value of 46 μM and showed weak activity against rice
-glucosidase (IC50 = 240 μM), almond -glucosidase (IC50 = 250 μM) and rat
epididymis -manosidase (IC50 = 390 μM). In addition, hyacinthacine A2 showed weak
activity against almond -glucosidase (IC50 = 150 μM) and porcine kidney trehalase
(IC50 = 260 μM).

Figure 1.12 Muscari armeniacum 28

In 2002, Asano and co-workers published the structures of seven new hyacinthacine
alkaloids which were named as hyacinthacines A4 4, A5 5, A6 6, A7 7, B4 11, B5 12 and
B6 13.29 These new hyacinthacines were isolated from the bulbs of Scilla sibirica
(Figure 1.13). Hyacinthacines A5, B4 and B5 showed moderate activity against
amyloglucosidase with IC50 values of 110, 89 and 110 μM, respectively. Hyacinthacine
B4 also showed moderate inhibitory activity against bovine epididymis -L-fucosidase
with an IC50 value of 23 μM. The other hyacinthacines showed no significant activity
against the other tested enzymes.
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Figure 1.13 Scilla sibirica 30

In 2004, Asano and co-workers published the structures of three C5 butyl substituted
hyacinthacine alkaloids, α-5-C-(3-hydroxybutyl)-hyacinthacine A1 20, α-5-C-(1,3dihydroxybutyl)-hyacinthacine A1 21 and α-5-C-(1,3,4-trihydroxybutyl)-hyacinthacine
A1 22, which were isolated from the bulbs of Scilla peruviana (Figure 1.14).31
α-5-C-(1,3-Dihydroxybutyl)-hyacinthacine A1 showed potent activity against yeast
α-glucosidase and bacterial β-glucosidase (Caldocellum saccharolyticum) with IC50
values of 3.6 and 5.1 μM, respectively. α-5-C-(1,3,4-Trihydroxybutyl)-hyacinthacine
A1 also showed good activity against bacterial β-glucosidase (from Caldocellum
saccharolyticum) and human placenta β-glucosidase with IC50 values of 11.4 and
25.4 μM, respectively. α-5-C-(3-Hydroxybutyl)-hyacinthacine A1 showed moderate
activity against almond β-glucosidase with an IC50 value of 49 μM.
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Figure 1.14 Scilla peruviana 32

In 2007, Kato and co-workers published the structures of five new hyacinthacine
alkaloids, B7 14, C2 16, C3 17, C4 18 and C5 19, and one C5 butyl substituted
hyacinthacine alkaloid, A2 (-5-C-(3-hydoxybutyl)-hyacinthacine A2 23), which were
isolated from the bulbs of Scilla socialis (Figure 1.15).33 Hyacinthacines C2, C3 and C5
showed moderate activity against bacterial β-glucosidase (from C. saccharolyticum)
with IC50 values of 13, 25 and 48 μM, respectively. Moreover hyacinthacine C2 showed
moderate inhibition (IC50 = 17 μM) against human placenta α-L-fucosidase, while
hyacinthacine C3 showed moderate activity (IC50 = 52 μM) against bovine liver
β-galactosidase. Hyacinthacines C4 and C5 were moderate inhibitors of -glucosidase
(from rat intestinal maltase) with IC50 values of 45 and 77 μM, respectively and
amyloglucosidase (from Aspergillus niger) with IC50 values of 57 and 57 μM,
respectively. Hyacinthacine B7 and α-5-C-(3-hydroxybutyl)-hyacinthacine A2 showed
weak inhibition against amyloglucosidase (from Aspergillus niger) with IC50 values of
270 and 180 μM, respectively.
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Figure 1.15 Scilla socialis34

Noteworthy was that the structure proposed for hyacinthacine C1 1524 by Asano in 1999
was the same as that proposed for hyacinthacine C4 1833, which was reported by the
same research group in 2007 (Figure 1.8), even though both natural products showed
significant differences in their 1H and

13

C NMR spectroscopic data (Tables 1.1 and

1.2). The 13C NMR spectrum of hyacinthacine C1 showed signals for C6, C7 and C9 at

 77.1, 75.7 and 12.8, respectively while those of hyacinthacine C4 resonated at
 82.9, 80.0 and 16.0, respectively. Moreover, the 1H NMR signals for H5 and H7 of
hyacinthacine C1 resonated much further downfield ( 3.29 (1H, dt, J = 7.0, 3.9 Hz) and

 4.50 (1H, dd, J = 8.6, 4.6 Hz), respectively) than those of hyacinthacine C4 ( 2.96
(1H, dq, J = 9.2, 6.9 Hz) and  4.15 (1H, t, J = 8.2 Hz), respectively). These data
indicated that either one of these structures is incorrect or that hyacinthacine C 1 may
have been isolated as its salt (protonated) form.
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Table 1.1 A comparison of the

13

C NMR chemical shifts of natural hyacinthacine C1

1524 (100 MHz, D2O) and those of natural hyacinthacine C4 1833 (125 MHz, D2O)
Carbon
1
2
3
5
6
7
7a
8
9

Natural hyacinthacine C1 1524
C (ppm)
74.6
77.7
64.7
60.4
77.1
75.7
68.3
65.9
12.8

Natural hyacinthacine C4 1833
C (ppm)
75.2
77.3
65.1
62.0
82.9
80.0
67.3
66.4
16.0

Table 1.2 A comparison of the 1H NMR chemical shifts (500 MHz, D2O) of natural
hyacinthacine C1 15 24 (400 MHz, D2O) and those of hyacinthacine C4 1833 (500 MHz,
D2O)
Proton
1
2
3
5
6
7
7a
8
8′
9

1.3.2

Natural hyacinthacine C1 1524
H (ppm)
Mult., J (Hz)
4.15
t (3.9)
4.00
dd (9.0, 3.9)
3.44
dt (9.0, 4.4)
3.29
dt (7.0, 3.9)
3.89
dd (4.6, 3.9)
4.50
dd (8.6, 4.6)
3.66
dd (8.6, 3.9)
3.67
m
3.67
m
1.27
d (7.0)

Natural hyacinthacine C4 1833
H (ppm)
Mult., J (Hz)
4.18
t (4.0)
4.00
dd (8.7, 4.0)
3.38
dt (8.7, 4.6)
2.96
dq (9.2, 6.9)
3.90
dd (9.2, 8.2)
4.15
t (8.2)
3.57
dd (8.2, 3.7)
3.65
d (4.6)
3.65
d (4.6)
1.29
d (6.9)

Total syntheses of the hyacinthacine alkaloids

Because there is no single crystal X-ray structures of these alkaloids to confirm their
relative or absolute configurations, many research groups have tried to confirm their
structures by the way of total synthesis. Moreover, a number of unnaturally occurring
epimers of the hyacinthacine alkaloids have also been prepared to study their biological
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activities against glycosidases for structure-activity studies. The synthesis of the
hyacinthacine alkaloids can be classified into three different types based on the type of
the starting material, which are (1) from ‘chiral pool’ precursors (sugars and sugar
derivatives, amino acids and tartaric acid); (2) using a chiral auxiliary; and (3) using
catalytic asymmetric synthesis or enzymatic resolution and then diastereoselective
synthesis. These syntheses have been recently reviewed35 and therefore only a few
examples of each type will be discussed here.

1.3.2.1 Synthesis from ‘chiral pool’ precursors

Sugars and sugars derivatives, amino acids and their derivatives and tartaric acid have
been extensively used as “chiral-pool” precursors for the synthesis of several
hyacinthacine alkaloids.

From sugars and sugar derivatives

Sugar derivatives have been most commonly used as starting materials for the synthesis
of the hyacinthacine alkaloids. For example, in 2001 Martin and co-workers reported
the total synthesis of hyacinthacine A2 2 starting with commercially available 2,3,5-triO-benzyl-D-arabinofuranose 24 (Scheme 1.1).36 The highly diastereoselective reaction
of divinylzinc with 24 afforded the heptendiol 25. The regeoselective esterification of
25 provided a 3.5:1 mixture of 26a and 26b which was treated under Swern oxidation
reaction conditions to give the ketone 27. At this stage the major product was readily
separated from the minor diastereomer. The one-pot reductive amination of the ketone
27 followed by an intermolecular nucleophilic displacement of the secondary amine to
the allylic benzoate ester provided a mixture of 28a and 28b in a ratio of 3:1. The ringclosing metathesis of the HCl salts of 28a and 28b upon treatment with Grubbs’ first
generation ruthenium (Grubbs’ I) catalyst, followed by a chromatographic separation
then gave the pyrrolizidine 29. The catalytic hydrogenation and hydrogenolysis of the
tribenzyl ether 29 over Pd/C afforded hyacinthacine A2 2. This total synthesis was
accomplished in six synthetic steps and in 11% overall yield.
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Scheme 1.1 The first total synthesis of hyacinthacine A2 2 by Martin et al. 36

From Amino Acid Derivatives

An example of the total synthesis of a hyacinthacine alkaloid starting with an amino
acid derivative is the one reported by Yoda and co-workers in 2008 (Scheme 1.2).37
The synthesis started with the N-Boc lactam 30 which was prepared from (S)-(-)-2pyrrolidone-5-carboxylic acid ((S)-(-)-pyroglutanic acid) in 10 steps and in 30% overall
yield. The chain-lengthening Grignard reaction of 30 provided the hemiaminal product
31a which was in equilibrium with the chain-opened ketone product 31b. This mixture
was reduced using sodium borohydride to afford a diastereomeric mixture of 32a and
32b in a ratio of 95:5. Mesylation of this mixture, followed by a base promoted
cyclization reaction gave a separable mixture of the pyrrolidines 33a and 33b. The
N-protecting group of 33a was then changed from N-Boc to N-Cbz to give 34.
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Sharpless ADH reactions of the terminal alkene of 34, using AD-mix- or AD-mixafforded the diol 35 (dr = 71:29) or the diol 37 (dr = 80:20), respectively. The
regioselective protection of the primary hydroxy group of the diol 35 with TBSCl and
then, mesylation, followed by N-deprotection and concomitant cyclization provided a
separable diastereomeric mixture of 36 and 38. Deprotection of all protecting groups by
treatment of compound 36 with TBAF and then TFA gave hyacinthacine B1 8. In a
similar fashion hyacinthacine B2 9 was synthesized from the intermediate 37. From
these synthetic routes, the total syntheses of hyacinthacine B1 8 and B2 9 were
accomplished from (S)-(-)-pyroglutamic acid in 24 synthetic steps with overall yields of
21% and 22%, respectively.
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Scheme 1.2 The total synthesis of (+)-hyacinthacine B1 8 and B2 9 by Yoda et al. 37
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From Tartaric acid

Tartaric acid contains two stereogenic centres which can be incorporated into the
structure of the hyacinthacine alkaloids by synthesis. In 2008, Chandrasekhar and
co-workers reported the synthesis of hyacinthacine A1 1 using the (+)-diethyl tartrate
derivative 39 as the starting material (Scheme 1.3).38 Compound 39 was prepared from
(+)-diethyl tartrate in three synthetic steps in 57% overall yield. This synthesis started
with the IBX oxidation of the alcohol 39 to the aldehyde followed by a chainlengthening Wittig reaction by treatment with Ph3P=CHCO2Et to provide the
,-unsaturated ester 40. This ester was reduced with DIBAL-H to give the alcohol 41
which was treated under the Sharpless asymmetric epoxidation reaction conditions to
afford the epoxide 42. The IBX oxidation reaction followed by a chain-lengthening
Wittig reaction by treatment with Ph3P=CHCO2Et gave the ,-unsaturated ,-epoxy
ester 43. The ring-opening-azidation reaction of 43 by treatment with trimethylsilyl
azide (TMSN3) and Pd(0) gave the intermediate A which upon intramolecular attack by
azide provided the syn-azido alcohol 44. The secondary alcohol of 44 was then
protected to form compound 45. Acetonide deprotection of 45 by treatment with
pyridinium p-toluenesulfonate (PPTS)/MeOH provided the diol 46. The selective
protection of the primary alcohol of 46 as the TBS ether followed by mesylation of the
secondary alcohol gave the mesylate 47. The azide group of 47 was then reduced under
a H2 atmosphere over Pd/C. Upon treatment with K2CO3 an intramolecular SN2
substitution-lactamization process took place to give the pyrrolizidone 48. The global
hydrolysis of 48 by treatment with p-toluenesulfonic acid (PTSA)/MeOH gave the
bicyclic lactam 49 which was reduced with lithium aluminium hydride (LAH) to afford
hyacinthacine A1 1. This total synthesis was accomplished in a total of 18 synthetic
steps in 6% overall yield.
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Scheme 1.3 The total synthesis of hyacinthacine A1 1 by Chandrasekhar et al. 38
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1.3.2.2 Using a chiral auxiliary

Delair and co-workers published the synthesis of (+)-hyacinthacine A1 1 from the
lactam 51 which was prepared from the chiral auxiliary (S)-(-)-stericol® 50 in six
synthetic steps and in 57% overall yield (Scheme 1.4).39 A diastereoselective [2+2]
dichloroketene-chiral enol ether cycloaddition of the chiral enol A with Cl3CCOCl to
give the dichlorobutanone intermediate B (dr > 93:7) was a key step in the synthesis of
51.40,41 N-Boc protection of 51 provided the carbamate 52 which was reduced using
super hydride® (lithium triethylborohydride) and then treated with PTSA/MeOH to
afford the hemiaminal 53. A copper(I) salt-catalyzed Grignard reaction of 53 afforded a
mixture of the diastereomeric products 54a and 54b in a ratio of 6:1, respectively. This
mixture was treated under hydroboration reaction conditions, which was followed by
oxidation of the resulting primary alcohol to the carboxylic acid and then methylation
with diazomethane to give a mixture of the esters 55a and 55b (dr = 6:1). N-Boc
deprotection of this mixture using TMSOTf followed by heating in toluene allowed for
the isolation of the desired cyclized product 56, via N-Boc deprotected 55a. An adverse
steric interaction between the ester side chain and the surrogate hydroxymethyl group
of 55b was thought to be the main factor that obstructed the cyclization of this
diastereomer. The chiral auxiliary of 56 was removed by treatment with trifluoroacetic
acid to provide the alcohol 57 which was then converted to its xanthate derivative
followed by pyrrolysis to give the alkene 58. The cis-dihydroxylation of alkene 58
provided the diol 59. A Tamao-Fleming oxidation of 59 gave the alcohol 60 which was
reduced by treatment with boranedimethylsulfide complex to provide hyacinthacine A1
1. The total synthesis was accomplished in 20 synthetic steps in 6.5% overall yield.
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Scheme 1.4 The total synthesis of (+)-hyacinthacine A1 1 by Delair et al. 39

1.3.2.3 Synthesis from non-chiral precursors

Using diastereoselective synthesis

In 2007, Donohoe and co-workers reported that synthesis of (±)-hyacinthacine A1 1
from achiral dimethyl N-Boc-2,5-pyrroledicarboxylate (Scheme 1.5).42 The Birch
reduction

of

this

compound

gave

the

2,5-dihydropyrrole

61

with

good

diastereoselectivity; the ratio of the trans and cis products was 6:1. The
cis-dihydroxylation reaction of 61 provided the diol 62 which was protected as the
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acetal 63. The selective reduction of the least hindered ester of 63, by treatment with
sodium borohydride, followed by TBS protection of the resulting primary alcohol
provided the silyl ether 64. Reduction of 64 by treatment with DIBAL-H gave the
aldehyde 65 which was treated with Ph3P=CHCO2Me to afford the ,-unsaturated
ester 66. Hydrogenation of the alkene group of 66 provided the ester 67 which was
reduced by treatment with DIBAL-H to provide the alcohol 68. Mesylation of 68
followed by N-Boc deprotection using TESOTf and 2,6-lutidine gave the pyrrolizidine
70. The global deprotection of 70 under acidic conditions then afforded
(±)-hyacinthacine A1 1 in 14 synthetic steps and 31% overall yield.

Scheme 1.5 The synthesis of (±)-hyacinthacine A1 1 by Donohoe et al.42
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Using enzymatic resolution and then diastereoselective synthesis

Blechert and co-workers reported the synthesis of hyacinthacine A2 2 starting from the
(S)-allylamine 72 (Scheme 1.6).43 This compound was prepared from (±)-N-Cbzvinylglycine 71 by enzymatic resolution using subtilisin (Carlsberg), in 34% overall
yield in three synthetic steps.44 The olefin-cross metathesis of compound 72 with the
alkene 73 using Grubbs’ second generation ruthenium catalyst (Grubbs’ II) provided
the ,-unsaturated ketone 74. ADH of 74 using AD-mix- gave the diol 75 in 67%
yield as a single diastereomer. The Cbz deprotection of 75, under a H2 atmosphere over
Pd/C, followed by a diastereoselective intramolecular reductive alkylation provided the
pyrrolizidine 78, as its hydrochloride salt via the 2,5-trans-pyrrolidine intermediate 76.
Under the acidic conditions the O-TBS group was also removed. Neutralization of 78
using basic ion-exchange chromatography provided hyacinthacine A2 2 in eight
synthetic steps from (±)-N-Cbz-vinylglycine 71 in 12% overall yield.

Scheme 1.6 The synthesis of hyacinthacine A2 2 by Blechert et al.43
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In 2007, Donohoe and co-workers reported the synthesis of hyacinthacine A1 1 which
started with N-Boc pyrrole (Scheme 1.7).45 Lithiation and then acylation of this
compound with ClCO2Me gave the corresponding 2,5-dimethyloxycarbonyl compound.
A Birch-type reduction of this diester provided the 2,5-dihydropyrrole 79. Reduction of
the diester groups of 79 to their corresponding primary alcohols and then an enzymatic
desymmetrization of 79 using lipase gave the monoacetate 80. The cis-dihydroxylation
of 80 followed by ketal protection of the resulting cis-diol afforded the ketal 81. The
free hydroxyl group of 81 was protected as its methoxyisopropyl acetal (MIP)
derivative, and then hydrolysis of the acetate group gave the alcohol 82. Mesylation of
this alcohol followed by an elimination reaction using DBU provided the enamine 83.
The stereoselective hydroboration-oxidation of 83 from the less hindered alkene face
afforded the alcohol 84 (> 20:1 dr). This was oxidized to the aldehyde 85 which was
then treated with Ph3P=CHCO2Me to give the ,-unsaturated ester 86. The catalytic
hydrogenation of 86 followed by reduction of the resulting saturated ester gave the
alcohol 87. Mesylation of the alcohol 87 followed by N-Boc deprotection with ZnBr2
gave a pyrrolizidine which upon an aqueous work up gave hyacinthacine A1 1 in 8.3%
overall yield and in 16 synthetic steps.
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Scheme 1.7 The synthesis of (+)-hyacinthacine A1 1 by Donohoe et al.45

Moreover there are many other publications reporting the synthesis of the
hyacinthacine alkaloids and their stereoisomers. These have been reviewed by Pyne
and co-workers in 2012.35 These syntheses, along with those reported in 2013, are
presented in Table 1.3. Table 1.3 includes the starting material, the product, the number
of synthetic steps and the overall yields. Most of the syntheses use starting materials
from the “chiral pool”.
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Table 1.3 The synthesis of the hyacinthacine alkaloids and their stereoisomers
Published
year

Overall
steps

% Overall
yield

2001

6

11.5

46

2001

6

7.8

46

2001

4

32.6

Izquierdo et al.

47

2002

5

70.0

48

2003

5

18.7

49

2003

4

14.8

50

2004

7

51.8

50

2004

7

27.1

2005

5

33.9

Author

Martin et al.

36

Izquierdo et al.

Izquierdo et al.

Goti et al.

Izquierdo et al.

Izquierdo et al.

Izquierdo et al.

Py et al.

51

Starting
material

Product
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Table 1.3 The synthesis of the hyacinthacine alkaloids and their stereoisomers
(Continued)
Published
year

Author

Starting
material

Product

Overall
steps

% Overall
yield

52

2005

12

12.5-14.7

52

2005

12

16.1-19.0

53

2006

5

35.3

53

2006

7

21.3

43

2006

6

19.1

54

2007

8

4.2

Izquierdo et al.

54

2007

8

6.2

55

2007

2

80

55

2007

2

20

Renaud et al.

Renaud et al.

Izquierdo et al.

Izquierdo et al.

Blechert et al.

Izquierdo et al.

Clapés et al.

Clapés et al.
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Table 1.3 The synthesis of the hyacinthacine alkaloids and their stereoisomers
(Continued)
Published
year

Overall
steps

% Overall
yield

2007

2

55

42

2007

12

40.5

45

2008

16

8.3

45

2008

18

5.2

45

2008

18

5.4

2008

15

10.7

2008

6

21.1

39

2008

20

6.5

37

2008

12

70.5

Author

Clapés et al.

55

Donohoe et al.

Donohoe et al.

Donohoe et al.

Donohoe et al.

Chandrasekhar
38
et al.

Cao et al.

56

Delair et al.

Yoda et al.

Starting
material

Product
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Table 1.3 The synthesis of the hyacinthacine alkaloids and their stereoisomers
(Continued)
Published
year

Overall
steps

% Overall
yield

2008

12

73.5

2009

10

17.8

58

2009

16

7.0

58

2009

16

6.5

58

2009

16

2.1

58

2009

16

1.8

59

2009

8

37.4

59

2009

4

25.0

59

2009

4

20.6

Author

37

Yoda et al.

Laschat et al.

57

Yoda et al.

Yoda et al.

Yoda et al.

Yoda et al.

Marcro et al.

Marcro et al.

Marcro et al.

Starting
material

Product
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Table 1.3 The synthesis of the hyacinthacine alkaloids and their stereoisomers
(Continued)
Published
year

Author

Overall
steps

% Overall
yield

2010

12

5.6

60

2010

12

3.4

61

2010

10

27.8

61

2010

7

16.4

61

2010

7

8.1

2010

5

67.7

63

2010

9

70.6

63

2010

5

67.4

2010

7

3.9

Pyne et al.

Izquierdo et al.

Izquierdo et al.

Izquierdo et al.

Merino et al.

Yu et al.

Product

60

Pyne et al.

Yu et al.

Starting
material

62

Tamayo et al.

64
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Table 1.3 The synthesis of the hyacinthacine alkaloids and their stereoisomers
(Continued)
Published
year

Overall
steps

% Overall
yield

2010

7

4.7

65

2010

7

15.9

65

2010

10

16.0

66

2011

9

13.3

67

2011

6

28.3

68

2011

7

14.2

68

2011

7

10.1

69

2011

6

51.1

69

2011

8

19.0

Author

Tamayo et al.

Huang et al.

Huang et al.

Davies et al.

Zheng et al.

Franco et al.

Franco et al.

Yu et al.

Yu et al.

64

Starting
material

Product

Chapter 1 | 33

Table 1.3 The synthesis of the hyacinthacine alkaloids and their stereoisomers
(Continued)
Published
year

Overall
steps

% Overall
yield

2011

8

19.2

2011

12

11.3

71

2011

4

36.9

71

2011

5

26.5

71

2011

6

18.6

71

2011

6

8.8

2012

5

32.4

2013

5

21.8

2013

7

3.2

Author

Yu et al.

69

Fišera et al.

Goti et al.

Goti et al.

Goti et al.

Goti et al.

70

Huang et al.

Goti et al.

72

73

Davies et al.

74

Starting
material

Product
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Table 1.3 The synthesis of the hyacinthacine alkaloids and their stereoisomers
(Continued)
Published
year

Author

Davies et al.

Davies et al.

Starting
material

Product

Overall
steps

% Overall
yield

74

2013

6

18.3

74

2013

14

4.9

75

2013

5

48.6

75

2013

6

22.5

Ferjancic et al.

Ferjancic et al.

Up to the end of 2013, twelve different hyacinthacine alkaloids, A1 1, A2 2, A3 3, A6 6,
A7 7, B1 8, B2 9, B3 10, B7 14, C1 15, C3 17 and C5 19, had been synthesized. These
syntheses showed that the original structures assigned to hyacinthacines B7 1460, C3
1758 and C5 1968 were incorrect.
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1.3.3

Hyacinthacine alkaloid synthesis from our group

Pyne and co-workers published the first total synthesis of hyacinthacine B3 10 and the
proposed structure of hyacinthacine B7 14 in 2010.60
The structural elucidation of hyacinthacine B3 1027 and hyacinthacine B7 1433 was based
on an interpretation of their 1H and

13

C NMR spectroscopic data (Tables 1.4 and 1.5)

which were analysed using gHMQC, gCOSY and gHMBC experiments. The NMR
spectra of both compounds showed a single methyl, two methylene and six methine
carbon atoms. Moreover high resolution mass spectrometry indicated that
hyacinthacine B3 10 had the same molecular formula as hyacinthacine B7 14, which
was C9H17NO4. Hyacinthacine B7 14 was proposed to be the C5 epimer of
hyacinthacine B3 10. A summary of the 1H and 13C NMR spectroscopic data of 10 and
14 is shown in Tables 1.4 and 1.5.27,33 The structural elucidation of compound 10
showed the same connectivity of all atoms as compound 14. NOESY correlations
(Figure 1.16) and coupling constant analysis were used for identify the relative
configuration of all stereogenic centres. The observed 1D NOESY signal enhancement
of H1 and H2 in the 1H NMR spectrum of hyacinthacine B3 10 upon irradiation of H7a
indicated that H1, H2 and 7a were located on the same face of the pyrrolizidine ring.27
The strong NOESY correlations between H3 and H7 and H9 indicated that H3, H7 and
methyl group at C5 were located on the same face of the ring but on the opposite face
to H1, H2 and H7a. Hyacinthacine B7 14 showed NOESY correlations between H7a
and H1 and between H7a and H2 which indicated that these three protons were located
on the same face of the pyrrolizidine ring.33 This result was also confirmed by the
coupling pattern of H1 (J7a,1 = J1,2 = 4.4 Hz) and H2 (J1,2 = 4.4 Hz, J2,3 = 7.6 Hz). The
relatively large coupling constant between H2 and H3 and between H7 and H7a of
7.6 Hz indicated the pseudo-trans-axial positions of these protons. Moreover, the
observed NOESY signals between the H2 and H8 and also between H9 and H8 showed
that both ring substituents (CH2OH and CH3) were on the same face of the
pyrrolizidine ring. No NOESY information was provided however, to support the
assigned configuration at C7.
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Table 1.4 A comparison of the 13C NMR spectroscopic data (125 MHz, D2O) of
hyacinthacine B3 1027 and those of hyacinthacine B7 1433
Carbon
1
2
3
5
6
7
7a
8
9

hyacinthacine B3 1027
C (ppm)
72.2
77.4
63.8
57.1
44.4
71.5
77.0
65.0
17.5

hyacinthacine B7 1433
C (ppm)
77.9
74.9
66.2
57.7
45.2
76.5
69.9
66.8
18.4

Table 1.5 A comparision of the 1H NMR spectroscopic data (500 MHz, D2O) of
hyacinthacine B3 1027 and those of hyacinthacine B7 1433

Proton
1
2
3
5
6
6
7
7a
8
8′
9

hyacinthacine B3 1027

H
4.13
4.03
2.81
3.02
2.38
2.81
4.60
3.32
3.70
3.74
1.17

Mult., J (Hz)
t (4.0)
dd (9.1, 4.0)
dd (9.1, 4.9)
m
ddd (12.2, 7.0, 5.0)
dd (9.1, 4.9)
ddd (9.2, 7.0, 5.8)
dd (5.8, 4.0)
dd (11.7, 4.9)
dd (11.7, 4.9)
d (6.3)

hyacinthacine B7 1433

H
4.35
3.97
3.29
3.22
1.68
2.16
4.50
3.45
3.57
3.63
1.25

Mult., J (Hz)
t (4.4)
dd (7.6, 4.4)
ddd (7.6, 5.5, 3.5)
m
m
m
m
dd (7.6, 4.4)
dd (11.5, 3.5)
dd (11.5, 5.5)
d (7.0)
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9

7a
7

7a

1
2

6
5

7

3
8

1

8

5

2

3

6

9

Hyacinthacine B3 10

Hyacinthacine B7 14

Figure 1.16 NOESY correlations of hyacinthacine B3 10 and hyacinthacine B7 14 taken
from references 27 and 33, respectively

1.3.3.1 The total synthesis of the hyacinthacine B3 1060
The total synthesis of hyacinthacine B3 10 used commercially available (S)-4-penten-2ol 118 as the starting material (Scheme 1.8).60 The total synthesis started with the
protection of the free alcohol to give the O-PMB ether 151 in 90% yield. The olefincross metathesis between alkene 151 and phenyl vinyl sulfone using Grubbs’ II
ruthenium catalyst under microwave heating conditions at 90 oC afforded the (E)-vinyl
sulfone 152 (68% yield) which was then treated under modified Sharpless ADH
conditions with K2OsO4-DHQD-IND to give the -hydroxy aldehyde 153 which most
likely existed as its dimeric hemi-acetal form since no RCHO signal was observed in
the 1H NMR spectrum. Without purification the ADH product 153 was directly treated
under Petasis boronic acid Manich reaction conditions by treatment with the allyl
amine 154 and -styrenyl boronic acid to provide the 1,2-anti amino alcohol 155 in
53% yield over the two steps. The 1,2-anti amino alcohol 155 was then reacted with
triphosgene to protect both the free hydroxy and amino groups as the oxazolidinone
derivative 156 in good yield (81%). The ring-closing metathesis reaction of diene 156
by using Grubbs’ II ruthenium catalyst with microwave heating at 90 oC provided the
bicyclic alkene 157 in good yield (76%). The syn-dihydroxylation of 157 was carried
out with a catalytic amount of Os(VIII)-catalyst and a stoichiometric amount of
4-methylmorpholine N-oxide (NMO) as co-oxidant to give the 6,7-diol 158 (88%
yield) which was protected as the tribenzyl ether 159 (100% yield). O-PMB
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deprotection of 159 by treatment with DDQ gave the free alcohol 160 (89% yield).
Basic hydrolysis of the oxazolidinone of 160 under microwave heating (110 oC)
provided the amino diol 161 in excellent yield (84%). The amino diol 161 was then
treated with 1.0 molar equivalent of methanesulfonyl chloride and triethylamine where
selective mesylation of the hydroxy group occurred followed by a nucleophilic
substitution cyclization by the pyrrolizidine amino group to generate the pyrrolizidine
derivative 162 (63% yield). After a hydrogenolysis reaction of compound 162 over
PdCl2/H2 the three benzyl protecting groups were removed to give hyacinthacine B3 as
the hydrochloride salt. Neutralization of this salt using basic ion-exchange
chromatography then gave hyacinthacine B3 10 (68% yield). The total synthesis of
compound 10 was accomplished in 12 steps and in 5.6% overall yield.60
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Scheme 1.8 Total synthesis of the proposed structure of hyacinthacine B3 10 by Pyne
et al.60

The 1H and

13

C NMR spectroscopic data of synthetic 10 were compared to those of

natural hyacinthacine B3.60 The 1H and

13

C NMR chemical shifts of synthetic 10 and

hyacinthacine B3 were in very close agreement. The specific rotation of synthetic 10
([] 23
D + 10.8, c 0.33, H2O) was of larger magnitude but of the same sign to that of the
natural product ([] D + 3.3, c 0.31, H2O).60 These comparisons indicated that the
proposed structure and absolute configuration of hyacinthacine B3 10, which was
published by Asano co-workers in 2000, was correct.60
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1.3.3.2 The total synthesis of the proposed structure of hyacinthacine B7 1460
The total synthesis of the proposed structure of hyacinthacine B7 14 followed the same
synthetic strategy of the total synthesis of hyacinthacine B3 10, except that
commercially available (R)-4-penten-2-ol 119 used as the starting material (Scheme
1.9).60 The total synthesis of compound 14 was accomplished in 12 steps and in 3.4%
overall yield.

Scheme 1.9 Total synthesis of the proposed structure of hyacinthacine B7 14 by Pyne
et al.60
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For the structural verification of synthetic hyacinthacine B7 14, 2D NMR techniques
strongly confirmed that it was the correct structure, especially NOESY correlations
which were used for identify the relative configuration of all stereogenic centres, as
shown in Figure 1.17. Importantly, there was an observed NOESY correlation between
H5 and H7 of synthetic hyacinthacine B7 14 but this correlation was not reported in the
original publication that reported the structure of natural hyacinthacine B7.60

Figure 1.17 The NOESY correlations of synthetic hyacinthacine B7 14, shown on the
HF/6-31G* optimized structure (SPARTAN)60

A comparison of the 1H and 13C NMR spectroscopic data of synthetic hyacinthacine B7
14 with those of natural hyacinthacine B7 are shown in Tables 1.6 and 1.7. Clearly the
1

H and 13C NMR spectroscopic data of these compounds did not match which indicated

that the proposed structure of natural hyacinthacine B7 was incorrect.60
Table 1.6 A comparison of the

13

C NMR chemical shifts (125 MHz, D2O) of natural

hyacinthacine B733 and those of synthetic 1460
Carbon
1
2
3
5
6
7
7a
8
9

Natural hyacinthacine B733
C (ppm)
77.9
74.9
66.2
57.7
45.2
76.5
69.9
66.8
18.4

Synthetic 1460
C (ppm)
73.6
78.1
71.8
65.2
46.2
71.3
75.4
65.6
22.5

C
-4.3
+3.2
+5.6
+7.5
+1.0
-5.2
+5.5
-1.2
+4.1
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Table 1.7 A comparison of 1H NMR chemical shifts (500 MHz, D2O) of natural
hyacinthacine B733 and those of synthetic 1460
Proton
1
2
3
5
6
6
7
7a
8
8′
9

Natural hyacinthacine B733
H (ppm)
Mult., J (Hz)
4.35
t (4.4)
3.97
dd (7.6, 4.4)
3.29
ddd (7.6, 5.5, 3.5)
3.22
m
1.68
m
2.16
m
4.50
m
3.45
dd (7.6, 4.4)
3.57
dd (11.5, 3.5)
3.63
dd (11.5, 5.5)
1.25
d (7.0)

Synthetic 1460
H (ppm)
Mult., J (Hz)
4.13
t (3.9)
4.03
dd (9.0, 3.9)
2.81
ddd (9.1, 4.9, 4.9)
3.01
m
1.60
m
2.38
m
4.61
m
3.32
dd (5.9, 3.8)
3.70
dd (11.5, 4.9)
3.74
dd (11.5, 4.9)
1.17
d (6.4)

Based on the lack of a NOESY correlation between H5 and H7 in natural hyacinthacine
B7 we proposed that the correct structure of the natural product was that of 7-epihyacinthacine B7 or 5-epi-hyacinthacine B5 174 (Figure 1.18). Thus the synthesis of
5-epi-hyacinthacine B5 174 become the first synthetic target of this project. The second
synthetic target was hyacinthacine B5 12, the C5 epimer of 174. The structure of this
compound has not been confirmed by total synthesis.

Figure 1.18 The stereochemical relationships between 5-epi-hyacinthacine B5 174
(or 7-epi-hyacinthacine B7), synthetic hyacinthacine B7 14 and hyacinthacine B5 12
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1.4 Aims of this project

The main aims of this PhD project were:
1. To synthesize 5-epi-hyacinthacine B5 174 and to compare its NMR
spectroscopic data with those of hyacinthacine B7.
2. To synthesize hyacinthacine B4 11 and B5 12 to confirm their structures and
absolute configurations.

The plan was to prepare the above mentioned target alkaloids from a common starting
material, (S)-4-penten-2-ol 118 (Schemes 1.10) via the anti-1,2 amino alcohol 155
(Scheme 1.10). The synthesis of 174 requires inversion of the configuration at C4 of
155 and the overall retention of configuration at C6 of 155. While the synthesis of 12
requires inversion of the configurations at C4 and C6 of 155 (Scheme 1.10).

Scheme 1.10 Synthetic plan for the synthesis of 5-epi-hyacinthacine B5 174 and
hyacinthacine B5 12
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Chapter 2
The total synthesis of 5-epi-hyacinthacine B5
2.1 A synthetic analysis of 5-epi-hyacinthacine B5 174
The synthetic plan for the total synthesis of 5-epi-hyacinthacine B5 174, starting from
the commercially available (S)-alcohol 118, is shown in Figure 2.1. This synthesis was
designed to also enable the synthesis of hyacinthacine B5 12 by inversion of the
configuration at the pro-C5 stereocentre before formation of the B ring (Chapter 3).
The C7 hydroxy and C7a amino moiety of 174 will be obtained using the Petasis
boronic acid Mannich reaction that has been developed by our group to obtain 1,2-anti
amino alcohols.76 Inversion of the configuration at C7 will then give the desired
(S)-configuration. The (S)-configuration at C5 of 5-epi-hyacinthacine B5 174 should
originate from (S)-4-penten-2-ol, the stereochemistry at this centre will be inverted
twice for the synthesis of 5-epi-hyacinthacine B5 174. The syn diol at C1 and C2 should
be formed by a syn-dihydroxylation reaction of the corresponding cyclic alkene, which
could be prepared from a ring-closing metathesis reaction of a diene.

Figure 2.1 Synthetic analysis of 5-epi-hyacinthacine B5 174
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2.2 Our first synthetic plan for the total synthesis of 5-epi-hyacinthacine B5 174
The total synthesis of 5-epi-hyacinthacine B5 174 was designed to start with
commercially available (S)-4-penten-2-ol 118 which will be protected as the O-PMB
ether 151 (Scheme 2.1). The olefin cross-metathesis of alkene 151 with phenyl vinyl
sulfone will give the sulfone 152 which will be treated under Sharpless ADH reaction
conditions to generate an -hydroxyl aldehyde or its cyclic hemiacetal form 153.60 The
three component Petasis boronic acid Mannich reaction of the hemiacetal intermediate
153, -styrenyl boronic acid and the allyl amine 154 would provide the known 1,2-anti
amino alcohol 155. In order to invert the stereocentre at C4 (pro-C7) and to protect the
1,2-amono alcohol moiety in 155, which may retard or inhibit the subsequent RCM
reaction by coordinate to the Ru catalyst, the amino group of 155 was to be N-Boc
protected as compound 175. It was anticipated that O-mesylation of 175, and then an
intramolecular cyclization reaction would provide the oxazolidinone 177 that would
serve as a protecting group and allow inversion at the carbinol (C4) centre.77 A ringclosing metathesis reaction of the diene 177 should then provide the bicyclic alkene
178.

Scheme 2.1 Synthetic plan for the total synthesis of 5-epi-hyacinthacine B5 174
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The syn-dihydroxylation of the alkene 178 should then provide the syn diol 179
(Scheme 2.2). The free hydroxy groups of 179 will then be protected as their benzyl
ethers (180). PMB deprotection of compound 180 will give the alcohol 181.
Stereoinversion at pro-C5 would be achieved using the Mitsunobu reaction to provide
the p-nitrobenzoate 182. Base hydrolysis of the p-nitrobenzoate group and the
oxazolidinone ring of 182 will give the amino diol 183. The B-ring of 174 will be
realized via a one pot O-mesylation-cyclization of 183 to give the pyrrolizidine 184.
For the mesylation, the stoichiometry of the methanesulfonyl chloride will be
controlled to allow for the selective mesylation of only the desired hydroxy group.
Finally, the benzyl ether groups of 184 will be cleaved by hydrogenolysis to provide
the final product, 5-epi-hyacithacine B5 174. The NMR spectroscopic data of this
compound will then be compared with those reported for natural hyacinthacine B7.

Scheme 2.2 Synthetic plan for the total synthesis of 5-epi-hyacinthacine B5 174
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2.2.1 Preparation of the allyl amine 154
The preparation of the allyl amine 154 followed the method of Trost and coworkers.78
The synthesis started with the highly regeoselective-nucleophilic substitution of
butadiene monoepoxide 185 with phthalimide using -allylpalladium chloride dimer as
the pre-catalyst and (1R, 2R)-(+)-NAPHTHYL (Trost’s ligand) as a chiral ligand to
give the product 186 in high yield (97%) (Scheme 2.3). The specific rotation of
o
synthetic 186, [] 25
(c 0.92, CH2Cl2) was in close agreement with the literature
D -71.7
o
78
value ([] 28
D -72.2 , c 2.02, CH2Cl2) for material that had an ee of 96%.

Scheme 2.3 The asymmetric synthesis of 186

Trost et al. published a proposed mechanism for the nucleophilic substitution of
racemic allyl systems (A + ent-A) to give enantiomerically enriched products (E and F)
as shown in Scheme 2.4.78 Palladium(0) reacts with the allyl substrates A and ent-A
from the alkene face anti to the leaving group X to give the enantiomeric allyl
palladium complexes, B and D, respectively. These complexes are interconverted via
the -complex C. By employing the Trost chiral ligand, (R,R)-ligand or (S,S)-ligand,
the complexes B and D become diastereomeric and their nucleophilic substitution
reactions are made highly regeoselective in favour of the terminal alkene products.
Further they are made highly enantioselective with the (R,R)-chiral ligand giving the
enantiomeric product E, while the (S,S)-chiral ligand gives the enantiomer F.

Chapter 2 | 48

Scheme 2.4 Asymmetric induction with monosubstituted allyl systems

In the synthesis of 186, the -allyl Pd complex G acts as a base to deprotonate the pronucleophile phthalimide to deliver the nucleophile regeoselective to the allyl system
(Scheme 2.5).78 This regioselectivity is assisted by H-bonding and then deprotonation
by the alkoxy group in G.

Scheme 2.5 Asymmetric induction with monosubstituted allyl systems

The free hydroxy group of compound 186 was protected as the benzyl ether 187 by
treatment with benzyl bromine in the presence of sodium hydride (NaH) and
tetrabutylammonium iodide (TBAI) to give benzyl ether 187 in 80% yield (Scheme
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2.6). The specific rotation of 187 ([] 25
D - 8.2

o

agreement with that of the literature ([] 28
D - 9.0

(c 2.31, CH2Cl2).78 Cleavage of the

o

(c 1.05, CH2Cl2)) was in close

phthalimide of compound 187 with ethylenediamine in refluxing ethanol provided the
allyl amine 154 in 99% yield. The 1H and 13C NMR spectroscopic data of 154 matched
o
well with those reported.79 The specific rotation of 154 ([] 25
(c 0.46, CHCl3))
D - 21.2

was of the same sign but of higher magnitude to that reported previously ([] D - 16.5 o
(c 1.2, CHCl3).79 This difference in specific rotation might be due to differences in
temperature. The literature did not mention the actual temperature that the measurement
was made.

Scheme 2.6 The synthesis of allyl amine 154

2.2.2 The synthesis of vinyl sulfone 152 via olefin cross-metathesis

The synthesis of vinyl sulfone 152 started with commercially available (S)-4-penten-2ol 118 which was protected as the O-PMB ether 151 by treatment with
p-methoxybenzyl chloride (PMBCl) in the presence of NaH and TBAI to give the
O-PMB ether 151 in 91% yield (Scheme 2.7).60 An olefin cross-metathesis reaction of
the alkene 151 and phenyl vinyl sulfone using Grubbs’ II ruthenium catalyst under
refluxing CH2Cl2 gave the vinyl sulfone 152 in 65% yield.60 The structure of 152 was
confirmed from a comparison of its 1H and 13C NMR spectroscopic data with those in
the literature. The protons H4 and H5 showed a large coupling constant (J4,5 = 14.7 Hz)
which indicated that the trans alkene had formed.60
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Scheme 2.7 The synthesis of the vinyl sulfone 152 via an olefin cross-metathesis
reaction

2.2.3 The synthesis of the 1,2-anti amino alcohol 155

A Sharpless ADH reaction of the vinyl sulfone 152 was undertaken using potassium
osmate as the oxidizing agent, DHQD-IND as the chiral ligand and potassium ferric
cyanide as the co-oxidant, under basic conditions in the presence of potassium
carbonate (Scheme 2.8).60 This reaction was done under two phase conditions between
water and tert-butanol with the use of methanesulfonamide as a phase-transfer catalyst.
The expected product was an -hydroxy aldehyde which most likely existed as its
dimeric form 153 since no RCHO signal was observed in the 1H NMR spectrum which
also indicated a mixture of products. Without purification, compound 153 was treated
with the allyl amine 154 and -styrenyl boronic acid in hexafluoroisopropanol/CH2Cl2
(1:9) at rt for two days. This two step sequence resulted in quite a low yield of the
desired 1,2-anti amino alcohol 155 (37% for the two steps).60 The NMR spectroscopic
data of 155 matched closely with those which were published in 2010.60
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Scheme 2.8 The synthesis of the 1,2-anti amino alcohol 155 via the ADH reaction of
the vinyl sulfone 152

2.2.4 Asymmetric dihydroxylation reaction of the vinyl sulfone 152 using
DHQD2PHAL as chiral ligand
In order to enhance the overall yields of 155 the asymmetric dihydroxylation reaction
of the vinyl sulfone 152 was repeated by changing the chiral ligand from DHQD-IND
to DHQD2PHAL by using commercially available AD-mix  (Scheme 2.9). Monitoring
the reaction by TLC analysis showed only unreacted starting material after three days.
It was suggested that the steric hindrance of protecting group in 152 might be
responsible for the poor reactivity with this larger chiral ligand. Thus the analogous
acetate protected substrate 189, with a relatively smaller protecting group, was prepared
as shown in Scheme 2.10.

Scheme 2.9 The attempted ADH reaction of the vinyl sulfone 152
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2.2.5 Attempted asymmetric dihydroxylation reaction of the vinyl sulfone when
using a relatively smaller protecting group
The acetate 18880 was prepared by treating racemic 4-penten-2-ol (±)-118 with acetic
anhydride in the presence of triethylamine and 4-N,N-dimethylaminopyridine (DMAP)
in CH2Cl2 at rt to provide the protected product 188 in 31% yield (unoptimized)
(Scheme 2.10). The olefin cross-metathesis of alkene 188 with phenyl vinyl sulfone
using Grubbs’ II ruthenium catalyst under refluxing CH2Cl2 gave the vinyl sulfone 189
in 38% yield (unoptimized). The coupling constant, J4,5, between H4 and H5, was 15.0
Hz which showed that 189 was the trans alkene product. The vinyl sulfone 189 was
treated under Sharpless ADH conditions using DHQD-IND as the chiral ligand but no
reaction occurred (Scheme 2.10). The lack of reactivity of 189 compared to 152
(Scheme 2.8) under identical ADH reaction conditions might be due to the electron
withdrawing nature of the acetate group in 189 which makes the alkene even more
electron deficient and thus unreactive.

Scheme 2.10 The attempted ADH reaction of the vinyl sulfone 189

Because of the poor efficiency of the above reactions a second synthetic plan for the
synthesis 5-epi-hyacinthacine B5 174 (Scheme 2.11) was developed to improve the
yield of the 1,2-anti amino alcohol 155.
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2.3 The second synthetic plan for the synthesis of 5-epi-hyacinthacine B5 174
The second synthetic plan (Scheme 2.11) started with the Shapless ADH reaction of the
alkene 151 to give the diol 190 which upon selective oxidation of the primary alcohol
should give the hemiacetal intermediate 153.81,82 All other synthetic steps after the
Petasis reaction would remain the same as that shown earlier in Schemes 2.1 and 2.2.

Scheme 2.11 The second synthetic plan for the synthesis of 5-epi-hyacinthacine B5 174

2.3.1 The Sharpless asymmetric dihydroxylation reaction of terminal alkenes

Sharpless and co-workers published an improved method for the ADH of terminal
olefins.81 Their study compared the enantioselectivity of the two resulting diols (R and
S configuration) from several terminal alkenes upon treatment with two different chiral
ligands, (DHQD)2PYR and (DHQD)2PHAL (Table 2.1). The linear terminal alkene
1-decene (entry 1), showed little difference in enantioselectivity for the diol products
when using either (DHQD)2PYR (89% ee) or (DHQD)2PHAL (84% ee) as the chiral
ligand. The (DHQD)2PYR chiral ligand however, showed significantly higher
enantioselectivities for the diol products than (DHQD)2PHAL for terminal alkenes with
two or more allylic alkyl substituents (Table 2.1, entries 2 - 6). For example, the ADH
reactions of 3,3-dimethylbutene with (DHQD)2PYR gave the resulting diol in 92% ee
while with (DHQD)2PHAL the ee was only 64%. In contrast, the (DHQD)2PYR ligand
showed lower enantioselectivities for styrenes (Table 2.1, entries 6 and 7).
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Figure 2.2 Structure of the chiral ligands (DHQD)2PHAL, DHQD-IND and
(DHQD)2PYR83
Table 2.1 A comparison of the enantioselectivities of the resulting diols in the ADH
reaction using (DHQD)2PYR or (DHQD)2PHAL as the chiral ligand81

Entry

Olefin

% ee and configuration of the
resulting diol
(DHQD)2PYR (DHQD)2PHAL

1

89, R

84, R

2

92, R

64, R

3

93, R

80, R

4

96, R

88, R

5

94, R

87, R

6

80, R

97, R

7

69, R

94, R

*This ADH reactions were run with 1.0 mol% of O SO4, 1.0 mol% of ligand and stirred at
0 oC. The enantiomeric excesses were determined by HPLC or GLC analysis of the diol or
MTPA esters
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The Sharpless ADH reactions of the alkene 151 were examined at room temperature
and 3 oC using AD-mix  with stirring for two days (Scheme 2.12 and Table 2.2). The
reactions, using (DHQD)2PHAL as the chiral ligand, showed no diastereoselectivity for
the diol 190 over the diol 2-epi-190. Moreover, the reaction that was run at 3 oC
showed nearly twice the yield than the one performed at rt with yields of 24% and 15%,
respectively. The diastereomeric diols 190 and 2-epi-190 were quite difficult to
separate. These reactions were repeated using the chiral ligands DHQD-IND and
(DHQD2PYR).60,81 These

ligands

showed

significant

improvement

in

diol

diastereoselectivity (Table 2.2). The chiral ligand (DHQD)2PYR gave the diols with a
dr of 4:1 while the dr was 3:1 with the chiral ligand DHQD-IND. Both ligands resulted
in improved yields of around 60%. Excitingly, when the ratio of tert-butanol/water was
changed from 1:1 to 1:2 the overall yield was increased from 61% to 99 %.

Scheme 2.12 The general conditions for Sharpless ADH reation of the teminal alkene
151

Table 2.2 The Sharpless ADH reaction of the teminal alkene 151 from the reactions
using 1.2 mol% K2OsO4.H2O, 1 mol% chiral ligand, potassium ferricyanide (3.0 mol),
methanesulfonamide (1.0 mol) and potassium carbonate (3.0 mol) with stirring for two
days (Scheme 2.12)
Chiral ligand

Diastereomeric Ratio

t-BuOH:H2O

emp

Yield*

(DHQD)2PHAL

1:1

rt (25 oC)

15%

1:1

(DHQD)2PHAL

1:1

3 oC

24%

1:1

DHQD-IND

1:1

3 oC

65%

3:1

(DHQD)2PYR

1:1

3 oC

61%

4:1

(DHQD)2PYR

1:2

3 oC

99%

4:1

(1 mol%)

*Combined yield of of 190 and 2-epi-190

(190:2-epi-190)
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The diastereoselectivities of these reactions were determined by 1H NMR spectroscopy
by integration of one diastereotopic benzylic proton of the O-PMB protecting group for
each diastereomeric diol. These protons showed as resolved doublets at 4.54 (J = 11.2
Hz) and 4.59 (J = 11.2 Hz) for 190 and 2-epi-190, respectively (Figure 2.3).

190

2-epi-190

Figure 2.3 1H NMR spectrum (500 MHz, CDCl3) of a 4:1 mixture of diols 190 and
2-epi-190 from the ADH reaction of 151 using 1.2 mol% K2OsO4.H2O, 1 mol%
(DHQD)2PYR, potassium ferricyanide (3.0 mol), methanesulfonamide (1.0 mol) and
potassium carbonate (3.0 mol) with stirring for two days

2.3.2 The synthesis of the 1,2-anti amino alcohol 155 via the diol 190

The synthesis of the 1,2-anti amino alcohol 155 started with the Shapless ADH reaction
of 151 using the best conditions developed above (Table 2.2) which provided the diol
190 in 99% yield (dr = 4:1) (Scheme 2.13). The regioselective oxidation of the primary
hydroxy group in diol 190 with 2,2,6,6-tetramethylpiperidinyl-1-oxy (TEMPO) and
commercial sodium hypochlorite in a mixture of saturated sodium hydrogen carbonate
(sat. NaHCO3) and CH2Cl2 at 0 oC for 30 min provided what we assume is the cyclic
hemiacetal intermediate 153.82 This was directly treated with the allyl amine 154
(1.2 mol equivalent) and -styrenyl boronic acid (1.2 mol equivalent) in a Petasis
boronic acid Mannich reaction to give the 1,2-anti amino alcohol 155, after column
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chromatography, in 73% yield for the two synthetic steps. Compound 155 was obtained
as essentially (dr > 19 : 1) a single diastereomer. The other diastereoisomer expected to
arise from the reaction of 2-epi-190 could not be isolated pure.

Scheme 2.13 The synthesis of the 1,2-anti amino alcohol 155 via a regioselective
oxidation of the primary alcohol 190

A comparison of the overall yields of the 1,2-anti amino alcohol 155 from the two
synthetic routes showed that the second method, via the selective oxidation of the
primary alcohol 190, gave around three times a higher yield than that via the vinyl
sulfone 152 with 72% and 24% overall yields (base on the moles of 151) for the three
steps from 151, respectively (Scheme 2.14).

Scheme 2.14 A comparison of the two synthetic routes to the 1,2-anti amino alcohol
155
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2.3.3 A model study of oxazolidinone ring formation via N-Boc protection/Omesylation

As a model study for converting the amino alcohol 155 to the oxazolidinone 177 the
1,2-anti amino alcohol 192 was prepared (Scheme 2.15). The selective oxidation of the
diol 190 using TEMPO and sodium hypochlorite and then treatment of the crude
product with allylamine 191 and -styrenyl boronic acid provided the 1,2-anti amino
alcohol 192 in 49% yield (unoptimized) over the two steps.

Scheme 2.15 The synthesis of the 1,2-anti amino alcohol 192

N-Boc protection of the amine 192 was accomplished by treatment with di-tert-butyldicarbonate in the presence of triethylamine in methanol at rt to give the N-Boc
protected product 193 in 87% yield (Scheme 2.16). The 1H NMR spectrum of 193
indicated the presence of the Boc group from the signal at  1.46 (9H, s) while the 13C
NMR signal at  156.0, and the C=O stretching absorbance at max 1685 cm-1 in the IR
spectrum, further supported the presence of

the Boc protecting group in 193.

1

Moreover, the deshielding of the H NMR resonances for H3 and H1′, while the
chemical shift of H4 remained the same as that in 192, confirmed that the N-Boc
protection had occurred at the N atom and not at the C4 hydroxy group.
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Scheme 2.16 N-Boc protection of the 1,2-anti amino alcohol 192

Alcohol 193 was treated with methanesulfonyl chloride and triethylamine. Under the
basic reaction conditions, O-mesylation and then cyclization occurred to give the
oxazolidinone product 194 in 61% yield (Scheme 2.17). The

13

C NMR resonance at

 158.0, the C=O stretching absorbance at max 1750 cm-1 in the IR spectrum and the
disappearance of the 9H, singlet methyl signal at  1.46 in the 1H NMR spectrum
indicated the formation of the oxazolidinone ring. The NOESY correlation between H4
and H1′′, without an observed correlation peak between H4 and H5, and the magnitude
of the H4 to H5 coupling constant (J4,5 = 6.8 Hz)84 confirmed that the configuration at
C5 of 194 was S.

Scheme 2.17 The O-mesylation of 193

For the proposed mechanism of this reaction, one of the N-Boc protons of intermediate
195 was abstracted by the base (Et3N) leading to a possible E2-elimination-SN2cyclization process to provide the oxazolidinone derivative 194 (Scheme 2.18).77
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Scheme 2.18 The proposed mechanism for the formation of oxazolidinone 194

2.3.4 N-Boc protection of the 1,2-anti amino alcohol 155

Since the above model study was successful, the N-Boc protection of compound 155
was attempted using di-tert-butyl-dicarbonate and triethylamine in methanol.85 The
reaction was stirred at rt for two days but there was no sign of the expected N-Boc
product 175 by TLC analysis. There was just the spot of unreacted starting material
155. Moreover, this result was confirmed by 1H NMR analysis of the crude reaction
mixture after work up. N-Boc protection of compound 155 with di-tert-butyldicarbonate was then attempted under several different reaction conditions. Acetonitrile
was tried as the solvent and 1-methylimidazole and guanidine hydrochloride86 were
used as catalysts. In addition, N-Boc protection of 155 was attempted using
2-(tert-butoxycarbonyloxyimino)-2-phenylacetonitrile (Boc-ON) in the presence of
triethylamine in tetrahydrofuran87 or a mixture of water/dioxane.88 None of these
reaction conditions showed any sign of the expected N-Boc product 175. However
when compound 155 was treated with Boc anhydride in the presence of triethylamine
and DMAP89 in CH2Cl2 at rt for 1 day a new product was observed by TLC analysis
(Scheme 2.19). Interestingly, a cyclic oxazolidinone had formed instead of the expected
N-Boc protected product in 45% yield. Unfortunately, 1H and 13C NMR analysis of this
product indicated that the known oxazolidinone 156 had formed. This compound had
been previously synthesized from 155 by treatment with triphosgene/triethylamine
(Chapter 1, Scheme 1.8).60
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Scheme 2.19 The cyclization of 155 during attempted N-Boc protection

For this result, two possible mechanisms were possible (Scheme 2.20). One pathway
involved cyclization of the intermediate carbonate A while the other involved
cyclization of the intermediate carbamate B. Because of the hindered nature of the
amino group in 155 the former pathway seemed more likely.

Scheme 2.20 Proposed mechanisms for the formation of the oxazolidinone 156

2.4 The third synthetic plan for the total synthesis of 5-epi-hyacinthacine B5 174
The third synthetic plan for the total synthesis of 5-epi-hyacinthacine B5 174 was then
initiated (Scheme 2.21). The first three synthetic steps remained the same as before.
Both the amino and the hydroxy groups of 155 will be protected to form the
oxazolidinone 156 which will be converted to the known pyrrolizidine 160 via the
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known intermediates 157 – 159 used in the synthesis of hyacinthacine B3. A-ring
formation via a ring-closing metathesis reaction of 156 will provide the bicyclic alkene
157. DH of alkene 157 will give the syn-diol which will be protected as the bisbenzyl
ether 159. The O-PMB ether of 159 would then be deprotected to form the free alcohol
160 which can be converted, via an inversion reaction at C2′ from S to R, via the
Mitsunobu reaction to the p-nitrobenzoate 196. Base hydrolysis of 196 would give the
amino diol 172. Regioselective O-mesylation-cyclization of 172 will give the B-ring
cyclised product 173 with a -hydroxy group at C7. Inversion of the configuration at
this stereocentre will be achieve by oxidation to the ketone 197 followed by a
stereoselective reduction to the alcohol 184. The target product 174 will be obtained
after removal of the O-benzyl protecting groups of 184 by hydrogenolysis follow by
neutralization and purification by basic ion-exchange chromatography.

Scheme 2.21 The third synthetic plan for the total synthesis of 5-epi-hyacinthacine B5
174
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2.4.1 Synthesis of the oxazolidinone 156

Following the third synthetic plan, the oxazolidinone 156 was prepared by treating the
1,2-anti amino alcohol 155 with triphosgene and triethylamine in CH2Cl2 at rt for 18 h
to give the oxazolidinone 156 in 66% yield (Scheme 2.22). All spectroscopic data of
156 matched with those previously reported for this compound.60 This yield for the
oxazolidinone 156 was better than that obtained in Scheme 2.19 using Boc anhydride
and DMAP (45% yield).

Scheme 2.22 Preparation of the oxazolidinone 156

2.4.2 The synthesis of the cyclic diol 158
Ring-closing metathesis of the diene 156 using 5 mol % of Grubbs’ II ruthenium
catalyst in CH2Cl2 at refluxing temperature provided the cyclic alkene 157 (90% yield)
(Scheme 2.23) which showed two clearly resolved cis-alkene 1H NMR resonances at

5.99 (1H, d, J = 5.9 Hz) and 5.89 (1H, d, J = 5.9 Hz).60 Compound 157 was treated
with potassium osmate(VI) dihydrate and NMO as co-oxidant to give the syn-cyclic
6R,7S-diol 158. All spectroscopic data of 158 matched with those previously reported
for this compound.60 Pyne and Au provided two reasons for the high
diastereoselectivity of 158.60 The first one was based on stereoelectronic effects. The

-orbitals on the alkene are better overlapped with the non-bonding orbital of the N
atom on the -face which enhances the LUMO coefficients on the -face of the alkene
favouring dihydroxylation from this face. The second one was the steric effect of the
-benzyloxymethyl substituent at C5 that also favours DH from the -face of the ring.
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Scheme 2.23 The ring-closing metathesis of 156 followed by syn dihydroxylation

2.4.3 Synthesis of the alcohol 160

The free hydroxy groups of compound 158 were protected as their benzyl ethers by
treatment with an excess amount (4.0 equivalents) of benzyl bromide in the presence of
tert-butyl ammonium iodide and sodium hydride in tetrahydrofuran at rt for 1 d to give
159 in excellent yield (92%) (Scheme 2.24).60 The PMB group of 159 was removed by
oxidation with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in a two phase
system using CH2Cl2 and water at rt for 2.5 h to give the free alcohol 160 in 84%
yield.60

Scheme 2.24 The synthesis of alcohol 160
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2.4.4 The Mitsunobu reaction of compound 16090

The Mitsunobu reaction of 160 was investigated to invert the configuration at C2′
(Scheme 2.25). The alcohol 160 was treated with p-nitrobenzoic acid in the presence of
triphenylphosphine and diisopropyl azodicarboxylate in toluene at rt for 24 h to give
the p-nitrobenzoate 196 in 85% yield.90 The 1H NMR spectrum of 196 showed a
deshielded resonance at (1H, m) for H2′ and two sets of doublets at

d,J = 8.8 Hz)and d, J = 8.8 Hz)for the p-nitrobenzoate
moiety.The stereochemistry at C2′ could not be confirmed at this stage, however it was
confirmed after the next synthetic step from a comparison of the NMR spectra of the
resulting product 172 with that obtained from a different synthetic route (Chapter 1,
Scheme 1.9).60

Scheme 2.25 The stereoinversion at C2′ of compound 160 via the Mitsunobu reaction

2.4.5 Hydrolysis of 196 and then mesylation-cyclization

Both the p-nitrobenzoate and the oxazolidinone ring of compound 196 were
hydrolytically cleaved by treatment with sodium hydroxide in ethanol with microwave
heating (power at 220 W and a maximum temperature of 110 oC) for 2 h to provide the
amino diol 172 in 97% yield (Scheme 2.26). The 1H and 13C NMR spectroscopic data
of the hydrolysis product 172 matched well with those previously reported for this
compound.60 Compound 172 was treated with 1.05 equivalents of methanesulfonyl
chloride and triethylamine in CH2Cl2 at 0 oC for 1.5 h to give the cyclised product 173
in 77% yield.60 Even with the intended stoichiometric control of the amount of
methanesulfonyl chloride there was some over mesylation product 198 (13% yield)
produced as a side product. The 1H NMR spectrum of 198 showed a downfield
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resonance at 5.36 - 5.40 (1H, m) for H7 and also a 3H singlet at 2.81 for the
mesylate group (OSO3CH3).

Scheme 2.26 Synthesis of the pyrrolizidine 173

2.4.6 The stereoinversion at C7 of the cyclic alcohol 173

For the stereoinversion process, the cyclic alcohol 173 was treated under Swern
oxidation conditions with oxalyl chloride and dimethyl sulfoxide and then
triethylamine in anhydrous CH2Cl2 at -78 oC for 1 h to provide the cyclic ketone 197 in
63% yield (Scheme 2.27).91 Unreacted starting material 173 was also recovered in 30%
yield. The 1H NMR spectrum of ketone 197 showed the absence of the H7 signal and a
significant deshielding of the two C6 protons ( 2.10 and 2.61) compared to those in
173 ( 1.59 and 2.27). The

13

C NMR spectrum of 197 showed a resonance for a

cyclopentanone type carbonyl group at . The sharp C=O stretching band at
1750 cm-1 in the IR spectrum further supported the presence of the carbonyl group of
compound 197. Moreover NOESY correlations between H7a and H1, H1 and H2, H2
and H8, and H8 and H9 strongly indicated that the relative stereochemistry of all
stereogenic centres, including that of C7a, was the same as that found in compound 173
(Figure 2.4).
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Scheme 2.27 The Swern oxidation of the cyclic alcohol 173
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Figure 2.4 2D NOESY spectrum (500 MHz, CDCl3) of compound 197

The stereoselective reduction of the ketone 197 was achieved using L-selectride
(LiBH(s-Bu)3) in tetrahydrofuran at -78 oC to rt (Scheme 2.28).92 This reaction gave the
alcohol 184 in 70% yield and as a single diastereomer.
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Scheme 2.28 The stereoselective reduction of the cyclic ketone 197 using L-selectride

Zhang and co-workers explained the mechanism of action of the stereoselective
reduction of bicyclic ketone A using L-selectride (Scheme 2.29). The bulky
L-selectride attacks the carbonyl group from the less hindered convex face of the
molecule resulting in the endo-configulation of the cyclic alcohol product C.92

Scheme 2.29 Proposed mechanism of the L-selectride reduction of ketone A92

For the structural elucidation of compound 184, IR spectroscopy showed the
appearance of an O-H stretching band (3390 cm-1) and no C=O stretching band.
Moreover, the

13

C NMR spectrum showed the presence of a new carbinol carbon

resonance (C7,  73.2) and the loss of the carbonyl carbon signal. The 1H and 13C NMR
spectroscopic data of compound 184 were similar to those of compound 173 but were
not the same chemical shifts. The results from gCOSY, gHSQC, gHMBC and APT
indicated that the structure of 184 was the diastereoisomer of 173. The chemical shifts
of H1 and H7 were too close to allow for a clear analysis of a NOESY correlation
between the H7 and H7a protons, which would be required to determine their relative
configurations (Figure 2.5).
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Figure 2.5 2D NOESY spectrum (500 MHz, CDCl3) of compound 184

2.4.7 O-Benzyl ether deprotection

Finally, the tribenzyl ether 184 was treated with palladium chloride and hydrogen gas
(balloon) in methanol at rt for 3 h. The resulting hydrochloride salt product was
neutralized using basic ion-exchange chromatography to give 5-epi-hyacinthacine B5
174 in 84% yield (Scheme 2.30).

Scheme 2.30 The hydrogenolysis of compound 184
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The structure of 5-epi-hyacinthacine B5 174 was established from 1H and

13

C NMR

spectroscopic analysis using gCOSY, gHSQC and gHMBC experiments and IR and
high resolution mass spectrometry. The 1H NMR spectrum showed ten well resolved
resonances while the

13

C NMR spectrum showed nine (Figures 2.6 and 2.7,

respectively). The APT and gHSQC spectra showed resonances for one methyl, two
methylene and six methine carbons. The connectivity of each carbon atom was
determined from analysis of its gCOSY, TOCSY and gHMBC spectra.

H9

H1

H8

H7

H7a

H2

H3
H5
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H6

Figure 2.6 1H NMR spectrum (500 MHz, D2O) of 5-epi-hyacinthacine B5 174
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C3 C7a

C8
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Figure 2.7 13C NMR spectrum (125 MHz, D2O) of 5-epi-hyacinthacine B5 174
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The 2D NOESY correlatons of 174 were used to identified the relative, and thus the
absolute, configuration of all stereogenic centres (Figues 2.8 and 2.9). Strong NOESY
correlations were seen between H7 and H7a, H7 and H1, H1 and H8, and H2 and H8.
these correletions strongly indicated that these protons were all located on the same
face of the pyrrolizidine ring. In addition, the strong NOESY correlation beween H3
and H5 also confirmed that they had a syn relationship on the pyrrolizidine ring but
were on the opposite face to H1, H2, H7 and H7a. A weak NOESY correlation was also
observed beween H2 and H3. All NOESY correlation confirmed that the relative
stereochemistry of all stereogenic centres were correct and matched with that of 5-epihyacinthacine B5 174.
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Figure 2.8 2D NOESY NMR spectrum (500 MHz, D2O) of 5-epi-hyacinthacine B5
174
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Figure 2.9 The NOESY correlations of 174 shown on the HF/6-31* optimized
structure (Spartan) (the blue and light green allows showed strong and weak NOESY
correlation signal, respectively)

After we had confirmed the structure and absolute configuration of 5-epi-hyacinthacine
B5 174, the 1H-NMR and

13

C NMR spectroscopic data of 5-epi-hyacinthacine B5 174

were compared to those of natural hyacinthacine B7 33 as shown in Tables 2.3 and 2.4.
The

13

C NMR spectroscopic data of 5-epi-hyacinthacine B5 174 was significantly

different to those of natural hyacinthacine B7, especially the chemical shifts of C3, C5
and C9 which had a C of -7.1, -6.5 and -4.4 ppm, respectively. The 1H NMR
spectroscopic data also showed a marked difference between those of natural
hyacinthacine B7 and synthetic 174. For example H3 of natural hyacinthacine B7
resonated at  3.29 with the splitting pattern as a doublet of doublet of doublets (J = 7.6,
5.5, 3.5 Hz) while that of synthetic 174 was observed at  3.04 with the spiting pattern
as a doublet of triplets (J = 6.3, 5.4 Hz).
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Table 2.3 Comparison of the literature 13C NMR chemical shifts (125 MHz, D2O) of
natural hyacinthacine B7 33 and those of 5-epi-hyacinthacine B5 174
Carbon
1
2
3
5
6
7
7a
8
9

atural hyacinthacine B733
C (ppm)
77.9
74.9
66.2
57.7
45.2
76.5
69.9
66.8
18.4

5-epi-hyacinthacine B5 174
C (ppm)
75.3
77.8
73.3
64.2
46.5
75.7
70.6
65.5
22.8

C
(ppm)
2.6
-2.9
-7.1
-6.5
-1.3
0.8
-0.7
1.3
-4.4

Table 2.4 Comparison of the literature 1H NMR chemical shifts (500 MHz, D2O) of
natural hyacinthacine B733 and those of 5-epi-hyacinthacine B5 174

Proton
1
2
3
5
6
6
7
7a
8
8′
9

Natural hyacinthacine B733
H (ppm)
Mult., J (Hz)
4.35
t (4.4)
3.97
dd (7.6, 4.4)
3.29
ddd (7.6, 5.5, 3.5)
3.22
m
m
1.68
m
2.16
4.50
m
3.45
dd (7.6, 4.4)
3.57
dd (11.5, 3.5)
3.63
dd (11.5, 5.5)
1.25
d (7.0)

5-epi-hyacinthacine B5 174
H (ppm)
Mult., J (Hz)
4.41
dd (5.4, 4.9)
3.99
dd (7.3, 4.9)
3.04
dt (6.3, 5.4)
3.36
m
1.71
ddd (13.7, 10.2, 5.8)
2.11
dd (13.7, 5.8)
4.59
t (4.9)
3.58
t (5.4)
3.67
dd (11.7, 5.8)
3.71
dd (11.7, 5.4)
1.18
d (5.9)

In addition, the specific rotation of the natural product ([ ] D - 4.4 o, c 0.20, H2O)33 and
o
the synthetic compound 174 ([] 25
D + 18.5 , c 0.14, H2O) were of opposite signs. This

synthesis confirmed that the structure and absolute configuration of hyacinthacine B7
did not match with that of 5-epi-hyacinthacine B5 174. Further discussion on the likely
structure of natural hyacinthacine B7 are provided at the end of Chapter 3 (Section 3.8).
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In summary, the total synthesis of 5-epi-hyacinthacine B5 174 was accomplished in 15
synthetic steps in 5.58% overall yield form commercially available (S)-4-pentan-2-ol
118. This synthesis confirmed that natural hyacinthacine B7 is not 5-epi-hyacinthacine
B5 174.
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Chapter 3
Total synthesis of hyacinthacine B5
3.1 The isolation and structural elucidation of hyacinthacine B5 12
The polyhydroxylated pyrrolizidine alkaloid hyacinthacine B5 12 (Figure 3.1) was first
isolated from the bulbs of Scilla sibirica (Figure 3.2) and its structure was published by
Asano and co-workers in 2002 along with that of another six new hyacinthacines
(A4, A5, A6, A7, B4 and B6).29 Compound 12 showed modest activity against
amyloglycosidase with an IC50 value of 110 M.29

Figure 3.1 The proposed structure of hyacinthacine B5 1229

The structural elucidation of hyacinthacine B5 12 was determined from its 1H and

13

C

NMR spectroscopic data (Table 3.1) which were analysed using gHMQC, gCOSY and
gHMBC experiments and also HRFABMS.29 The high resolution mass spectrum
showed a molecular formula of C9H17NO4, the same as hyacinthacines B3, B4 and B7.
The gCOSY and gHMBC spectra indicated that this compound was an isomer of the
aforementioned hyacinthacines. The relative configuration of hyacinthacine B5 17 was
determined from the NOESY correlations between H5 and H7, H7 and H7a, H7a and
H1, H7a and H2, H1 and H2, and H2 and H8 which indicated that all of those protons
were located on the same face of the pyrrolizidine ring (Figure 3.2). Moreover, the
observed NOESY correlation between H3 and H9 indicated that H3 and the methyl
group at C5 were on the same face of the pyrrolizidine ring but on the opposite face to
the hydroxylmethyl group at C3.
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Table 3.1 1H (500 MHz, D2O) and 13C NMR (125 MHz, D2O) spectroscopic data of
natural hyacinthacine B5 1229
1

Position
1
2
3
5
6
6
7
7a
8
8′
9

H
4.37
4.08
3.48
3.44
1.86
2.22
4.55
3.66
3.70
3.73
1.32

13

H NMR

C NMR

Mult., J (Hz)
dd (4.4, 4.2)
dd (8.0, 4.2)
ddd (5.1, 4.6, 4.2)
m
ddd (12.5, 10.0, 8.0)
ddd (12.5, 6.4, 6.0)
ddd (8.0, 7.6, 6.4)
dd (7.6, 4.4)
dd (12.0, 5.1)
dd (12.0, 4.6)
d (7.0)

C
74.8
76.9
65.5
58.5
43.9
75.0
70.1
64.7
17.9

7a
7

1

2

5

3
6

9

8

Figure 3.2 NOESY correlations of hyacinthacine B5 12 taken from reference 29

There have been no reports on the synthesis of hyacinthacine B5 12. The main aim of
this research was to synthesize the proposed structure of hyacinthacine B5 12 to confirm
the structure and absolute configuration of this natural product.
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3.2 The total synthesis of hyacinthacine B5 12
3.2.1 A synthetic analysis of hyacinthacine B5 12
The synthetic plan for the total synthesis of hyacinthacine B5 12 was similar to that
employed in the total synthesis of 5-epi-hyacinthacine B5 174 (Chapter 2, Figures 2.11
and 2.21) except that the (S)-methyl substituent at C5 of hyacinthacine B5 12 should
originate from (S)-4-penten-2-ol 118 without performing a stereoinversion step before
the SN2 displacement-cyclization of the amino group to generate the B-ring (Figure
3.3). The synthetic plan was designed to hydrolyse the intermediate 160 (from the total
synthesis of 5-epi-hyacinthacine B5 174) to its corresponding diol without the prior
stereoinversion of C2′.

Figure 3.3 Synthetic analysis of hyacinthacine B5 12

3.2.2 The synthetic plan for the total synthesis of hyacinthacine B5 12
The total synthesis of hyacinthacine B5 12 will start with the bicyclic oxazolidinone
intermediate 160 which was synthesized from (S)-4-penten-2-ol 118 (10 steps in 29%
overall yield (Chapter 2, Scheme 2.24). The hydrolysis of the oxazolidinone ring of 160
will provide the amino diol 161. The B-ring of 162 will be realized via a one pot
mesylation-cyclization of 161 to give the pyrrolizidine 162. The stereoinversion of the
hydroxy group at C7 of the cyclic alcohol 162 was planned to be achieved by oxidation
to the ketone 199 follow by a stereoselective reduction to give the bicyclic alcohol 200.
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Finally, the O-benzyl ether groups of 200 will be removed by hydrogenolysis to
provide the final product, hyacinthacine B5 12. The NMR spectroscopic data of this
compound will then be compared with those reported for natural hyacinthacine B5.

Scheme 3.1 The first synthetic plan for the total synthesis of hyacinthacine B5 12

3.2.3 The synthesis of pyrrolizidine 162

The hydrolysis of oxazolidinone 160 by treatment with sodium hydroxide in ethanol
with microwave heating (200 W, 110 oC) gave the amino diol 161 in 96% yield
(Scheme 3.2).60 The mesylation of the amino alcohol 161 using 1.0 equivalent of
methanesulfonyl chloride in the presence of triethylamine in CH2Cl2 at 0 oC for 1.5 h
provided the desired pyrrolizidine 162 in the quantitative yield.60 The structures of 161
and 162 were confirmed from a comparison of their 1H and
data with those in the literature.60

13

C NMR spectroscopic
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Scheme 3.2 The mesylation-cyclization of 161 via hydrolysis of the oxazolidinone 160

3.2.4 The oxidation of the cyclic alcohol 162

The oxidation reaction of the cyclic alcohol 162 was attempted under Swern oxidation
conditions by treatment with oxalyl chloride/dimethyl sulfoxide in CH2Cl2 and then
triethylamine was added at -78 oC for 1 h (Scheme 3.3 (a)).91 After the purification
process by column chromatography, one separated fraction showed a LRESIMS with a
m/z at 472 [M+H]+ which matched that for the expected ketone product 199.
Unfortunately, the 1H NMR spectrum of this fraction showed a complex mixture
containing at least three products which were indicated by the three sets of doublet
signals for the C5 methyl group in the region of1.2 - 1.4 ppm. Another fraction from
the column chromatography gave the unexpected carboxylic acid 201 which was
obtained in 16% yield. The Swern oxidation of alcohol 162 was repeated using the
same conditions as described above but the reaction mixture was left to warm to rt
before quenching with water. This reaction gave only the carboxylic acid 201 in 38%
yield, without the formation of any cyclic ketone products (Scheme 3.3 (b)).
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Scheme 3.3 The Swern oxidation of 162

The 1H and

13

C NMR spectra of 201 are shown in Figures 3.5 and 3.6, respectively.

The 1H NMR spectrum of 201 showed the disappearance of the H7 and H7a resonances
and a significant deshielding of the two C2′ protons at dd, J = 16.1, 6.8 Hz)
and 2.96 dd, J = 16.1, 7.3 Hz)compared to those corresponding to C6 in 162
which resonated at 1.85 (2H, dd, J = 7.3, 5.4 Hz). The extra C=O resonance in the 13C
NMR spectrum at 174.9 and the broad O-H stretching band at max 2400 - 3500 cm-1
in the IR spectrum indicated the presence of a carboxylic acid group which was
connected to a methylene carbon (C2′) from the gHMBC correlation between the
signals for the H2′ protons and the CO2H carbon. The

13

C NMR spectrum also

indicated a lactam carbonyl group at 172.6. In addition, the high resolution mass
spectrum indicated the molecular fomula as C30H33NO6. The gCOSY, TOCSY and
gHMBC spectra indicated the connectivity of all carbon atoms. The relative synstereochemistry of the stereogenic centres at C3 and C4 in the lactam ring were
confirmed from the NOESY correlation between these protons (Figure 3.6).
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Figure 3.6 2D NOESY spectrum (300 MHz, CDCl3) of compound 201

The Dess-Martin periodinane93 oxidation method was tried for the oxidation reaction of
the alcohol 162, however, only the starting alcohol (162) was recovered.

3.2.5 Sequential Swern oxidation and then L-selectride reduction of compound
162

The Swern oxidation reaction of alcohol 162 was repeated (Scheme 3.4) under the
conditions shown in Scheme 3.3 (a).91 After work up, but without purification, the
crude product reaction mixture was directly treated with L-selectride in tetrahydrofuran
at -78 oC for 1 h and then at rt for 1 h.92 After purification, four different products were
isolated which were the desired compound 200 (4% yield), the unexpected alcohol 202
(7% yield), the unexpected ketone 203 (7% yield) and the lactam 204 (8% yield)
(Scheme 3.4).
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Scheme 3.4 The Swern oxidation of 162 followed by stereoselective reduction

For the structural elucidation of compound 200, the high resolution mass spectrum
indicated that the molecular formula of this compound was C30H34NO4, the same as the
alcohol 162. The 1H NMR and

13

C NMR spectroscopic data of 200 were similar to

those of 162 except for the 1H NMR signals of the methylene protons at C6 which
resonated at 1.69 - 1.78 (1H, m) and 2.17 (td, J = 12.2, 6.3 Hz). gCOSY, TOCSY
and gHMBC NMR experiments indicated that compound 200 was the C7 epimer of
162. The relative configurations of the stereogenic centres of 200 were confirmed by
the NOESY correlations between H1 and H7a, H1 and H2, H7 and H2, and H2 and H8
which showed that all of these protons were located on the same face of the
pyrrolizidine ring (Figure 3.7). Moreover, the observed correlation between H5 and H8
indicated that H5 and the benzyloxymethyl group at C3 were syn and were both located
on the opposite face of the pyrrolizidine ring to the aforementioned protons.
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Figure 3.7 2D NOESY spectrum (300 MHz, CDCl3) of compound 200

For compound 202, the high resolution mass spectrum indicated that its molecular
formula (C30H34NO4) was the same as that of the alcohol 162. The 1H NMR and

13

C

NMR spectroscopic data of 202 were similar to those of 162 except for the 1H NMR
signals of the methylene protons at C6 which resonated at 1.72 (td, J = 12.7, 3.4 Hz)
and 2.05 (td, J = 12.7, 5.4 Hz). gCOSY, TOCSY and gHMBC experiments indicated
that 202 was a diastereoisomer of 162. Unfortunaterly, NOESY spectra could not be
used to identify the relative configuration of compound 202 due to overlapping signals.
The relative, and thus the absolute, configuration of this compound however, could be
elucidated, after the next reaction step, on its deprotected product 207.
For the structural elucidation of ketone 203, the deshielded 1H NMR signal for the
methylene protons at 2.25 - 2.13 (2H, m), the

13

C NMR signal at 218.0, and the

sharp C=O IR absorbance at max 1717 cm-1 indicated that the C7 carbonyl group was
not reduced under the reduction reaction conditions. Moreover, its structure was
comfirmed by high resolution mass spectrometry which indicated that the molecular
formula was C30H33NO4. Unfortunaterly, the NOESY correlations of 203 were not well
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resolved so it was decided to confirm its relative configuration after stereoselective
reduction to 206 using L-selectride (Scheme 3.9).

For compound 204 the high resolution mass spectrum indicated that the molecular
formula of this compound was C30H35NO5. The 1H and 13C NMR spectroscopic data of
204 (Figures 3.8 and 3.9) were similar to those of compound 201 but there were some
notable differences. These were the shielding of the methylene protons at C2′ from
around 2.90 and 2.85 in 201 to 1.74 – 1.70 in 204 and the shielding of the

13

C

NMR signal of C3′ from 174.9 in 201 to 58.6 in 204. Moreover, the broad O-H
stretch at max 3400 cm-1 in the IR spectrum indicated a hydroxy group. These results
confirmed that compound 204 was the reduced form of compound 201. The relative
stereochemistry of the stereogenic centres in the lactam ring were confirmed by the
NOESY correlations between H3 and H4 and H4 and H1′′′ (Figure 3.10) which
indicated that these protons were all located on the same face of the lactam ring.
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Figure 3.8 1H NMR spectrum (500 MHz, CDCl3) of compound 204
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Figure 3.10 NOESY spectrum (500 MHz, CDCl3) of compound 204

A proposed mechanism for the formation of compounds 201 and 204 is shown in
Scheme 3.5. Compound 162 can react with the intermediate dimethylchlorosulfonium
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species (Me2S(+)Cl)94 either at the C7 hydroxy, resulting in the corresponding C7
ketone, or the nitrogen (Scheme 3.5). The reaction of 162 at nitrogen would give the
intermediate A. Intermediate A can undergo a fragmentation reaction to the iminium
ion B. Nucleophilic attack of DMSO at the aldehyde group of B would lead to the
bicyclic intermediate C. The base promoted elimination-fragmentation of C would give
the resonance stabilized cationic intermediate D which would be hydrolyzed by water
during the reaction quenching process to form intermediate F. Ring opening of F under
the acidic conditions of silica gel would give compound 201. The stereoselective
reduction of F using L-selectride would produce compound 204. Consistent with this
mechanism is the finding that the carboxylic acid 201 could not be reduced to alcohol
204 upon subsequent treatment with L-selectride.

Scheme 3.5 Proposed mechanism for the formation of the side products 201 and 204
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In the total synthesis of 5-epi-hyacithacine B5 174 (Chapter 2, Scheme 2.27), the
alcohol 173 underwent Swern oxidation to its corresponding ketone without the
formation of a ring cleaved side product analogous to 201. We suspect that the steric
hindrance of the C5 -methyl group of compound 173 made the nitrogen too hindered
for attack by Me2S(+)Cl and thus formation of intermediate G was much less likely
(Scheme 3.6).

Scheme 3.6 The steric effect from the C5 -methyl group of compound 173 (in the
total synthesis of 5-epi-hyacithacine B5 174) that inhibits the formation of the
intermediate G in the Swern oxidation reaction

The proposed mechanism for formation of the unexpected alcohol 202 is shown in
Scheme 3.7. The Swern oxidation of alcohol 162 gave the desired ketone 199. Because
of the adverse axial-axial like steric interactions between the C5 methyl group and the
C1 benzyl ether group the molecule can epimerize to the more stable C7a epimeric
ketone 205 in the presence of triethylamine. In this isomer the C5 and C1 substituents
are now both equatorial. The stereoselective reduction of ketone 205 from the less
hindered convex face then gives the unexpected alcohol 202.
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Scheme 3.7 The proposed mechanism for the formation of the alcohol 202

The proposed mechanism for the formation of the unexpected ketone 203 is shown in
Scheme 3.8. Compound 162 could react with two dimethylchlorosulfonium species
(Me2S(+)Cl) at O and N atom to give the intermediate A. Base promoted elimination of
A could provide the intermediate B. Deprotonation at C1 of intermediate B by Et3N
could give the enone C which upon 1,4-reduction by L-selectride, with addition of
hydride at C1 from the stereoelectronically favoured pseudo-axial direction, would give
an enolate anion which upon quenching with water and protonation at C7a, from the
stereoelectronically favoured pseudo-axial direction, would give 203.

Scheme 3.8 The proposed mechanism for side product 203
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A comparison of the minimized energy of the three ketones, 199, 203 and 205, which
were calculated from HF/6-31* optimized structures (Spartan) (Figure 3.11), shows
that the ketone 199 had the highest molecular energy of 724 kJ/mol followed by the
ketone 205 with an energy of 711 kJ/mol. The ketone 203 showed the lowest molecular
energy of 692 kJ/mol. These results support the suggestion that the higher instability
the Swern oxidation product 199 was the main factor which lead to the formation of the
observed side products.

Figure 3.11 A comparison of the minimized energies of the three ketones, 199, 203 and
205, which were calculated from HF/6-31* optimized structures (Spartan)

3.2.6 The stereoselective reduction of compound 203
Reduction of the ketone 203 with L-selectride in tetrahydrofuran at -78 oC for 1 h and
then at room temperature for 1 h provided the alcohol 206 in 58% yield as a single
diastereomer (Scheme 3.9).92

Scheme 3.9 The stereoselective reduction of ketone 203
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The IR spectrum of compound 206 showed a broad O-H stretch at max 3369 cm-1
which was indicative of the desired C7 hydroxyl group. The high resolution mass
spectrum indicated that the molecular formula of compound 206 was C30H35NO5. The
1

H and

13

C NMR spectroscopic data of 206 were similar to those of compound 200

however the 1H NMR signals for the two C6 methylene protons were at significantly
different chemical shifts (1.37 (1H, dd, J = 12.5, 10.5 Hz) and 2.24 (1H, dt, J =
12.5, 5.9 Hz)). The gCOSY, TOCSY and gHMBC spectra indicated that this structure
was a diastereoisomer of 200. The observed NOESY correlation between H7 and H7a
showed that these protons were located on the same face of the ring but unfortunately
the 1H NMR chemical shifts of H1, H2 and H7 were too close and their NOESY
correlations overapped with the diagonal signal (Figure 3.12). The relative
configuration of this compound was more readily determined, after the next synthetic
reaction step, on it deprotected derivative 11.
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H7 H6 A
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H3
H8
H7a
H7 H7a

H2
H1
H7

Figure 3.12 2D NOESY spectrum (500 MHz, CHCl3) of compound 206
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3.2.7 The hydrogenolysis of compounds 200, 202 and 206

The O-benzyl protecting groups of compounds 200, 202 and 206 were removed by
treatment with palladium chloride and hydrogen gas (balloon) in methanol to give the
deprotected products as their hydrochloride salts (Scheme 3.10). They were neutralized
using basic ion-exchange chromatography to give hyacinthacine B5 12, compound 207
and hyacinthacine B4 11 in 21%, 100% and 100% yields, respectively.

Scheme 3.10 The hydrogenolysis of compounds 200, 202 and 206

The structure of synthetic hyacinthacine B5 12 was established from 1H and 13C NMR
analysis using gCOSY, gHSQC and gHMBC experiments, IR and high resolution mass
spectrometry. The 1H NMR spectrum showed ten well resolved resonances while the
13

C NMR spectrum showed nine carbon signals as shown in Figures 3.13 and 3.14,

respectively. The results from APT and gHSQC experiments indicated one methyl, two
methylene and six methine carbon atoms. gCOSY, TOCSY and gHSQC spectroscopy
established the correct core structure. The relative and thus absolute configuration of all
stereogenic centres were confirmed by 2D NOESY and 1D NOESY correlations
(Figure 3.15). The NOESY correlations between H7 and H7a, H7a and H1, H7a and
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H2, H1 and H2, and H2 and H8 confirmed that H7, H7a, H1 and H2 were located on
the same face of the pyrrolizidine ring as the hydroxymethyl group at C3. Moreover,
the NOESY correlation between H3 and H9 showed that their positions were located on
the opposite face of the pyrrolizidine ring as the aforementioned hydrogens. A weak
NOESY correlation was also observed beween H2 and H3. All NOESY correlations
confirmed that the stereochemistry of all stereogenic centres were correct and matched
the structure of natural hyacinthacine B5. The NMR spectroscopic data of synthetic 12
and natural hyacinthacine B5 matched closely. This is discussed in more detail in
Section 3.3.1.
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Figure 3.13 1H NMR spectrum (500 MHz, D2O) of synthetic hyacinthacine B5 12
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C NMR spectrum (75 MHz, D2O) of synthetic hyacinthacine B5 17
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Figure 3.15 2D NOESY spectrum (300 MHz, D2O) of synthetic hyacinthacine B5 12
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Figure 3.16 The NOESY correlations of 12 shown on a HF/6-31* optimized structure
(Spartan) (the blue and light green allows showed strong and weak NOESY correlation
signal, respectively)

The 1H NMR and 13C NMR spectroscopic data of compound 207 were similar to those
of compound 12, which showed eleven 1H NMR resonances and nine 13C NMR signals
(Figures 3.17 and 3.18). Mass spectrometry indicated that 207 had the same molecular
formula as 12, which was C9H17NO4. The results from gCOSY, TOCSY and gHSQC
spectra indicated that 207 was a diastereoisomer of compound 12. The observed 1D
NOESY and 2D NOESY correlations between H7 and 7a and H1 and H2, without a
NOESY correlation between H7a and H1, indicated that H7 and 7a were located on the
same face of the pyrrolizidine ring but on a different face to that of H1 and H2 (Figures
3.19 and 3.20). Moreover, the weak correlation between H5 and H8 confirmed the
stereochemistry of the -methyl group at C5. It was therefore concluded that 207 was
7a-epi-hyacinthacine B3.
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Figure 3.17 1H NMR spectrum (500 MHz, D2O) of compound 207
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Figure 3.18

13

C NMR spectrum (125 MHz, D2O) of compound 207
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Figure 3.19 2D NOESY spectrum (500 MHz, D2O) of compound 207

Figure 3.20 The NOESY correlations of 207 shown on a HF/6-31* optimized structure
(Spartan) (the blue and light green allows showed strong and weak NOESY correlation
signal, respectively)

The high resolution mass spectrum of 11 showed the molecular formula was
C9H17NO4, the same as that of compound 12. Compound 11 showed ten 1H NMR
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resonances and nine 13C NMR signals similar to compound 12 (Figures 3.21 and 3.22).
The connectivity of all atoms were indicated from gCOSY, TOCSY and gHMBC
spectra which showed that compound 11 was a diastereomer of 12. The relative, and
thus absolute, configurations of all stereogenic centres were determined using 1D and
2D NOESY correlations (Figures 3.23 and 3.24). The observed NOESY correlations
between H7 and H7a, H2 and H8 and the weak correlations between H7a and H2, and
H7 and H5 strongly indicated that H2, H5, H7 and H7a were located on the same face
of the pyrrolizidine ring as the hydroxymethyl group at C3. In addition, the NOESY
correlations between H1 and H3 and H3 and H9 confirmed that H1 and H3 were on the
same side of pyrrolizidine ring as the methyl group at C5. These NOESY correlations
confirmed the structure and relative stereochemistry of 11 which matched with that of
hyacinthacine B4.
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Figure 3.21 1H NMR spectrum (500 MHz, D2O) of compound 11
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Figure 3.23 2D NOESY spectrum (500 MHz, D2O) of compound 11
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Figure 3.24 The NOESY correlations of 11 shown on a HF/6-31* optimized structure
(Spartan) (the blue and light green allows showed strong and weak NOESY correlation
signal, respectively)

3.3 A comparison of the spectroscopic data of the synthetic compounds with those
of the natural hyacinthacines
After the structures of compounds 12, 207 and 11 were confirmed, the 1H and

13

C

NMR spectroscopic data of compounds 12 and 11 were compared with those of natural
hyacinthacine B5 and hyacinthacine B4, respectively.

3.3.1 A comparison of the spectroscopic data of compound 12 with those of natural
hyacinthacine B5
The 1H and

13

C NMR spectroscopic data of synthetic 12 were compared to those of

natural hyacinthacine B5.29 The

13

C NMR chemical shifts of synthetic 12 and

hyacinthacine B5 were in very close agreement with differences (C) of only between
0.2 - 1.3 ppm. These small differences may be due to concentration or pH differences.
The 1H NMR spectroscopic data also showed little difference between those of the
natural product and synthetic 12 with H ranging from 0 - 0.9 ppm and the coupling
constants and multiplicities in close agreement (in some cases dd signals in the natural
product were apparent t signals in 12). The specific rotation of synthetic 12 ([] 25
D
- 21.6, c 0.08, H2O) and the natural product ([] D - 25.4, c 0.26, H2O)29 were close in
magnitude and of the same sign. These comparisons indicated that synthetic 12 and

Chapter 3 | 101

natural hyacinthacine B5 were the same and that the proposed structure and absolute
configuration of hyacinthacine B5, that was published by Asano co-workers in 2002,
was correct.

Table 3.2 Comparison of the 13C NMR chemical shifts (75 MHz, D2O) of natural
hyacinthacine B5 29 and those of synthetic 12
Carbon
1
2
3
5
6
7
7a
8
9

atural hyacinthacine B529
C (ppm)
74.8
76.9
65.5
58.5
43.9
75.0
70.1
64.7
17.9

Synthetic 12
C (ppm)
75.1
77.6
65.3
57.7
44.3
75.6
69.7
66.0
18.1

C
-0.3
-0.7
0.2
0.8
-0.4
-0.6
0.4
-1.3
-0.2

Table 3.3 Comparison of the 1H NMR chemical shifts (500 MHz, D2O) of natural
hyacinthacine B5 29 and those of synthetic 12

Proton
1
2
3
5
6
6
7
7a
8
8′
9

Natural hyacinthacine B529
H (ppm)
Mult., J (Hz)
4.37
dd (4.4, 4.2)
4.08
dd (8.0, 4.2)
3.48
ddd (5.1, 4.6, 4.2)
3.44
m
1.86
ddd (12.5, 10.0, 8.0)
2.22
ddd (12.5, 6.4, 6.0)
4.55
ddd (8.0, 7.6, 6.4)
3.66
dd (7.6, 4.4)
3.70
dd (12.0, 5.1)
3.73
dd (12.0, 4.6)
1.32
d (7.0)

Synthetic 12
H (ppm)
Mult., J (Hz)
4.34
dd (4.4, 3.9)
4.04
dd (7.3, 4.4)
3.39
td (6.1, 5.3)
3.32
m
1.79
dt (12.7, 8.3)
2.19
dt (12.7, 6.3)
4.55
td (7.1, 6.8)
3.52
dd (6.9, 4.4)
3.65
dd (11.2, 5.4)
3.69
dd (11.2, 4.4)
1.29
d (6.8)
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3.3.2 A comparison of the spectroscopic data of compound 11 with natural
hyacinthacine B429
A comparison of the

13

C NMR chemical shifts of compound 11 and those of natural

hyacinthacine B429 showed a difference (C) of between 0.2-0.8 ppm (Table 3.4). The
1

H NMR spectroscopic data of synthetic 11 and the natural product were also in close

agreement (H 0.1 – 0.9 ppm) (Table 3.5). One difference was the splitting pattern in
the 1H NMR spectrum for H1 and H7. The 1H NMR of synthetic 11 showed resonances
for these protons as a doublet of doublets (J = 7.8, 7.3 Hz) and an apparent triplet of
doublets (J = 6.4, 5.7 Hz), respectively, while those of natural hyacinthacine B4 were
reported as a triplet (J = 7.6 Hz) and a doublet of doublet of doublets (J = 6.6, 6.3, 5.9
Hz), respectively. These differences were due the lack of resolution of the observed
triplets which were actually a doublet of doublets with two similar J values. The
specific rotation of compound 11 ([] 25
D - 7.7, c 0.18, H2O) and natural hyacinthacine
B4 ([] D - 6.7, c 1.19, H2O)29 were close in magnitude on of the same sign. From these
comparisons, we can concluded that synthetic 11 and hyacinthacine B4 were the same
and that the proposed structure and absolute configuration of hyacinthacine B4, that was
published by Asano and co-workers in 2002, was also correct.
Table 3.4 Comparison of the 13C NMR chemical shifts (125 MHz, D2O) of natural
hyacinthacine B4 29 and those of compound 11
Carbon
1
2
3
5
6
7
7a
8
9

atural hyacinthacine B429
C (ppm)
76.9
81.4
64.8
57.7
42.4
72.8
73.1
65.2
18.8

Compound 11
C (ppm)
77.1
82.0
64.5
57.0
42.7
73.1
72.9
66.0
19.0

C
-0.2
-0.6
0.3
0.7
-0.3
-0.3
0.2
-0.8
-0.2
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Table 3.5 Comparison of the 1H NMR chemical shifts (500 MHz, D2O) of natural
hyacinthacine B4 29 and those of compound 11

Proton
1
2
3
5
6
6
7
7a
8
8′
9

Natural hyacinthacine B429
H (ppm)
Mult., J (Hz)
4.18
t (7.6)
3.98
dd (8.1, 7.6)
3.19
dt (8.1, 4.9)
3.34
m
1.72
ddd (13.2, 7.8, 6.3)
2.17
dt (13.2, 5.9)
4.45
ddd (6.6, 6.3, 5.9)
3.39
dd (7.6, 6.6)
3.70
d (4.9)
3.70
d (4.9)
1.27
d (7.1)

Compound 11
H (ppm)
Mult., J (Hz)
4.16
dd (7.8, 7.3)
3.97
dd (7.8, 7.0)
3.14
dt (7.8, 5.4)
3.26
m
1.71
ddd (13.2, 7.3, 6.4)
2.14
dt (13.3, 5.7)
4.44
td (6.4, 5.7)
3.30
dd (7.3, 6.8)
3.69
d (5.4)
3.69
d (5.4)
1.26
d (7.3)

Thus the total synthesis of hyacinthacine B5 12 was accomplished in 14 steps with an
overall yield of 0.21%. Moreover, this total synthesis gave two side products which
were hyacinthacine B4 11 and 7a-epi-hyacinthacine B3 207, which were obtained in
1.11% and 2.03% overall yields, respectively.

3.4 The second synthetic plan for hyacinthacine B5 12
Because of the low yield of hyacinthacine B5 a second and alternative synthesis of this
natural product was attempted. The formation of several side products from the Swern
oxidation of 162 from the first synthetic plan was the main factor that lead to a low
overall yield. The second synthetic plan was designed to employ the Mitsunobu
reaction to invert the stereochemistry at C7 of 162 via the p-nitrobenzoate 208 (Scheme
3.11). The hydrolysis of 208 would then give the target inverted alcohol 200.
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Scheme 3.11 The second synthetic plan for the synthesis of hyacinthacine B5 12

The alcohol 162 was treated under Mitsunobu reaction conditions using p-nitrobenzoic
acid, triphenylphosphine and diisopropyl azodicarboxylate in toluene (Scheme 3.12).90
The reaction mixture was stirred at room temperature for 24 h but no new spot was
observed when the reaction was monitor by TLC. The reaction mixture was then heated
to 80 oC for 24 h. This resulted in the p-nitrobenzoate 209 being formed in only 8%
yield with unreacted 162 being recovered in 32% yield. The 1H NMR spectrum of 209
showed a deshielded resonance for H7 at and two sets of doublets at

J = 8.8 Hz)and J = 8.8 Hz)for the p-nitrobenzoate moiety.
Unfortunately, the lack of a NOESY correlation between H7 and H7a indicated the
reaction had occurred with retention of configuration at C7 (Figure 3.25). This result
was confirmed by the hydrolysis of 209 using potassium carbonate in methanol at room
temperature for 4 h (Scheme 3.12). The resulting alcohol had 1H and
spectroscopic data identical to those of 162.

13

C NMR
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Scheme 3.12 The Mitsunobu reaction of compound 162
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Figure 3.25 2D NOESY NMR spectrum (500 MHz, CDCl3) of compound 209

The mechanism for the formation of compound 209 was suggested to follow the
common mechanism of the Mitsunobu reaction.95 It started with the nucleophilic attack
of triphenylphosphine to diisopropyl azodicarboxylate A to provide the betaine
intermediate B which can deprotonate p-nitrobenzoic acid C to give D and E. The
nucleophilic substitution of D by E provides the intermediates F and G, then
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deprotonation of alcohol H by G would give the alkoxide J. If the alkoxide J is
hindered then nucleophilic attack by J on F at the less hindered carbonyl carbon gives
the benzoate M with retention of configuration. If J is unhindered it can attack at the
more hindered phosphorous cation of F to give the oxyphosphonium salt K. A SN2
nucleophilic substitution of K with p-nitrobenzoate anion E gives p-nitrobenzoate L
with inversion of configuration. In the case of 162 this alcohol is clearly acting as a
hindered alcohol to give the p-nitrobenzoate 209 with retention of configuration.

Scheme 3.13 Mechanism for the Mitsunobu reactions of hindered and unhindered
alcohols

The Mitsunobu reaction of compound 162 was attempted using the relatively smaller
carboxylic

acid

(trifluoroacetic

acid),

triphenylphosphine

and

diisopropyl

azodicarboxylate in toluene (Scheme 3.14). The reaction mixture was stirred at 0 oC to
room temperature for two days but no new product spots were evident from TLC
analysis.
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Scheme 3.14 The Mitsunobu reaction of compound 162 using relatively smaller
carboxylic acid

3.5 The third synthetic plan for hyacinthacine B5 12
A third synthetic plan for the total synthesis of hyacinthacine B5 12 was designed
which involved the SN2 nucleophilic substitution of the mesylate 210 with cesium
benzoate to give the inverted benzoate 211 (Scheme 3.15).96

Scheme 3.15 The third synthetic plan for the synthesis of hyacinthacine B5 12

The mesylate 210 was prepared by two different synthetic routes (Scheme 3.16). The
first one was the mesylation of compound 162 by treatment with methansulfonyl
chloride, triethylamine and 4-N,N-dimethylaminopyridine in CH2Cl2 at 0 oC to room
temperature to give compound 210 in 87% yield. The second one was the over
mesylation-cyclisation of compound 161 by using an excess of methansulfonyl
chloride, triethylamine and 4-N,N-dimethylaminopyridine in CH2Cl2 at 0 oC to provide
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compound 210 in 88% yield. The 1H NMR spectrum of 210 showed a deshielded
resonance at - 5.49(1H, m)for and also a 3H singlet at for the
OSO3CH3. The mesylate 210 was treated with cesium benzoate in dimethyl sulfoxide at
70 oC. This gave the undesired benzoate 212 in 42% yield.96 The 1H NMR spectrum of
212 showed a deshielded resonance at - 5.72(1H, m)for H7 and three sets of
aromatic 1H NMR signals at d,J = 7.8 Hz), t,J = 7.3 Hz)and

dd,J = 7.8, 7.3 Hz)for the benzoate moiety. Unfortunately, the lack of a
NOESY correlation between H7 and H7a indicated the retention of configuration of the
benzoate 212 (Figure 3.26). This result was confirmed by the hydrolysis of 212 using
potassium carbonate in methanol at rt for 4 h. The resulting alcohol had 1H and
NMR spectroscopic data identical to those of 162.

Scheme 3.16 The nucleophilic substitution of 210 with cesium benzoate

13

C
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Figure 3.26 2D NOESY NMR spectrum (500 MHz, CDCl3) of synthetic 212

The stereochemical outcome of this reaction suggested that steric hindrance on the
-face of the B-ring by the C1, C2 and C5 -substituents obstructed the desired SN2
nucleophilic substitution of the mesylate 210 by benzoate anion (Scheme 3.17). We
propose that this reaction proceeds via the ammonium salt A. The SN2 nucleophilic
substitution (overall a double SN2 process) of A with benzoate anion from the -face
results in formation of the benzoate 212 with overall retention of configuration.
A similar intermediate to A (Scheme 3.17) may also be involved in the Mitsunobu
reaction of 162 (Scheme 3.12).
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Scheme 3.17 The proposed mechanism for the formation of the compound 212

3.6 The fourth synthetic plan for the synthesis of hyacinthacine B5 12
Our fourth synthetic plan for preparing hyacinthacine B5 12 from the diol 172 is
outlined in Scheme 3.18. This plan relies on a double Mitsunobu reaction on the diol
172 to give the doubly inverted p-nitrodibenzoate 213.

Scheme 3.18 The fourth synthetic plan for hyacinthacine B5 12
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Diol 172 was treated with an excess amount of p-nitrobenzoic acid, triphenylphosphine
and diisopropyl azodicarboxylate in toluene at rt for 24 h.90 The result of this reaction
was the isolation of the cyclized product 173 in 50% yield (Scheme 3.19).

Scheme 3.19 The Mitsunobu reaction of compound 172

We suggested that compound 172 was converted to the oxyphosphonium salt A under
the Mitsunobu reaction conditions (Scheme 3.20). A SN2 nucleophilic substitution of
compound A, via the secondary amino group, then provided the pyrrolizidine 173.

Scheme 3.20 The proposed mechanism of Mitsunobu reaction of compound 172

In summary, several methods were attempted to improve the yield of the inverted C7
alcohol 200, but these were unsuccessful. It appears that the C5 -methyl substituent
was the main cause of this problem as it obstructed the stereoinversion of the hydroxyl
group at C7 by an SN2 inversion process.
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3.7 The preparation of p-bromobenzoate derivatives of compounds 173 and 162

For X-ray crystallographic studies of the compounds 173 and 162, we prepared their
p-bromobenzoate derivatives 215 and 216 by treatment with p-bromobenzoyl chloride,
triethylamine and 4-N,N-dimethylaminopyridine in CH2Cl2 at room temperature for two
days (Scheme 3.21).97 The 1H NMR spectrum of 215 showed a deshielded resonance
for H7 at dt,J = 10.9, 5.7 Hz)and two sets of doublets at J =
8.0 Hz)and J = 8.0 Hz)for the p-bromobenzoate moiety. While that of 216
showed a deshielded resonance at - 5.71 (1H, m) for H7 and two sets of doublets
at J = 8.4 Hz)and J = 8.4 Hz)for the p-bromobenzoate moiety.
Unfortunately, neither 215 nor 216 formed single crystals suitable for X-ray structural
analysis.

Scheme 3.21 The synthesis of p-bromobenzoate derivatives of compounds 173 and 162
for potential X-ray crystallography analysis
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3.8 A study of the relationship between the 13C NMR chemical shifts and the
configurations at C5 and C7 of the hyacinthacine alkaloids
13

To study of the relationship between the

C NMR chemical shifts and the

configurations of the methyl group at C5 and the hydroxy group at C7 of the
hyacinthacine alkaloids we compared the

13

C NMR chemical shifts of natural

hyacinthacine B7, natural hyachithacine B3 1027, natural hyachithacine B5 1229, synthetic
hyacinthacine B7 1460 and synthetic 5-epi-hyacinthacine B5 174 (Table 3.6 and Figure
3.27). It is clear that the configuration at C5 affects the 13C NMR chemical shifts at C3,
C5 and C9 of these compounds. The

13

C NMR signals for C3, C5 and C9 of the

compounds 14 and 174 having a -methyl group at C5, were significantly downfield of
their respective chemical shifts in compounds 10 and 12, having an -methyl group at
C5. For example, the 13C NMR signals of C3, C5 and C9 for synthetic hyacinthacine B7
14 ( 71.8, 65.2 and 22.5, respectively) and synthetic 5-epi-hyacinthacine B5 174
( 73.3, 64.2 and 22.8, respectively) were very close in magnitude and were
significantly downfield of those for hyacinthacine B3 10 ( 63.8, 57.1 and 17.5,
respectively) and natural hyacinthacine B5 12 ( 65.5, 58.5 and 17.9, respectively). The
chemical shifts of C3, C5 and C9 of these latter two compounds were also similar in
magnitude.
Compounds 10 and 14, having a C7 -hydroxy substituent had very similar

13

C NMR

chemical shifts for C7 and C7a (10:  71.5 and 77.0, respectively and 14:  71.3 and
75.4, respectively). This was also true for compounds 12 and 174, having a C7
-hydroxy substituent (12:  75.0 and 70.1, respectively and 174:  75.7 and 70.6,
respectively). The 13C NMR chemical shifts for C7 was upfield of those for C7a in the
former two compounds while this trend was revered in the latter two compounds.
The 13C NMR chemical shifts reported for C3, C5 and C9 of natural hyacinthacine B7
at  71.8, 65.2 and 22.5, respectively indicated that natural hyacinthacine B7 should
have an -methyl group at C5, rather than a -methyl group in its propose structure.
The 13C NMR chemical shifts for C7 and C7a reported for natural hyacinthacine B7 at

 71.3 and 75.4, respectively, indicated that this structure should have an -hydroxy
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group at C7 rather than a -hydroxy group in its propose structure. This suggests that
the structure of natural hyacinthacine B7 should have an -methyl group at C5 and an
-hydroxy group at C7. That is, it should be the same structure as natural hyacinthacine
B5, assuming that they have the same A-ring structures.

Table 3.6 A comparison of the

13

C NMR chemical shifts (125 MHz, D2O) of natural

hyacinthacine B7, natural hyachithacine B3 1027, natural hyachithacine B5 1229, synthetic
hyacinthacine B7 14 60 and synthetic 5-epi-hyacinthacine B5 174

Carbon
1
2
3
5
6
7
7a
8
9

Nat.
hyacinthacine
B733
C (ppm)
77.9
74.9
66.2
57.7
45.2
76.5
69.9
66.8
18.4

Nat.
hyacinthacine
B3 1027
C (ppm)
72.2
77.4
63.8
57.1
44.4
71.5
77.0
65.0
17.5

Nat.
hyacinthacine
B5 1229
C (ppm)
74.8
76.9
65.5
58.5
43.9
75.0
70.1
64.7
17.9

Syn.
hyacinthacine
B7 1460
C (ppm)
73.6
78.1
71.8
65.2
46.2
71.3
75.4
65.6
22.5

Figure 3.27 The relationship between the structure and the

13

Syn. 5-epihyacinthacine
B5 174
C (ppm)
75.3
77.8
73.3
64.2
46.5
75.7
70.6
65.5
22.8

C NMR chemical shifts

(rounded to the nearest integer) of natural hyacinthacine B7, natural hyachithacine B3
1027, natural hyachithacine B5 1229, synthetic hyacinthacine B7 1460 and synthetic 5-epihyacinthacine B5 174
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The 13C NMR chemical shifts of natural hyacinthacine B7 were very close to those of
natural hyacinthacine B5 except for those for C1 and C2 which are reported at  77.9
and 74.9, respectively for 14 and at  74.8 and 76.9, respectively for 12 (Table 3.7).
Given that the chemical shifts of C1 for compounds 10, 12, 14 and 174 are found in the
range  75.3 - 72.2, and that for C2 in the range  78.1 - 76.9, it would seem likely that
the chemical shifts reported for these carbons in natural hyacinthacine B7 were
inadvertently transposed. Further evidence to support our hypothesis that the structures
of hyacinthacine B5 and B7 are the same, is the close similarity of their 1H NMR
spectroscopic data (Tables 3.8).

Table 3.7 Comparison of the literature

13

C NMR chemical shifts (125 MHz, D2O) of

natural hyacinthacine B733 and those of natural hyacinthacine B5 1229
Carbon
1
2
3
5
6
7
7a
8
9

Nat. hyacinthacine B733
C (ppm)
77.9*
74.9*
66.2
57.7
45.2
76.5
69.9
66.8
18.4

Nat. hyacinthacine B5 1229
C (ppm)
74.8
76.9
65.5
58.5
43.9
75.0
70.1
64.7
17.9

*These signals may have been inadvertently transposed.
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Table 3.8 Comparison of the literature 1H NMR chemical shifts (500 MHz, D2O) of
natural hyacinthacine B733 and those of natural hyacinthacine B5 1229

Proton
1
2
3
5
6
6
7
7a
8
8′
9

atural hyacinthacine B733
H (ppm)
Mult., J (Hz)
4.35
t (4.4)
3.97
dd (7.6, 4.4)
3.29
ddd (7.6, 5.5, 3.5)
3.22
m
m
1.68
m
2.16
4.50
m
3.45
dd (7.6, 4.4)
3.57
dd (11.5, 3.5)
3.63
dd (11.5, 5.5)
1.25
d (7.0)

atural hyacinthacine B5 1229
H (ppm)
Mult., J (Hz)
4.37
dd (4.4, 4.2)
4.08
dd (8.0, 4.2)
3.48
ddd (5.1, 4.6, 4.2)
3.44
m
1.86
ddd (12.5, 10.0, 8.0)
2.22
ddd (12.5, 6.4, 6.0)
4.55
ddd (8.0, 7.6, 6.4)
3.66
dd (7.6, 4.4)
3.70
dd (12.0, 5.1)
3.73
dd (12.0, 4.6)
1.32
d (7.0)

From the above study of the relationship between the configuration at C3 and C7 and
the

13

C NMR chemical shifts, we conclude that the structure of natural hyacinthacine

B7 is most likely the same as that as hyacinthacine B5. While the specific rotation of the
natural hyacinthacine B7 ([] D - 4.4, c 0.08, H2O)33 and that of natural hyacinthacine
B5 12 ([] D - 25.4, c 0.26, H2O)29 were not close in magnitude they were of the same
sign. This difference have been may due to differences in purities of these samples.
However without access to the authentic samples we cannot make an unequivocal
conclusion about the structure of hyacinthacine B7.
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Chapter 4
Progress towards the synthesis of hyacinthacine B4
4.1 The isolation and structural elucidation of hyacinthacine B4 11
The polyhydroxylated pyrrolizidine alkaloid hyacinthacine B4 11 (Figure 3.11) was first
isolated from the bulbs of Scilla sibirica. Its structure was published by Asano and
co-workers at the same time as that of hyacinthacine B5 12 as discussed in Chapter 3.29
Compound 11 showed moderate activity against amyloglycosidase with an IC50 value
of 89 M and bovine epididymis -L-fucosidase with an IC50 value of 23 M.29

Figure 4.1 The proposed structure of hyacinthacine B4 1129

The structural elucidation of hyacinthacine B4 11 was based on an interpretation of its
1

H and

13

C NMR spectroscopic data (Table 4.1) which were analysed using gHMQC,

gCOSY and gHMBC experiments and also HRFABMS, which indicated that its
molecular formula was C9H17NO4.29 The analysis of the gCOSY and gHMBC
spectroscopic data indicated that the structure of this compound was an isomer of
hyacinthacine B7 14. The relative configuration of hyacinthacine B4 11 was determined
by the large vicinal coupling constants between H1 with H2 (J1,2 = 7.6 Hz) and between
H2 and H3 (J2,3 = 8.1 Hz) which indicated that these three protons had vicinal pseudo
trans-axial dispositions.29 In the 1D NOESY spectrum, irradiation of H7 resulted in
NOE enhancements of the signals of H2, H5 and H7a which indicated that these three
protons were all located on the same face of the pyrrolizidine ring (Figure 4.2). While
NOESY correlations between H1 and H3; H3 and H6 and H9; and H6 and H9;
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indicated these protons were on the same face of the pyrrolizidine ring but on the
opposite face to that of H2, H5 and H7a.
Table 4.1 1H (500 MHz, D2O) and

13

C NMR (125 MHz, D2O) spectroscopic data of

natural hyacinthacine B4 1129
1

Position
1
2
3
5
6
6
7
7a
8
8′
9

H

13

H NMR

C NMR

Mult., J (Hz)
t (7.6)
dd (8.1, 7.6)
dt (8.1, 4.9)
m
ddd (13.2, 7.8, 6.3)
dt (13.2, 5.9)
ddd (6.6, 6.3, 5.9)
dd (7.6, 6.6)
d (4.9)
d (4.9)
d (7.1)

4.18
3.98
3.19
3.34
1.72
2.17
4.45
3.39
3.70
3.70
1.27

C (ppm)
76.9
81.4
64.8
57.7
42.4
72.8
73.1
65.2
18.8

7a
7

1

2

5
3

6

9

8

Figure 4.2 NOESY correlations of hyacinthacine B4 11 taken from reference 29

There have been no reports on the synthesis of hyacinthacine B4 11. In our total
synthesis of hyacinthacine B5 (Chapter 3), we obtained hyacinthacine B4 as a side
product in 15 synthetic steps and in 1.11% overall yield. This synthesis established the
structure and configuration of the natural product. The main aim of this project was to
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developed a method to synthesize hyacinthacine B4 11 in less steps with an improved
overall yield.

4.2 A synthetic analysis and the first synthetic plan towards hyacinthacine B4 11
The synthetic plan for the total synthesis of hyacinthacine B4 11 started from 3,5-di-Obenzyl-,-L-xylofuranose 217,98,99 as shown in Figure 4.3 and Scheme 4.1. The C1,
C2 and C3 stereogenic centres on the A-ring of 11 will be obtained from the original
stereochemistry of the sugar starting material (217) which would be treated under
Petasis boronic acid Mannich reaction conditions to give the 1,2-anti amino alcohol
219. The pro-C5 methyl group in 11 should originate from the chiral allyl amine 218.
The stereoinversion of C2 in 219 (pro-C3) will result from an SN2 displacementcyclization reaction to form the A-ring of 11 in the later stages of the synthesis. After
the conversion of 219 to the oxazolidinone 220 a ring-closing metathesis reaction
should then provide the bicyclic alkene 221. Base hydrolysis of the oxazolidinone 221
will give the amino diol 222. The B-ring of 223 will be realized via a one pot Omesylation-cyclization of 222 to give the pyrrolizidine 223. For the mesylation, the
stoichiometry of the methanesulfonyl chloride will be controlled to allow for the
selective mesylation of only the desired hydroxy group. The free hydroxy group of 223
would be protected to be the O-benzyl ether 224. The C7 hydroxy group in 11 will be
obtained from the hydroboration of the cyclic alkene 224 followed by a stereoinversion
reaction at C7 on the synthetic intermediate 225. Inversion of the configuration at the
C7 stereocentre of 225 will be achieve by oxidation to the ketone 203 followed by the
stereoselective reduction to the alcohol 206. Hyacinthacine B4 11 will then be obtained
after removed of the O-benzyl protecting groups by hydrogenolysis follow by
neutralization and purification by basic ion-exchange chromatography.
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Figure 4.3 Synthetic analysis of hyacinthacine B4 11

Scheme 4.1 Synthetic plan for the synthesis of hyacinthacine B4 11

4.2.1 The Petasis boronic acid Manich reaction using 3,5-di-O-benzyl-,-Lxylofuranose 217

The synthesis of hyacinthacine B4 11 started with the Petasis boronic acid Mannich
reaction of 3,5-di-O-benzyl-,-L-xylofuranose 217, the allyl amine 218 and
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-styrenyl boronic acid in ethanol at rt for 3 days. 100 This reaction provided the 1,2-anti
amino alcohol 219 in 67% yield (Scheme 4.2). The 1H NMR spectrum of 219 showed
olefinic proton resonances at  6.46 (1H, d, J = 16.0 Hz) for H7 and at  6.09 (1H, dd, J
= 16.0, 8.9 Hz) for H6 and three other olefinic proton resonances at  5.71 (1H, ddd, J
= 17.2, 10.1, 7.4 Hz),  5.04 (1H, d, J = 17.2 Hz) and  4.98 (1H, d, J = 10.1 Hz) for
H2′, H3′ trans and H3′cis, respectively.

Scheme 4.2 The Petasis boronic acid Mannich reaction using compound 217

4.2.2 Preparation of the oxazolidin-2-one 220 and the oxazepin-2-one 226

Treatment of the amino diol 219 with triphosgene and triethylamine in CH2Cl2 at rt for
1 h gave the desired five-membered oxazolidin-2-one 220 in only 5% yield along with
the unexpected oxazepin-2-one 226 as the major product in 30% yield (Scheme 4.3).

Scheme 4.3 The preparation of the oxazolidinone 220 and the oxazepinone 226

The 13C NMR signal at  157.0 and the C=O stretching absorbance at max 1744 cm-1 in
IR spectrum of 220 indicated the formation of the oxazolidinone ring. The 1H NMR
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spectrum of 220 showed the deshielding of the protons H4 and H5 compared to those in
compound 219. In compound 219 these protons resonated at  3.95 (1H, t, J = 4.8 Hz)
and  3.46 (1H, dd, J = 8.6, 4.8 Hz), respectively while in compound 220 these protons
resonated at  4.85 (1H, t, J = 7.4 Hz) and  4.57 - 4.40 (1H, m), respectively. These
changes in chemical shift clearly indicated the formation of the five-membered
oxazolidinone ring of 220. The NOESY correlation between H4 and H5 further
indicated that they were located on the same face of the oxazolidinone ring (Figure
4.4).

H1″

H4, H1′
H2‴
H1‴
H2′

H1″

H1‴′

H3′ H5

H3‴′

H2‴′

OH

H1′ H1″

H3″ OH
OH

H3″ OH
H3‴′

H1‴ H1‴′
H1‴′

H2‴′
H2‴ H1′
H4, H1′

H5
H4 H5

H3′

H2′
H1‴
H2‴

Figure 4.4 2D NOESY NMR spectrum (500 MHz, CDCl3) of compound 220

The

13

C NMR spectrum of 226 showed a resonance for the oxazepin-2-one carbonyl

group at . The sharp C=O stretching band at 1664 cm-1 in the IR spectrum
further supported the presence of the carbonyl group of compound 226. The 1H NMR
spectrum of 226 showed the deshielding of the protons H7 and H1′ that corresponded
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to H2 ( 4.03, 1H, s (br)) and H1′ ( 3.29 - 3.25, 1H, m), respectively in compound
219, to  4.53 - 4.50 (1H, m) and  4.83 - 4.76 (1H, m), respectively in 226. The
gHMBC correlations between C2 and H4 and C2 and H7 further supported the
formation of the seven-membered oxazepinone ring. The NOESY correlation between
H6 and H7 indicated that they were located on the same face of the oxazepinone ring
(Figure 4.5). The unexpected product 226 and the low yield of 220 lead to a second
synthetic plan (Schemes 4.4).

H7
H6

H5
H1′

H1‴′
H4

H7 H6

H6
H1‴′

H4
H5

H7

H1′

Figure 4.5 2D NOESY NMR spectrum (500 MHz, CDCl3) of 226

4.3 The second synthetic plan for hyacinthacine B4 11
The second synthetic plan started with N-Boc protection of compound 219 as the
N-Boc derivative 227. A ring-closing metathesis reaction of 227 would then provide the
cyclic alkene 228. Mesylation of compound 228 followed by N-Boc deprotection
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followed by base catalysed cyclization would give the pyrrolizidine 223. All other
synthetic steps after this cyclization reaction would remain the same as shown earlier in
Scheme 4.4.

Scheme 4.4 The second synthetic plan for the synthesis of hyacinthacine B4 11

4.3.1 The N-Boc protection of compound 219

N-Boc protection reactions were attempted by treatment of compound 219 with Boc
anhydride, triethylamine in methanol at rt for 1 d and Boc anhydride and DMAP in
acetonitrile with heating at reflux for 4 h but there was no sign of the expected N-Boc
product 227 by TLC analysis (Scheme 4.5).85 Instead there was just the spot of the
unreacted starting material 219. Moreover these results were confirmed by 1H NMR
analysis of the crude reaction mixtures after work up. This lack of reactivity is similar
to that found from the hindered secondary amine 155 in Chapter 2. We suggested that
the steric hindrance of the methyl substituent of the amino side chain of 227 makes this
compound unreactive to standard N-Boc protection conditions.
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Moreover, compound 219 was also treated with 9-fluorenylmethyl chloroformate
(FmocCl) in a mixture of tetrahydrofuran and sat. aqueous sodium carbonate at 0 oC for
3 h.101 However, there was also no sign of any new products (Scheme 4.5).

Scheme 4.5 The N-Boc and N-Fmoc protection of 219

4.4 The third synthetic plan for the synthesis of hyacinthacine B4 11
The third synthetic plan started with the mesylation-cyclization of compound 219
which should give the diene 230 (Scheme 4.6). The ring-closing metathesis of the diene
230 using Grubbs’ II ruthenium catalyst and titanium isopropoxide would then provide
the alkene 223. All other synthetic steps after the ring-closing metathesis would remain
the same as shown earlier in Schemes 4.1.

Scheme 4.6 The third synthetic plan for the synthesis of hyacinthacine B4 11
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4.4.1 The mesylation-cyclization of 219

The mesylation-cyclization of 219 using 1.0 mol equivalent of methanesulfonyl
chloride and triethylamine in CH2Cl2 at 0 oC for 0.5 h gave the mesylate 231 which was
indicated by TLC analysis (Scheme 4.7).100 The reaction mixture was then treated with
1.0 mol equivalent of triethylamine and heated at 40 oC for 10 h to give the desired
product 230 in 47% yield and the over mesylation product 232 in 15% yield.
Unfortunately, we were unable to unequivocally confirm the relative configuration of
the pyrrolidine ring of 230 from NOESY experiments. The 1H NMR spectrum of 232
showed a downfield resonance at 4.88 (1H, s) for H3 and also a 3H singlet resonance
at 2.87 for the mesylate group (OSO3CH3).

Scheme 4.7 The mesylation-cyclization of 219

4.4.2 The ring-closing metathesis of 230

For the ring-closing metathesis of compound 230, titanium isopropoxide was added to
the solution of 230 in CH2Cl2 to form a Ti-N complex before treatment with 10 mol%
Grubbs’ II ruthenium catalyst at 45 oC for 24 h (Scheme 4.8, Table 4.2).100 The result
of this reaction was the isolation of the undesired pyrrole 233 in 43% yield without the
isolation of the desired compound 223. This reaction was also performed using
Hoveyda Grubbs 2nd generation catalyst under an argon atmosphere in CH2Cl2 at 40 oC
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for 20 h and in toluene at 60 oC for 20 h. Both of these conditions just gave the
undesired pyrrole 233 in yields of 10% and 17%, respectively.

Scheme 4.8 The ring-closing metathesis of 230

Table 4.2 The reaction conditions for the ring-closing metathesis of 230
Entry
1
2
3

Reagents
10 mol% Grubbs II cat.,
0.2 eq. Ti(OiPr)4, under N2
10 mol% Hoveyda Grubbs II
cat., 1.0 eq. Ti(OiPr)4, under Ar
10 mol% Grubbs II cat.,
0.3 eq. Ti(OiPr)4, under Ar

Solvent

Temperature
(oC)

Time
(h)

Yield of
233

CH2Cl2

45

24

43%

CH2Cl2

40

20

10%

Toluene

60

20

17%

The HRESIMS indicated that the molecular formula of 233 was C23H25NO3 which
showed that the number of hydrogen atoms was two less than the desired product 223.
The 1H NMR spectrum of 233 showed a resonance for a methyl group attached to an
sp2 carbon at  2.11 (3H, s) and pyrrole type resonances at  5.97 (1H, s (br)) for H6
and  6.04 (1H, d, J = 2.9 Hz) for H7 (Figure 4.6). The

13

C NMR spectrum showed

signals for the pyrrole carbons C5, C6, C7 and C7a at  123.5, 111.5, 101.6 and, 136.7
respectively (Figure 4.7). The chemical shifts for C5 and C7a were identified from the
gHMBC spectrum from the correlations of C5 and H9, and C7a and H2, respectively.

Chapter 4 | 128

H9

H8

ArH
2 x OCH2 Ph H2

OH

H3

ArH

H7 H6

Figure 4.6 1H NMR spectrum (500 MHz, CDCl3) of 233
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Figure 4.7 13C NMR spectrum (125 MHz, CDCl3) of 233

We suggest that the mechanism for the formation of 233 involves elimination of H7a
from the titanium complex B, that is formed upon the ring-closing metathesis reaction
of complex A (Scheme 4.9). This provides the unsaturated imminium ion C which can
aromatize to the pyrrole 233 by loss of a proton from C5. Alternatively, the conversion
of the dihydropyrrole to the pyrrole derivative could be catalysed by traces of oxygen
in the reaction vessel.
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Scheme 4.9 The proposed mechanism for the formation of 233

4.5 The fourth synthetic plan for the synthesis of hyacinthacine B4 11
The fourth synthetic plan started with the oxazepinone 226 that was formed as an
unexpected product from the first synthetic plan (Scheme 4.3). The ring-closing
metathesis of 226 would give the alkene 234. The free hydroxy group of 234 would be
protected as the O-benzyl ether 235. The hydroboration of 235 follow by oxidation
should provide the alcohol 236 which could be converted to the epimeric alcohol 237
by oxidation to the ketone and then stereoselective reduction. The resulting alcohol
could then be protected as its O-benzyl ether 237. Hydrolysis of the oxazepinone
moiety of 237 would give the amino alcohol 238 which would be treated with
methanesulfonyl chloride to provide the pyrrolizidine 239. Finally, the benzyl ether
groups of 239 will be deprotected to provide the final product, hyacithacine B4 11.
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Scheme 4.10 The fourth synthetic plan for the synthesis of hyacinthacine B4 11

4.5.1 The preparation of oxazepinone 226

The preparation of oxazepinone 226 from 219 was attempted under several different
reaction conditions with the aim of improving the yield of 226 (Scheme 4.11 and Table
4.3). The use of 1,1′-carbonyldiimidazole,102 instead of triphosgene in CH2Cl2 at rt for
2.5

h

gave

only

the

oxazolidinone

220

in

11%

yield.

The

use

of

triphosgene/triethylamine in CH2Cl2 at rt for 1 h gave the oxazolidinone 220 in 10%
yield and the oxazepinone 226 in 52% while the use of triphosgene in tetrahydrofuran
at rt for 24 h provided the oxazolidinone 220 in 53% yield and the oxazepinone 226 in
19% yield. While these latter two results indicated that 226 was formed initially
(kinetic product) and then rearranged slowly to 220 (thermodynamic product), time
constraints did not allow us to study this possibility.
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Scheme 4.11 Preparation of the oxazolidinone 220 and the oxazepinone 226

Table 4.3 The reaction conditions for the preparation of the oxazolidinone 220 and the
oxazepinone 226

Entry
1
2
3

Reagents
1.5 eq. 1,1′
carbonyldiimidazole
0.5 eq. triphosgene,
1.5 eq. Et3N
0.33 eq. triphosgene,
2.0 eq. Et3N

Temperature

Time

Yield

Yield

(oC)

(h)

of 220

of 226

CH2Cl2

rt (19)

2.5

11%

-

CH2Cl2

rt (18)

1

10%

52%

THF

rt (18)

24

53%

19%

Solvent

4.5.2 The ring-closing metathesis of 226
The ring-closing metathesis of 226 using Grubbs’ II ruthenium catalyst in CH2Cl2 at 45
o

C provided the alkene 234 in 77% yield (Scheme 4.12). The 1H NMR spectrum of 234

showed two characteristic cis-alkene resonances. One at  5.79 (1H, d, J = 6.3 Hz) for
H7 and the other at  5.87 (1H, d, J = 6.3 Hz) for H6.

Scheme 4.12 The ring-closing metathesis of 226
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4.5.3 The hydroboration of compound 234

The hydroboration of compound 234 was attempted, without the protection of the free
hydroxy at C5, to study the regioselectivity and stereoselectivity of this reaction
(Scheme 4.13). Compound 234 was treated with borane-THF complex (10 mol. equiv.)
in THF at rt for 3 h followed by oxidation using sodium perborate tetrahydrate for
2 h.103 This resulted in the isolation of the alcohol 240 in 8% yield and the two
reductive ring-cleavage products, compound 241 in 8% yield and compound 242 in 5%
yield. The latter two products resulted from reduction of the oxazepinone ring as well
as hydroboration of the alkene group of 234.

Scheme 4.13 The hydroboration and oxidation of 234

The gCOSY, TOCSY and gHSQC experiments of 240 indicated that the hydroxy group
was located at C6 of 240. The 1H NMR spectrum of 240 showed the methylene
resonances of H7 at  2.03 - 1.95 (1H, m) and  1.90 (1H, dd, J = 11.7, 6.0 Hz). The
NOESY correlations between H3 and H4 and H4 and H5a of 240 indicated that these
protons were located on the same face of the oxazepinone ring (Figure 4.8). The lack of
a NOESY correlation between H5a and H6 suggested that the hydroxy group at C6 had
the -configuration.
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Figure 4.8 2D NOESY spectrum (500 MHz, CDCl3) of compound 240

The high resolution mass spectrum of 241 indicated the molecular fomula as
C24H33NO5. The 1H NMR spectrum of 241 showed the chemical shift of H3 at  4.58 4.51 (1H, m) and two resonances for H4 at  1.98 - 1.92 (1H, m) and at  1.91 - 1.82
(1H, m) which indicated the formation of hydroxy group at C3 (Figure 4.9). The
observed extra methyl protons in the 1H NMR spectrum of 241 at  2.21 (3H, s), the
observed extra methyl group for C1′ in the 13C NMR spectrum of 241 at  37.0 and the
disappearance of the 13C NMR signal of the carbonyl group of the oxazepinone ring at

 153.8 indicated that reduction of the oxazepinone ring had occurred (Figure 4.10).
The NOESY spectrum of 241 showed no correlation between H2 and H3 which
suggested the -configuration of the C3 hydroxy group (Figure 4.11).

Chapter 4 | 134

H1‴

ArH
H1′
H3

2 x OCH2 Ph

H2″, H4″ A

H3″

H4″ B
H1″

H5

H2

OH
OH
OH

H4
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Figure 4.11 2D NOESY spectrum (500 Mz, CDCl3) of compound 241

The high resolution mass spectrum of 242 indicated that this molecule had the same
molecular formula as 241, that is C24H33NO5. The observed extra methyl proton
resonances in the 1H NMR spectrum at  2.21 (3H, s), the observed extra methyl group
resonance in the

C NMR spectrum at  37.7 and the disappearance of the

13

13

C NMR

signal for the carbonyl group of the oxazepinone ring at  153.8 indicated that
reduction of the oxazepinone ring had occurred (Figures 4.12). The 1H NMR resonance
of H4 at  3.93 (1H, s (br)) and the two resonances for H3 at  2.62 - 2.52 (1H, m) and

 1.70 - 1.59 (1H, m) indicated the location of the hydroxy group at C4 (Figure 4.13).
The NOESY spectrum of 242 showed no correlation between H4 and H5 which
suggested the -configuration of the hydroxy group at C4 (Figure 4.14).
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Figure 4.14 2D NOESY spectrum (500 MHz, CDCl3) of compound 242

4.5.4 The O-benzylation of compound 234

The oxazepinone 234 was protected as the O-benzyl ether 235 by treatment with benzyl
bromide in the presence of NaH and TBAI at rt for 18 h to give the O-benzyl ether 235
in 33% yield (unoptimized) (Scheme 4.14). The 1H NMR spectrum of 235 was similar
to that of 234 except for the deshielding of the H4 resonance from  3.68 (dd, J = 9.1,
5.0 Hz) in 234 to  4.55 - 4.49 (1H, m) in 235. The 1H NMR signal for H5a in 25 was
at higher field, at  3.96 (1H, s (br)), than that of 234 which was observed at  4.30
(1H, d, J = 9.1 Hz). The identification of this product was also confirmed by HRMS
which indicated the molecular fomula as C31H33NO5.
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Scheme 4.14 The O-benzylation of 234

Because of time constraints no further synthetic studies on compound 235 were
attempted. However, we have successfully executed the first four steps in the proposed
synthesis of 11 as outlined in Scheme 4.10. In principle, 235 can be converted to 11 in
another eight synthetic steps (Schemes 4.10 and 4.15). Future work will require an
examination of the hydroboration of 235 and the optimization of the reaction conditions
to prevent reduction of the oxazepinone ring.

Scheme 4.15 A summary of the progress made towards the synthesis of hyacinthacine
B4 11
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Chapter 5
Conclusions
In conclusion, we have successfully achieved the two main aims of this PhD project.
One aim was to synthesize 5-epi-hyacinthacine B5 174 and to compare its NMR
spectroscopic data with those of natural hyacinthacine B7. This synthesis would assist
in the structural elucidation of hyacinthacine B7, the structure of which was incorrectly
assigned. The second aim of this project was to synthesize hyacinthacine B5 12 in order
confirm its structure and absolute configuration.

In Chapter 2, the preparation of the 1,2-anti amino alcohol 155, using the Petasis
boronic acid Mannich reaction, was reported using a modification of the previous
synthetic method. The new synthetic route, involving the Sharpless ADH of the
terminal alkene 151, followed by the regioselective oxidation of the resulting diol 190,
and then the Petasis boronic acid Mannich reaction gave 155 in 72% over 3 steps. This
was a significant improvement over the previous method that proceeded in 24% overall
yield over 3 steps.

Our attempts to invert the configuration of the pro-C7 carbon of the 1,2-anti amino
alcohol 155 by cyclization of its N-Boc, O-mesylate derivative 176 to an oxazolidinone
were unsuccessful due to the steric hindrance caused by the N--methyl substituent
which made N-Boc protection difficult. In one attempt at N-Boc protection, using
DMAP as a catalyst, the undesired oxazolidinone product 156 formed, however the
pro-C7 carbon was not inverted. In contrast, a model study using a 1,2-anti amino
alcohol substrate 192, that lacked the problematic -methyl substituent, ready formed
its N-Boc protected derivative which was used to prepare the desired oxazolidinone
194, via cyclization of its O-mesylated derivative 193, with inversion of configuration.

Consequently our synthetic route was changed to follow our previous work on the total
synthesis of hyacinthacine B3 with the aim of inverting the stereochemistry at pro-C7
after the pyrrolizidine ring was formed.
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In this new route, 5-epi-hyacinthacin B5 was synthesized starting with (S)-4-penten-2-ol
118 which was protected as the O-PMB ether 151 (91% yield) (Scheme 5.1). The
Sharpless ADH reaction of the alkene 151 gave the diol 190 (99% yield, dr = 4:1)
which upon regioselective oxidation of the primary alcohol gave the hemiacetal
intermediate 153 which was directly treated with the allyl amine 154 and -styrenyl
boronic acid in a Petasis boronic acid Mannich reaction to give the 1,2-anti amino
alcohol 155 (73% yield, two steps). Both the amino and the hydroxyl group of 155
were protected to form the oxazolidinone 156 (66% yield) by treatment with
triphosgene/triethylamine. A-ring formation via a ring-closing metathesis reaction of
156 using Grubbs’ II ruthenium catalyst provided the bicyclic alkene 157 (90% yield).
DH of alkene 157 gave the syn-diol 158 (96% yield) which was protected as the bis
benzyl ether 159 (92% yield). The O-PMB ether of 159 was then deprotected to form
the free alcohol 160 (84% yield) which was converted, via an inversion reaction at C2′
from S to R, via the Mitsunobu reaction to the p-nitrobenzoate 196 (85% yield). Base
hydrolysis of 196 gave the amino diol 172 (97% yield). Regioselective O-mesylationcyclization of 172 affored the B-ring cyclised product 173 (77% yield) with a
-hydroxy group at C7. Inversion of the configuration at this stereocentre was achieved
by oxidation to the ketone 197 (63% yield) followed by the stereoselective reduction to
the alcohol 184 (70% yield). The target product 174 (84% yield) was obtained after
removed of the O-benzyl protecting groups by hydrogenolysis follow by neutralization
and purification by basic ion-exchange chromatography. The total synthesis of 5-epihyacinthacine B5 174 was accomplished in 15 steps with 5.58% overall yields form
commercially available (S)-4-pentan-2-ol 118. The structure of 5-epi-hyacinthacine B5
174 was established from 1H and

13

C NMR analysis using gCOSY, gHSQC and

gHMBC experiments and IR and high resolution mass spectrometry. The 1D and 2D
NOESY correlatons of 174 were used to identified the relative, and thus the absolute,
configuration of all stereogenic centres. After we had confirmed the structure and
absolute configuration of 5-epi-hyacinthacine B5 174, the

1

H and

13

C NMR

spectroscopic data of 5-epi-hyacinthacine B5 174 were compared to those of natural
hyacinthacine B7. The 1H and 13C NMR data were markedly different. In addition, the
specific rotation of the natural product ([] D - 4.4 o, c 0.20, H2O)33 and synthetic
o
compound 174 ([] 25
D + 18.5 , c 0.14, H2O) were different in magnitude and opposite
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in sign. This synthesis confirmed that the structure and absolute configuration of
hyacinthacine B7 did not match with that of 5-epi-hyacinthacine B5 174.

Scheme 5.1 A summary of the total synthesis of 5-epi-hyacinthacine B5 174
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In Chapter 3, the total synthesis of hyacinthacine B5 is described starting with the
bicyclic oxazolidinone intermediate 160 from Chapter 2 (Scheme 5.2). The hydrolysis
of the oxazolidinone ring of 160 provided the amino diol 161 (96% yield). The B-ring
of 162 was realized via a one pot mesylation-cyclization of 161 to give the
pyrrolizidine 162 (100% yield). The stereoinversion of C7 of the cyclic alcohol 162
was planned to be achieved by oxidation to the ketone 199 follow by a stereoselective
reduction to give the bicyclic alcohol 200. Unfortunately, the oxidation of 162 under
Swern oxidation reaction conditions led to the unexpected carboxylic acid 201 and a
complex mixture containing at least 3 ketone products. This acid was thought to arise
from a fragmentation reaction of an N-S(+)Me2 intermediate, while one of the
unexpected ketones formed from an epimerization process. The Swern oxidation was
repeated followed by reduction of the crude reaction mixture with L-selectride.
Purification gave four different products which were, the target compound 200 (4%
yield), the unexpected alcohol 202 (7% yield), the unexpected ketone 203 (7% yield)
and the lactam 204 (8% yield). The ketone 203 upon stereoselective reduction provided
the alcohol 206 (58% yield). Finally, the benzyl ether groups of 200, 202 and 206 were
then cleaved by hydrogenolysis to provide the final products, hyacinthacine B5 12,
compound 207 and hyacinthacine B4 11 in 21%, 100% and 100% yields, respectively.
The total synthesis of hyacinthacine B5 12 was accomplished in 14 steps and in 2.21%
overall yield form commercially available (S)-4-pentan-2-ol 118. This total synthesis
also produced hyacinthacine B4 in 15 synthetic steps and in 1.11% overall yield and 7aepi-hyacinthacine B3 207 in 14 synthetic steps and in 2.03% overall yield as side
products. The structures of these compounds were established from 1H and

13

C NMR

spectroscopic analysis using gCOSY, gHSQC and gHMBC experiments and IR and
high resolution mass spectrometry. The 1D and 2D NOESY correlatons were used to
identified the relative configuration of all stereogenic centres. The 1H NMR and

13

C

NMR spectroscopic data of 12 and 11 were compared to those of natural hyacinthacine
B5 and B4, respectively. The 1H and

13

C NMR chemical shifts of synthetic 12 and 11

were in very close agreement with those of natural hyacinthacine B5 and B4,
respectively, as well as their specific rotation results. These comparisons indicated that
the proposed structure and absolute configuration of hyacinthacine B5 and B4, that were
published, were the correct ones.
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Scheme 5.2 A summary of the total synthesis of hyacinthacine B4 11, B5 12 and 7a-epihyacinthacine B3 207

After the proposed structure and absolute configuration of hyacinthacine B5 and B4
were confirmed, a study of the relationship between the configuration of the methyl
group at C5 and the hydroxy group at C7 on the

13

C NMR chemical shifts of natural

hyachithacine B3,27 natural hyachithacine B5,29 synthetic 5-epi-hyacinthacine B5,
synthetic hyacinthacine B760 and natural hyacinthacine B733 was made. This comparison
showed that the configuration at C5 affected the

13

C NMR chemical shifts of C3, C5

and C9. While the stereochemistry at C7 affected the

13

C NMR chemical shift of C7

and C7a. Using this information we suggested that natural hyacinthacine B7 should
have an -methyl group at C5 and an -hydroxy group at C7, similar to that of natural
hyacinthacine B5. From the above information and from a comparison of their NMR
spectroscopic data we concluded that natural hyacinthacine B7 is most likely to be
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hyacinthacine B5, however without access to the authentic samples we could not make
an unequivocal conclusion.

In Chapter 4, an attempted synthesis of hyacinthacine B4 11 was made, starting with the
boronic acid Mannich reaction of 3,5-di-O-benzyl-,-L-xylofuranose 217. In the first
attempted synthetic route N-Boc protection of the Petasis product 219 failed. In the
second synthetic route the attempted ring-closing metathesis reaction of the diene 230
resulted in the undesired pyrole 233.

In the third attempted synthetic route (Scheme 5.3), attempts to prepare the
oxazolidinone derivative of 219 by treatment with triphosgene gave the undesired
oxazepinone 226 (52% yield) as the major product. A ring-closing metathesis reaction
of this compound provided the alkene 234 (77% yield). The hydroboration of
compound 234 followed by oxidation provided the desired alcohol 240 (8% yield).
Because of the excessive amount of reducing agent this reaction also gave two other
products that resulted from reduction of the oxazepinone ring as well as hydroboration
of the alkene group of 234. The free hydroxy group of 234 was protected as the
O-benzyl ether 235 (33% yield). In principle 235 can be converted to 11 in another
eight synthetic steps.

Scheme 5.3 A summary of the synthesis of hyacinthacine B4 11
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Chapter 6
Experimental Section
6.1 General Experimental

6.1.1 General reaction conditions

In general, all reactions were performed under anhydrous conditions under a nitrogen
atmosphere in a single necked round bottom flask sealed with a suber seal and
connected to a nitrogen manifold with a gas bubbler. Reactions were monitored by
thin-layer chromatography (TLC). The solvents were purchased as Analytical Reagent
(AR) grade. Dry THF was freshly prepared by distillation (the THF was taken from a
dry solvent dispenser) from sodium wire under a nitrogen atmosphere, using
benzophenone as an indicator. Anhydrous diethyl ether, dichloromethane and toluene
were taken from a dry solvent dispenser. Anhydrous methanol and dimethyl sulfoxide
were purchased from Aldrich. Petrol refers to the hydrocarbon fraction of b.p. 40-60
C.
Where ‘dried’ is specified, this refers to the drying of the organic extract over
anhydrous magnesium sulfate or anhydrous potassium carbonate followed by filtration.
Where ‘in vacuo’ is specified, this refers to the evaporation of the organic solvent under
reduced pressure using a rotary evaporator. The pure compounds were then dried under
the high vacumm for at least 0.5 h before the calculation of their yields.

6.1.2 Chromatography

Aluminium backed Merck F254 sorbent silica gel was used for thin-layer
chromatography (TLC) analysis. Compounds were detected at 264 nm under an
ultraviolet lamp, for UV active compounds, and ceric ammonium molybdate dipping
solution followed by development with 1400 Watt heat gun. The ceric ammonium
molybdate stain solution was prepared by the slow addition of concentrated sulfuric
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acid (50 mL) to a solution of 50 g ammonium molybdate ((NH4)6MoO24) and 2 g
cesium(IV) sulfate (Ce(SO4)2) in 950 mL of distilled water.
Flash column chromatography was performed using Merck Kieselgel 60 PF254. Basic
ion-exchange chromatography was performed using Amberlyst A-26 resin. The column
was activated with 15% aqueous ammonia solution (v/v) for 15 min followed by
washing with distilled water until the pH of the eluent was close to 7, as indicated by
universal indicator pH paper. The compounds were applied to the column as their HCl
salts dissolved in water and eluted with water until the pure compound was eluted as
indicated by TLC analysis.

6.1.3 Polarimetry
Optical rotations were measured at 25 oC in a 10 mm length cell (2.0 mL), on a JASCO
2000 Series polarimeter. An average of ten measurements was used to calculate the
specific rotation.

6.1.4 Mass spectrometry

A Micromass Waters Platform LCZ (single quadrupole, MeOH as solvent) was used to
obtain low resolution mass spectra (LRESIMS). A Micromass Waters Q-ToF Ultima
(quadrupole time-of-flight) and a Waters XEVO (quadrupole time-of-flight) mass
spectrometers were used for acquiring high resolution mass spectra (HRESIMS and
HRASAPMS, respectively).

6.1.5 Nuclear magnetic resonance spectroscopy

A 500 MHz Varian Unity Inova, 500 MHz Varian Permium Shield (VNMRS PS 54),
and 300 MHz Varian Mercury spectrometer were used for obtaining the NMR spectral
data. 1H (500 or 300 MHz) and 13C NMR (125 or 75 MHz) spectra were recorded in
deuterochloroform (CDCl3), deuterium oxide (D2O) or deuterated methanol (CD3OD)
solution. All signals which were recorded in CDCl3 were relative to the
tetramethylsilane (TMS) signal for 1H NMR and the CDCl3 signal for

13

C NMR,
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referenced at 0.00 ppm and 77.16 ppm, respectively. All signals which were recorded
in CD3OD were relative to the CD2HOD signal for 1H NMR and the CD3OD for

13

C

NMR, referenced at 3.31 ppm and 49.00 ppm, respectively. All signals which were
recorded in D2O were relative to the D2O signal for 1H NMR, referenced at 4.49 ppm.
For

13

some

C NMR the referencing of peaks is relative to internal MeOH (49.50 ppm). In
cases

our

13

C

NMR

spectra

were

referenced

to

sodium

3-(trimethylsilyl)propionate (TSP) at  -2.19 in D2O. In order to compare our 13C NMR
data recorded in D2O with those of the literature which were run in D2O and referenced
to TSP at  -2.19 we have added 2.19 ppm to our observed

13

C NMR chemical shifts.

NMR assignments were based upon gCOSY, APT, gHSQC, gHMBC and NOESY
experiments. In some cases,

13

C NMR signals that were absent in the standard

13

C

NMR spectrum were identified using gHSQC and gHMBC experiments.

6.1.6 Infrared spectroscopy

A SHIMADZU MIRacle 10 IRAffinity 1 was used for obtaining IR spectral data on
neat samples.

6.1.7 Naming of pyrrolizidines

Pyrrolizidine compounds are named using systematic nomenclature. The NMR
assignments of the pyrrolizidine compounds in this thesis are based on the numbering
system of the hyacinthacine alkaloids and not the systematic name.

6.1.8 Melting points

Melting points were obtained using a Gallenkamp MF-370 capillary tube melting point
apparatus and are uncorrected.
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6.2 Experimental for Chapter 2

(-)-2-(R)-N-Phthalimido-3-buten-1-ol (186)78: A mixture of -allylpalladium chloride
dimer (36 mg, 0.099 mmol), (1R, 2R)-(+)-NAPHTHYL (0.236 g, 0.298 mmol),
phthalimide (3.653 g, 24.830 mmol), sodium carbonate (0.172 g, 1.240 mmol) and
CH2Cl2 (100 mL) under a nitrogen atmosphere was stirred at rt (22 oC) for 10 min.78
Butadiene monoepoxide (2.00 ml, 24.830 mmol) was then slowly added and the
solution was stirred at rt for 20 h. The resulting mixture was concentrated in vacuo and
purified by flash column chromatography (increasing polarity from 0:100 to 50:50 of
EtOAc/petrol) to give the title compound as a white solid (5.221 g, 97%). The
spectroscopic data of this compound matched with those in the literature.78

Rf 0.25 (30:70 EtOAc/petrol).
[] 25
- 71.7 (c 0.92, CH2Cl2). [Lit.78 [] D - 72.2 (c 2.20, CH2Cl2)]
D
IR max (cm-1): 3532, 2940, 1766, 1704, 1466, 1388, 1330, 1164, 1093, 1048, 993, 945,
885, 719, 679.

H (500 MHz, CDCl3) 7.84 - 7.79 (2H, m, ArH), 7.74 - 7.67 (2H, m, ArH), 6.20 - 6.07
(1H, m, H3), 5.31 - 5.23 (2H, m, H4), 4.93 - 4.91 (1H, m, H2), 4.20 - 4.10 (1H, m,
H1A), 3.98 - 3.90 (1H, m, H1B).

C (125 MHz, CDCl3) 168.6 (2 x C=O), 134.2 (2 x ArCH), 132.1 (C3), 131.8 (2 x
ArC), 123.4 (2 x ArCH), 118.9 (C4), 62.7 (C1), 56.0 (C2).
ESIMS m/z 218 (100%) [M+H]+.
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6.2.1 General method for O-benzylation78

(-)-2-(R)-N-Phthalimido-3-buten-1-yl benzyl ether (187)78: A solution of compound
186 (4.898 g, 22.569 mmol) and tetrabutylammonium iodide (TBAI) (0.834 g, 2.257
mmol) in anhydrous THF (100 mL) was stirred at rt (18 oC) for 15 min under a nitrogen
atmosphere.78 Benzyl bromide (8.042 mL, 67.707 mmol) was added and then the
solution was cooled to 0 oC. Sodium hydride (60% dispersion in mineral oil, 1.354 g,
0.812 g NaH, 33.850 mmol) was slowly added and the reaction mixture was allowed to
warm to rt and was stirred for 18 h. Quenching with H2O (50 mL) gave a cloudy
mixture, which was extracted with CH2Cl2 (3 x 100 mL). The combined organic layers
were dried (MgSO4) and concentrated in vacuo to give a light yellow solid. Purification
by flash column chromatography (increasing polarity from 0:100 to 50:50 of
EtOAc/petrol) gave the title compound (5.657 g, 80%) as a white solid. The
spectroscopic data of this compound matched with those in the literature.78

Rf 0.54 (30:70 EtOAc/petrol).
[] 25
- 8.2 (c 1.05, CH2Cl2). [Lit.78 [] D - 9.0 (c 2.31, CH2Cl2)].
D
IR max (cm-1): 2920, 2863, 1772, 1707, 1462, 1382, 1095, 936, 874, 719.

H (500 MHz, CDCl3) 7.81 (2H, dt, J = 6.8, 3.5 Hz, ArH), 7.68 (2H, dd, J = 5.3, 3.1
Hz, ArH), 7.27 - 7.19 (5H, m, ArH), 6.16 (1H, ddd, J = 17.4, 10.3, 7.3 Hz, H3), 5.31
(1H, d, J = 17.3 Hz, H4trans), 5.25 (1H, d, J = 10.3 Hz, H4cis), 5.08 (1H, ddd, J = 9.9,
7.3, 5.7 Hz, H2), 4.56 (1H, d, J = 12.1 Hz, OCHHPh), 4.48 (1H, d, J = 12.1 Hz,
OCHHPh), 4.12 (1H, t, J = 9.9 Hz, H1A), 3.76 (1H, dd, J = 9.9, 5.7 Hz, H1B).
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C (75 MHz, CDCl3) 168.1 (2 x C=O), 137.9 (ArC), 134.0 (2 x ArCH), 132.3 (C3),
131.9 (2 x ArCH), 128.3 (ArCH), 127.6 (2 x ArCH), 123.3 (2 x ArCH), 119.1 (C4),
72.8 (OCH2Ph), 70.0 (C1), 53.2 (C2).
ESIMS m/z 330 (100%) [M+Na]+.

(2S)-1-(Benzyloxy)but-3-en-2-amine (154)79: A solution of compound 187 (5.344 g,
17.406 mmol) and ethylenediamine (4.646 mL, 69.624 mmol) in ethanol (100 mL) was
stirred and heated at reflux for 19 h. The reaction mixture was cooled to rt and then
filtered through a pad of cotton wood. The filtrate was concentrated in vacuo to give a
yellow oil which was treated with 6N hydrochloric acid (90 mL) and then all volatiles
were removed in vacuo. The residue was dissolve in methanol (100 mL), filtered and
then concentrated in vacuo to give the light yellow solid which was dissolved in 3M
sodium hydroxide solution (90 mL) and then extracted with CH2CH2 (3 x 70 mL). The
combined layers was dried (MgSO4) and concentrated in vacuo to give compound 154
(3.048 g, 99%) as a yellow oil.

Rf 0.10 (5:95 MeOH/CH2Cl2).
[] 25
- 21.2 (c 0.46, CHCl3). [Lit.79 [] D - 16.5 (c 1.2, CHCl3)].
D
IR max (cm-1): 3260, 3065, 2859, 1639, 1543, 1361, 1094, 992, 920, 737, 696.

H (500 MHz, CDCl3) 7.38 - 7.24 (5H, m, ArH), 5.83 (1H, ddd, J = 16.8, 10.4, 6.1 Hz,
H3), 5.23 (1H, d, J = 17.0 Hz, H4trans), 5.11 (1 H, d, J = 10.4 Hz, H4cis), 4.54 (3H, s,
OCH2Ph), 3.61 (1H, dt, J = 7.6, 6.1 Hz, H2), 3.50 (1H, dd, J = 9.1, 4.1 Hz, H1A), 3.33 3.27 (1H, m, Hz, H1B).
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C (125 MHz, CDCl3) 139.3 (C3), 138.3 (ArC), 128.5 (2 x ArCH), 127.8 (3 x ArCH),
115.3 (C4), 75.2 (C1), 73.4 (OCH2Ph), 54.0 (C2).
ESIMS m/z 178 (100%) [M+H]+.

(S)-1-Methoxy-4-((pent-4-en-2-yloxy)methyl)benzene (151)60: A solution of (S)-4penten-2-ol 118 (1.380 g, 16.022 mmol), 4-methoxybenzyl chloride (4.350 mL, 32.044
mmol) and tetrabutylammonium iodide (0.592 g, 1.602 mmol) in anhydrous THF (50
mL) under a nitrogen atmosphere was cooled to 0 oC.60 Sodium hydride (60%
dispersion in mineral oil, 0.961 g, 0.570 g NaH, 24.033 mmol) was then added to the
reaction mixture which was allowed to warm to rt (24 oC) and then stirred for 24 h.
Water (80 mL) was then added to give a cloudy mixture which was extracted with
diethyl ether (3 x 60 mL). The combined ethereal extracts were dried (MgSO4) and
concentrated in vacuo to give a brown oil which was purify by flash column
chromatography (increasing polarity from 0:100 to 2:99 of Et2O/petrol) to give the title
compound (3.004 g, 91%) as a colorless oil.

Rf 0.68 (10:90 EtOAc/petrol).
[] 25
+ 16.8 (c 0.09, CHCl3).
D
IR max (cm-1): 3074, 2971, 2904, 1613, 1512, 1245, 1175, 1085, 1035, 913, 817.

H (500 MHz, CDCl3) 7.26 (2H, d, J = 7.4 Hz, ArH), 6.86 (2H, d, J = 7.9 Hz, ArH),
5.86 - 5.79 (1H, m, H4), 5.07 (1H, d, J = 17.8 Hz, H5trans), 5.04 (1H, d, J = 10.5 Hz,
H5cis), 4.48 (1H, d, J = 11.4 Hz, OCHHPMP), 4.43 (1 H, d, J = 11.4 Hz, OCHHPMP),
3.78 (3H, s, OCH3), 3.58 - 3.56 (1H, m, H2), 2.36 (1H, dd, J = 13.0, 6.3 Hz, H3A), 2.25
- 2.17 (1H, m, H3B), 1.18 (3H, d, J = 5.8 Hz, H1).
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C (75 MHz, CDCl3) 159.1 (ArC), 135.2 (C4), 131.1 (ArC), 129.2 (2 x ArCH), 116.9
(C5), 113.8 (2 x ArCH), 74.2 (C2), 70.1 (OCH2PMP), 55.4 (OCH3), 41.0 (C3), 19.6
(C1).
ESIMS m/z 229 (100%) [M+Na]+.

6.2.2 General method for olefin cross-metathesis using Grubbs’ II ruthenium
catalyst60

(S,E)-1-Methoxy-4-((5-(phenylsulfonyl)pent-4-en-2-yloxy)methyl)benzene (152)60:
Anhydrous CH2Cl2 (7 mL) was added to a mixture of compound 151 (0.447 g, 2.170
mmol) and phenyl vinyl sulfone (1.095 g, 6.510 mmol) under a nitrogen atmosphere
followed by Grubbs’ II ruthenium catalyst (92 mg, 0.108 mmol).60 The reaction
mixture was heated at reflux for 29 h, cooled to rt and then concentrated in vacuo to
give a black semi-solid. Purification by flash column chromatography with increasing
polarity from 0:0:100 to 1:2:5 of Et2O/CH2Cl2/petrol as eluent gave the title compound
(0.487 g, 65%) as a yellow oil. The spectroscopic data of this compound matched with
those reported in the literature.60

Rf 0.22 (1:5:2 Et2O/CH2Cl2/petrol).
[] 25
- 11.2 (c 0.96, CHCl3). [Lit.60 [] 25
- 6.7 (c 2.90, CHCl3)].
D
D
IR max (cm-1): 2969, 2866, 1613, 1512, 1448, 1303, 1245, 1177, 1142, 1082, 1032,
971, 813, 750, 714, 689.

H (500 MHz, CDCl3) 7.85 (2H, d, J = 8.2 Hz, ArH), 7.58 (1H, t, J = 7.3 Hz, ArH),
7.49 (2H, t, J = 7.6 Hz, ArH), 7.18 (2H, d, J = 8.4 Hz, ArH), 7.00 (1H, dt, J = 14.7, 7.2
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Hz, H4), 6.84 (2H, d, J = 8.2 Hz, ArH), 6.36 (1H, d, J = 14.7 Hz, H5), 4.46 (1H, d, J =
11.3 Hz, OCHHPMP), 4.33 (1H, d, J = 11.2 Hz, OCHHPMP), 3.77 (3H, s, OCH3), 3.68
- 3.61 (1H, m, H2), 2.47 - 2.34 (2H, m, H3), 1.18 (3H, d, J = 6.1 Hz, H1).

C (125 MHz, CDCl3) 159.1 (ArC), 143.6 (C4), 140.6 (ArC), 133.2 (ArC), 132.1 (C5),
130.2 (ArCH), 129.2 (4 x ArCH), 127.5 (2 x ArCH), 113.8 (2 x ArCH), 72.6 (C2), 70.1
(OCH2PMP), 55.2 (OCH3), 38.5 (C3), 19.6 (C1).
ESIMS m/z 369 (100%) [M+Na]+.

6.2.3 General method for Sharpless asymmetric dihydroxylation using DHQDIND60
A solution of 152 (0.358 g, 1.030 mmol) in tert-butanol (5 mL) was slowly added
dropwise to a solution of potassium ferric cyanide (1.017 g, 3.090 mmol), potassium
carbonate (0.427 g, 3.090 mmol), methanesulfonamide (98 mg, 1.030 mmol),
potassium osmate dihydrate (4 mg, 0.010 mmol) and DHQD-IND (5 mg, 0.010 mmol)
in H2O (5 mL) at rt (22 oC).60 The reaction mixture was stirred for 3 days. The reaction
was quenched by adding sodium sulfite (0.389 g, 3.090 mmol) and stirred for 30 min.
The reaction mixture was extracted with EtOAc (3 x 60 mL), dried (MgSO4), and
concentrated in vacuo to give a white solid which was used unpurified in the
subsequent Petasis reaction.

6.2.4 General method for the Petasis reaction60
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(3S,4R,6S,E)-3-((S)-1-(Benzyloxy)but-3-en-2-ylamino)-6-(4-methoxybenzyloxy)-1phenylhept-1-en-4-ol (155)60: A solution of 154 (0.146 g, 0.824 mmol) in anhydrous
CH2Cl2 (0.5 mL) was added to a solution of the above crude Sharpless ADH product
and (E)-2-phenylvinylboronic acid (0.122 g, 0.824 mmol) in 1:9 1,1,1,3,3,3hexafluoroisopropanol/CH2Cl2 (4 mL) under a nitrogen atmosphere.60 The reaction
mixture was stirred at rt (32 oC) for 2 d, diluted with EtOAc (50 mL) and washed with
0.5 M sodium hydroxide solution (3 x 50 mL). The organic layer was dried (MgSO4)
and concentrated in vacuo to give a dark brown oil. Purification by flash column
chromatography (0:100 to 40:60 EtOAc/CH2Cl2 as eluent) gave the title compound
(0.192 g, 37%, for the 2 steps) as a brown oil. The spectroscopic data of this compound
matched with those in the literature.60

Rf 0.45 (5:95 MeOH/CH2Cl2).
60
[] 25
[] 24
D + 11.9 (c 0.56, CHCl3). [Lit.
D + 18.2 (c 1.00, CHCl3)].

IR max (cm-1): 3438, 3066, 3027, 2905, 2860, 1648, 1611, 1511, 1452, 1245, 1076,
1035, 975, 925, 818, 746, 696.

H (500 MHz, CDCl3): 7.36 - 7.19 (12H, m, ArH), 6.8 (2H, d, J = 8.3, Hz, ArH), 6.43
(1H, d, J = 16.1 Hz, H1), 6.08 (1H, dd, J = 16.1, 8.3 Hz, H2), 5.63 - 5.56 (1H, m, H2′),
5.21 (1H, d, J = 17.1 Hz, H3′trans), 5.17 (1H, d, J = 10.2 Hz, H3′cis), 4.51 (1H, d, , J =
11.2 Hz, OCH2PMP), 4.49 (2H, s, OCH2Ph), 4.37 (1H, d, J = 11.2 Hz, OCH2PMP),
4.02 (1H, s (br), H4), 3.84 - 3.81 (1H, m, H6), 3.75 (3H, s, OCH3), 3.49 - 3.42 (3H, m,
H1′ and H1″), 3.24 (1H, dd, J = 8.3, 3.4 Hz, H3), 1.58 (2H, dd, J = 6.4, 5.4 Hz, H5),
1.21 (3H, d, J = 6.4 Hz, H7).

C (125 MHz, CDCl3): 159.1 (ArC), 138.2 (ArC), 138.0 (C2′), 136.9 (ArC), 132.8 (C1),
130.9 (ArC), 129.3 (2 x ArCH), 128.5 (2 x ArCH), 128.4 (2 x ArCH), 128.1 (C2),
127.7 (2 x ArCH), 127.5 (2 x ArCH), 126.4 (2 x ArCH), 117.9 (C3′), 113.8 (2 x
ArCH), 73.4 (C1″), 73.0 (OCH2Ph), 72.2 (C6), 70.4 (OCH2PMP), 70.4 (C4), 62.3 (C3),
58.0 (C1′), 55.3 (OCH3), 40.2 (C5), 19.8 (C7).
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ESIMS m/z 502 (100%) [M+H]+.

(±)-Pent-4-en-2-yl acetate (188)80: Triethylamine (2.420 mL, 17.400 mmol) and
4-N,N-dimethylaminopyridine (DMAP) (50 mg, 0.409 mmol) were added to the
solution of (±)-4-penten-2-ol (±)-118 (0.500 g, 5.800 mmol) and acetic anhydride
(0.822 mL, 8.700 mmol) in anhydrous CH2Cl2 (25 mL) under a nitrogen atmosphere at
rt (17 oC). The reaction mixture was stirred at rt for 1 day. The reaction was quenched
with water (10 mL) and then stirred for 10 min. The reaction mixture was extracted
with CH2Cl2 (3 x 50 mL), dried (MgSO4), and concentrated in vacuo to give a colorless
oil. Purification by flash column chromatography (0:100 to 2:98 EtOAc/petrol as
eluent) gave the title compound (0.232 g, 31%) as a colorless oil. The spectroscopic
data of this compound matched with those in the literature.80

Rf 0.35 (10:90 Et2O/petrol).
IR max (cm-1): 3080, 2981, 1734, 1642, 1430, 1371, 1242, 1126, 1061, 1024, 991.

H (500 MHz, CDCl3) 5.81 - 5.70 (1H, m, H4), 5.09 (1H, d, J = 15.0 Hz, H5trans), 5.07
(1H, d, J = 10.0 Hz, H5cis), 5.00 - 4.91 (1H, m, H2), 2.37 - 2.23 (2H, m, H3), 2.02 (3H,
s, OCOCH3), 1.22 (3H, dd, J = 6.5 Hz, H1).

C (75 MHz, CDCl3) 170.6 (C=O), 133.8 (C4), 117.7 (C5), 70.1 (C2), 40.3 (C3), 21.3
(OCOCH3), 19.4 (C1).
ESIMS m/z 129 (100%) [M+H]+.
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(±)-(E)-5-(Phenylsulfonyl)pent-4-en-2-yl acetate (189): Following the general
method for olefin cross-metathesis, compound 118 (0.136 g, 1.065 mmol) was treated
with phenyl vinyl sulfone (0.358 g, 2.130 mmol), Grubbs’ II ruthenium catalyst (90
mg, 0.106 mmol) in CH2Cl2 (3 mL) at reflux for 1 d. Purification by flash column
chromatography (15:85 to 40:60 Et2O/petrol as eluent) gave the title compound (108
mg, 38%) as a colorless oil.

Rf 0.12 (20:80 EtOAc/petrol).
IR max (cm-1): 3053, 2929, 1731, 1639, 1448, 1373, 1309, 1239, 1144, 1084, 1064,
1020, 973, 812, 752, 716, 689.

H (500 MHz, CDCl3) 7.88 (2H, d, J = 8.0 Hz, ArH), 7.62 (1H, t, J = 7.4 Hz, ArH),
7.55 (2H, t, J = 7.7 Hz, ArH), 6.92 (1H, dt, J = 15.0, 7.3 Hz, H4), 6.38 (1H, d, J = 15.0
Hz, H5), 5.07 - 4.95 (1H, m, H2), 2.51 - 2.45 (2H, m, H3), 1.94 (3H, s, OCOCH3), 1.24
(3H, d, J = 6.3 Hz, H1).

C (125 MHz, CDCl3) 170.4 (C=O), 141.8 (C4), 140.3 (ArC), 133.5 (ArCH), 133.2
(C5), 129.4 (2 x ArCH), 127.6 (2 x ArCH), 68.5 (C2), 37.6 (C3), 21.1 (OCOCH3), 19.8
(C1).
ESIMS m/z 291 (100%) [M+Na]+. HRESIMS found 291.0651, calc for C13H16O4SNa,
291.0667 [M+Na]+.
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(2R,4S)-4-(4-Methoxybenzyloxy)pentane-1,2-diol (190): A solution of 151 (2.577 g,
12.493 mmol) in tert-butanol (20 mL) was slowly added dropwise into a solution of
potassium ferric cyanide (12.340 g, 37.478 mmol), potassium carbonate (5.180 g,
37.478 mmol), methanesulfonamide (1.188 g, 12.493 mmol), potassium osmate
dihydrate (55 mg, 0.150 mmol) and (DHQD)2PYR (0.110 g, 0.125 mmol) in H2O (40
mL) which was cooled in an ice bath.81 The reaction mixture was stirred at 3 - 5 oC (in
a cold room) for 2 days. The reaction was quenched with sodium sulfite (9.442 g,
74.940 mmol) and then allowed to warm to rt (21 oC), stirred for 30 min and then
extracted with EtOAc (3 x 100 mL). The combined organic layers were dried (MgSO4)
and concentrated in vacuo. Purification by flash column chromatography (increasing
polarity from 0:100 to 4:96 of MeOH/CH2Cl2) gave the title compound as a colorless
oil (2.736 g, 99 % dr = 4:1).

Rf 0.50 (10:90 MeOH/CH2Cl2).
[] 25
- 46.5 (c 1.64, CHCl3).
D
IR max (cm-1): 3396, 2925, 1614, 1512, 1244, 1031, 818.

H (500 MHz, CDCl3): (major diastereomer) 7.25 (2H, d, J = 8.8 Hz, ArH), 6.87 (2H, d,
J = 8.8 Hz, ArH), 4.54 (1H, d, J = 11.2 Hz, OCHHPMP), 4.36 (1H, d, J = 11.2 Hz,
OCHHPMP), 3.96 (1H, s (br), H2), 3.87 - 3.82 (1H, m, H4), 3.78 (3H, s, OCH3), 3.56
(1H, dd, J = 10.8, 9.8 Hz, H1A), 3.43 (1H, dd, J = 9.8, 7.3 Hz, H1B), 1.74 - 1.65 (1H, m,
H3A), 1.55 (1H, ddd, J = 10.7, 7.8, 2.9 Hz, H3B), 1.24 (3H, d, J = 6.3 Hz, H5). (minor
diastereomer, in part) 4.59 (1H, d, J = 11.2 Hz, OCHHPMP), 4.34 (1H, d, J = 11.2 Hz,
OCHHPMP).

C (125 MHz, CDCl3): (major diastereomer) 159.3 (ArC), 130.4 (ArC), 129.5 (2 x
ArCH), 114.0 (2 x ArCH), 72.2 (C4), 70.3 (OCH2PMP), 69.3 (C2), 66.9 (C1), 55.3

Chapter 6 | 158

(OCH3), 39.3 (C3), 19.5 (C5). (minor diastereomer, in part) 132.1 (ArC), 131.9 (ArC),
114.4 (ArCH), 71.9 (C4), 70.1 (OCH2PMP), 66.7 (C1), 33.9 (C3), 19.7 (C5).
ESIMS m/z 263 (100%) [M+Na]+. HRESIMS found 263.1258, calc for C13H20O4Na,
263.1259 [M+Na]+.

6.2.5 General method for selective oxidation using TEMPO82

A mixture of 190 (0.208 g, 0.865 mmol), 2,2,6,6-tetramethyl-1-piperidinyloxy free
radical (TEMPO) (3 mg, 0.017 mmol), potassium bromide (0.113 g, 0.951 mmol),
anhydrous CH2Cl2 (9.5 mL) and sat. aq NaHCO3 (3.8 mL) was cool to 0 oC.82
Commercial 0.4 M sodium hypochlorite solution (3.0 mL, 1.211 mmol) was added
slowly dropwise and stirred at 0 oC for 30 min. Saturated aqueous sodium thiosulfate
solution (8.6 mL) was added at 0 oC. The reaction mixture was extracted with EtOAc
(3 x 100 mL), dried (MgSO4), and concentrated in vacuo to give a white solid which
was used unpurified in the subsequent Petasis reaction.

(3S,4R,6S,E)-3-((S)-1-(Benzyloxy)but-3-en-2-ylamino)-6-(4-methoxybenzyloxy)-4methoxy-1-phenylhept-1-en-4-ol (155): Following the general method for the Petasis
reaction, the above crude oxidation product was treated with (E)-2-phenylvinylboronic
acid (0.153 g, 1.032 mmol) and (2S)-1-(benzyloxy)but-3-en-2-amine 154 (0.183 g,
1.032 mmol) in 1:9 1,1,1,3,3,3-hexafluoroisopropanol/CH2Cl2 (3.5 mL) rt (32 oC) for
2 d. Purification by flash column chromatography (0:100 to 10:90 MeOH/CH2Cl2 as
eluent) gave the title compound (0.314 g, 73%, 2 steps) as a brown oil. The physical
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and spectroscopic properties of 155 were the same as those given above in section
6.2.4.

(3S,4R,6S,E)-3-(Allylamino)-6-(4-methoxybenzyloxy)-4-hydroxy-1-phenylhept-1en-4-ol (192): Following the general method for selective oxidation, compound 190
(0.119 g, 0.500 mmol) was treated with 2,2,6,6-tetramethyl-1-piperidinyloxy free
radical (TEMPO) (2 mg, 0.010 mmol), potassium bromide (65 mg, 0.550 mmol),
commercial 0.4 M sodium hypochlorite solution (2.0 mL, 0.700 mmol) and a mixture
of anhydrous CH2Cl2 (5.5 mL) and sat. aq NaHCO3 (2.2 mL) at 0 oC for 30 min.
Quenching with saturated aqueous sodium thiosulfate solution (5 mL) followed by the
general extraction protocol gave a white solid which was used unpurified in the
subsequent Petasis reaction.
Following the general method for the Petasis reaction, the above crude oxidation
product was treated with (E)-2-phenylvinylboronic acid (0.111 g, 0.750 mmol),
allylamine (65 L, 1.500 mmol) in 1:9 1,1,1,3,3,3-hexafluoroisopropanol/CH2Cl2
(2 mL) at rt (29 oC) for 4 d. Purification by flash column chromatography (0:100 to
7:93 MeOH/CH2Cl2 as eluent) gave the title compound (94 mg, 49%) as a white semisolid.

Rf 0.30 (6:94 MeOH/CH2Cl2).
[] 25
+ 46.0 (c 0.13, CHCl3).
D
IR max (cm-1): 3275, 3026, 2963, 2837, 1613, 1512, 1449, 1371, 1300, 1244, 1173,
1130, 1072, 963, 916, 812, 747, 692.

Chapter 6 | 160

H (300 MHz, CDCl3) 7.42 - 7.22 (7H, m, ArH), 6.89 - 6.84 (2H, m, ArH), 6.49 (1H, d,
J = 16.0 Hz, H1), 6.15 (1H, dd, J = 16.0, 8.8 Hz, H2), 5.91 (1H, ddt, J = 16.9, 10.3, 6.1
Hz, H2′), 5.19 (1H, dd, J = 16.9, 1.6 Hz, H3′trans), 5.12 (1H, dd, J = 10.3, 1.4 Hz,
H3′cis), 4.54 (1H, d, J = 11.2 Hz, OCHHPMP), 4.38 (1H, d, J = 11.2 Hz, OCHHPMP),
4.11 (1H, dt, J = 9.8, 2.9 Hz, H4), 3.88 - 3.81 (1H, m, H6), 3.79 (3H, s, OCH3), 3.35
(1H, dd, J = 14.1, 5.7 Hz, H1′A), 3.30 - 3.14 (2H, m, H3 and H1′B), 1.71 - 1.60 (1H, m,
H5A), 1.54 (1H, ddd, J = 14.4, 7.8, 2.7 Hz, H5B), 1.22 (3H, d, J = 6.2 Hz, H7).

C (75 MHz, CDCl3) 159.3 (ArC), 136.9 (ArC), 136.7 (C2′), 133.6 (C1), 130.9 (ArC),
129.5 (2 x ArCH), 128.7 (2 x ArCH), 127.7 (C2 and ArCH), 126.5 (2 x ArCH), 116.3
(C3′), 113.9 (2 x ArCH), 72.32 (C6), 70.6 (OCH2PMP), 69.6 (C4), 65.1 (C3), 55.4
(OCH3), 49.8 (C1′), 39.9 (C5), 19.7 (C7).
ESIMS m/z 382 (100%) [M+H]+. HRESIMS found 382.2383, calc for C24H32NO3,
382.2382 [M+H]+.

6.2.6 General method for N-Boc protection85

tert-Butyl

allyl((3S,4R,6S,E)-4-hydroxy-6-(4-methoxybenzyloxy)-1-phenylhept-1-

en-3-yl)carbamate (193): Triethylamine (42 L, 0.300 mmol) was added to a solution
of compound 192 (52 mg, 0.150 mmol) in anhydrous methanol (2 mL) under a nitrogen
atmosphere at rt (27 oC) and stirred for 10 min followed by the addition of di-tert-butyldicarbonate (82 mg, 0.375 mmol).85 The reaction mixture was stirred at rt (27 oC) for
33 h and concentrated in vacuo to give a white semi-solid. Purification by flash column
chromatography (0:100 to 4:96 EtOAc/CH2Cl2 as eluent) gave the title compound (63
mg, 87%) as a white semi-solid.
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Rf 0.49 (2:98 MeOH/CH2Cl2).
[] 25
+ 51.0 (c 0.36, CHCl3).
D
IR max (cm-1): 3459, 2971, 2931, 1685, 1613, 1513, 1452, 1397, 1367, 1302, 1247,
1170, 1145, 1035, 967, 921, 879, 819, 770, 693.

H (500 MHz, CDCl3) 7.38 (2H, d, J = 7.7 Hz, ArH), 7.29 (2H, t, J = 7.8 Hz, ArH),
7.27 - 7.18 (3H, m, ArH), 6.86 (2H, d, J = 8.5 Hz, ArH), 6.52 - 6.46 (2H, m, H1 and
H2), 5.85 - 5.76 (1H, m, H2′), 5.11 (1H, d, J = 19.0 Hz, H3′trans), 5.08 (1 H, d, J = 10.7
Hz, H3′cis), 4.55 (1H, d, J = 11.2 Hz, OCHHPMP), 4.37 (1H, d, J = 11.2 Hz,
OCHHPMP), 4.23 (1H, s (br), H4), 4.12 (1H, s (br), H3), 3.91 - 3.89 (1H, m, H6), 3.86
- 3.84 (2H, m, H1′), 3.78 (3H, s, OCH3), 1.71 - 1.62 (2H, m, H5), 1.46 (9H, s,
OC(CH3)3), 1.24 (3H, d, J = 6.1 Hz, H7).

C (125 MHz, CDCl3) 159.3 (ArC), 156.0 (C=O, br), 136.9 (C2′), 135.4 (C1), 133.8
(ArC, br), 130.8 (2 x ArCH), 129.4 (2 x ArCH), 128.6 (2 x ArCH), 127.7 (ArCH),
126.6 (2 x ArCH), 125.0 (C2, br), 116.5 (C3′, br), 113.9 (2 x ArCH), 80.4 (OC(CH3)3),
72.5 (C6), 70.4 (OCH2PMP), 70.1 (C4), 64.8 (C3, br), 55.3 (OCH3), 49.9 (C1′, br), 40.8
(C5, br), 28.6 (OC(CH3)3), 19.6 (C7, br).
ESIMS m/z 504 (100%) [M+Na]+. HRESIMS found 504.2750, calc for C29H39NO5Na,
504.2726 [M+Na]+.

6.2.7 General method for O-mesylation60
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(4S,5S)-3-Allyl-5-((S)-2-(4-methoxybenzyloxy)propyl)-4-styryloxazolidin-2-one
(194): Triethylamine (42 L, 0.300 mmol) was slowly added dropwise to the solution
of 193 (47 mg, 0.097 mmol) in CH2Cl2 (2 mL) at 0 oC under a nitrogen atmosphere
followed by methanesulfonyl chloride (12 L, 0.150 mmol).60 The reaction mixture
was stirred at 0 oC for 2.5 h, allowed to warm to rt (25 oC) and stirred for 17 h. The
reaction was quenched with sat. NaHCO3 solution (3 mL) and extracted with EtOAc
(3 x 20 mL). The combined organic extracts were dried (MgSO4) and concentrated in
vacuo to give a white semi-solid. Purification by flash column chromatography
(increasing polarity from 0:100 to 1:99 of MeOH/CH2Cl2 as eluent) gave the title
compound (24 mg, 61%) as a colorless semi-solid.

Rf 0.74 (2:98 MeOH/CH2Cl2).
[] 25
- 1.2 (c 0.56, CHCl3).
D
IR max (cm-1): 2971, 2925, 1750, 1686, 1610, 1512, 1393, 1246, 1176, 1084, 1026,
977, 919, 751, 715.

H (500 MHz, CDCl3) 7.36 - 7.30 (5H, m, ArH), 7.17 (2H, d, J = 8.3 Hz, ArH), 6.81
(2H, d, J = 8.5 Hz, ArH), 6.56 (1H, d, J = 15.8 Hz, H2‴), 5.96 (1H, dd, J = 15.8, 8.9
Hz, H1‴), 5.77 - 5.68 (1H, m, H2′), 5.20 (1H, d, J = 10.2 Hz, H3′cis), 5.16 (1H, d, J =
17.1 Hz, H3′trans), 4.47 (1H, d, J = 11.0 Hz, OCHHPMP), 4.39 (1H, td, J = 6.8, 6.4 Hz,
H5), 4.26 (1H, d, J = 11.0 Hz, OCHHPMP), 4.11 - 4.02 (2H, m, H4 and H1′A), 3.92 3.82 (1H, m, H2′), 3.76 (3H, s, OCH3), 3.56 (1H, dd, J = 15.6, 7.5 Hz, H1′B), 2.11 (1H,
dt, J = 14.0, 6.8 Hz, H1″A), 1.84 (1 H, dt, J = 14.0, 5.6 Hz, H1″B), 1.26 (3H, d, J = 6.2
Hz, H3″).

C (125 MHz, CDCl3) 159.3 (ArC), 157.5 (C2), 136.2 (C2‴), 135.5 (ArC), 132.1 (C2′),
130.6 (ArC), 129.3 (2 x ArCH), 128.9 (2 x ArCH), 128.8 (ArCH), 126.9 (2 x ArCH),
125.4 (C1‴), 118.8 (C3′), 113.9 (2 x ArCH), 77.1 (C5), 71.0 (C2″), 70.2 (OCH2PMP),
64.4 (C4), 55.4 (OCH3), 44.8 (C1′), 40.3 (C1″), 19.6 (C3″).
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ESIMS m/z 430 (100%) [M+Na]+. HRESIMS found 430.2007, calc for C25H29NO4Na,
430.1994 [M+Na]+.

6.2.8 General method for oxazolidinone preparation60

(4S,5R)-3-((S)-1-(Benzyloxy)but-3-en-2-yl)-5-((S)-2-(4-methoxybenzyloxy)propyl)4-styryloxazolidin-2-one (156)60:

Method A:
Triphosgene (0.186 g, 0.625 mmol) was slowly added to the solution of the 1,2-amino
alcohol 155 (0.625 g, 1.247 mmol) and triethylamine (0.697 mL, 4.988 mmol) in
anhydrous CH2Cl2 (35 mL) at 0 oC under a nitrogen atmosphere.60 After stirring for 15
min the reaction mixture was allowed to warm to rt (26 oC), stirred for 18 h and then
concentrated in vacuo to give a yellow solid. Purification by flash column
chromatography (increasing polarity from 0:100 to 1:99 of MeOH/CH2Cl2 as eluent)
gave the title compound (0.435 g, 66%) as a colorless oil.

Method B:
Following the general method for N-Boc protection, compound 155 (51 mg, 0.100
mmol) was treated with di-tert-butyl-dicarbonate (44 mg, 0.200 mmol), triethylamine
(27 L, 0.200 mmol), 4-N,N-dimethylaminopyridine (DMAP) (12 L, 0.100 mmol) in
anhydrous CH2Cl2 (0.5 mL) at rt (26 oC) for 1 d. Purification by flash column
chromatography (increasing polarity from 0:100 to 1:99 of MeOH/CH2Cl2 as eluent)
gave the title compound (24 mg, 45%) as a colorless oil. The spectroscopic data of this
compound matched with those in the literature.60
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Rf 0.66 (2:98 MeOH/CH2Cl2).
[] 25
+ 20.9 (c 0.05, CHCl3). [Lit.60 [] 21
D + 3.6 (c 8.30, CHCl3)].
D
IR max (cm-1): 3028, 2966, 2929, 2865, 1743, 1612, 1512, 1453, 1402, 1246, 1072,
1033, 977, 932, 820, 753, 695, 608.

H (500 MHz, CDCl3): 7.33 - 7.23 (12H, m, ArH), 6.86 (2H, d, J = 8.3 Hz, ArH), 6.30
(1H, d, J = 15.9 Hz, H2″′), 6.00 (1H, dd, J = 15.9, 9.8 Hz, H1″′), 5.86 - 5.78 (1H, m,
H2′), 5.25 (1H, d, J = 16.1 Hz, H3′trans), 5.18 (1H, d, J = 10.2 Hz, H3′cis), 4.86 (1H, ddd,
J = 10.3, 8.8, 1.5 Hz, H5), 4.61 (1H, d, J = 11.7 Hz, OCHHPh), 4.52 (1H, d, J = 10.7
Hz, OCHHPMP), 4.47 (1H, d, J = 11.7 Hz, OCHHPh), 4.37 - 4.40 (2H, m, H4 and
H1′), 4.34 (1H, d, J = 10.7 Hz, OCHHPMP), 3.89 (1H, dd, J = 10.0, 9.3 Hz, H4′A), 3.83
- 3.81 (1H, m, H2″), 3.79 (3H, s, OCH3), 3.61 (1H, dd, J = 10.0, 4.9 Hz, H4′B), 1.70
(1H, td, J = 11.9, 2.0 Hz, H1″A), 1.60 (1H, dd, J = 11.9, 11.2 Hz, H1″B), 1.19 (3H, d, J
= 6.3 Hz, H3″).

C (75 MHz, CDCl3): 159.3 (ArC), 157.5 (C2), 138.0 (ArC), 135.8 (ArC), 135.2 (C2″′),
133.9 (C2′), 130.8 (ArC), 129.6 (2 x ArCH), 128.8 (ArCH), 128.6 (2 x ArCH), 128.5
(ArCH), 128.1 (2 x ArCH), 128.0 (2 x ArCH), 126.8 (2 x ArCH), 125.1 (C1″′), 118.6
(C3′), 114.0 (2 x ArCH), 74.9 (C5), 73.2 (OCH2Ph), 71.5 (C2″), 71.1 (OCH2PMP),
69.1 (C4′), 61.4 (C4), 56.4 (C1′), 55.4 (OCH3), 38.8 (C1″), 20.3 (C3″).
ESIMS m/z 550 (100%) [M+Na]+.

6.2.9 General method for ring-closing metathesis60

Chapter 6 | 165

(1R,5S,7aS)-5-(Benzyloxymethyl)-1-((S)-2-(4-methoxybenzyloxy)propyl)-1,7adihydropyrrolo[1,2-c]oxazol-3(5H)-one (157)60: A solution of the oxazolidinone 156
(0.239 g, 0.452 mmol) and Grubbs’ II ruthenium catalyst (19 mg, 0.023 mmol) in
anhydrous CH2Cl2 (8 mL) under a nitrogen atmosphere was heated at reflux for 18 h.60
The reaction mixture was cooled to rt and was then concentrated in vacuo to give a
black semi-solid. Purification by flash column chromatography with increasing polarity
from 0:100 to 30:70 of EtOAc/petrol as eluent gave the title compound (0.172 g, 90%)
as a yellow oil. The spectroscopic data of this compound matched with those in the
literature.60

Rf 0.24 (30:70 EtOAc/petrol).
60
[] 25
[] 24
D - 22.5 (c 0.12, CHCl3). [Lit.
D - 32.4 (c 1.00, CHCl3)].

IR max (cm-1): 2967, 2864, 1745, 1610, 1513, 1454, 1375, 1246, 1213, 1072, 820, 746,
697, 608.

H (500 MHz, CDCl3): 7.34 - 7.23 (7H, m, ArH), 6.86 (2H, d, J = 8.3 Hz, ArH), 5.99
(1H, d, J = 5.9 Hz, H7), 5.89 (1H, d, J = 5.9 Hz, H6), 4.98 (1H, td, J = 9.3, 3.4 Hz, H1),
4.80 - 4.76 (2H, m, H5 and H7a), 4.55 (1H, d, J = 11.2 Hz, OCHHPMP), 4.54 (2H, s,
OCHHPh), 4.33 (1H, d, J = 11.2 Hz, OCHHPMP), 3.79 - 3.75 (1H, m, H2′), 3.78 (3H,
s, OCH3), 3.52 (2H, d, J = 4.5 Hz, H1″), 1.72 (1H, ddd, J = 12.4, 10.7, 3.4 Hz, H1′A),
1.62 (1H, ddd, J = 10.7, 9.3, 2.9 Hz, H1′B), 1.21 (3H, d, J = 5.8 Hz, H3′).

C (125 MHz, CDCl3): 162.4 (C3), 159.3 (ArC), 138.0 (ArC), 132.9 (C7), 130.6 (ArC),
129.5 (2 x ArCH), 128.5 (C6), 128.4 (2 x ArCH), 127.7 (ArCH), 127.6 (2 x ArCH),
113.9 (2 x ArCH), 76.4 (C1), 73.3 (OCH2Ph), 71.4 (C1″), 71.2 (C2′), 70.9
(OCH2PMP), 68.2 (C5), 67.0 (C7a), 55.3 (OCH3), 40.1 (C1′), 20.0 (C3′).
ESIMS m/z 446 (100%) [M+Na]+.
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(1R,5R,6R,7S,7aS)-5-(Benzyloxymethyl)-6,7-dihydroxy-1-((S)-2-(4methoxybenzyloxy)propyl)tetrahydropyrrolo[1,2-c]oxazol-3(1H)-one

(158)60:

N-methylmorpholine-N-oxide (0.335 g, 2.859 mmol) and potassium osmate dihydrate
(26 mg, 0.072 mmol) were added to a solution of 157 (0.605 g, 1.429 mmol) in 3:1
acetone/water (18 mL).60 The reaction mixture was stirred at 35 oC for 18 h,
concentrated in vacuo, diluted with H2O and extracted with EtOAc (3 x 30 mL). The
combined organic layers were dried (MgSO4) and concentrated in vacuo to afford a
black oil. Purification by flash column chromatography (0:100 to 3:97 MeOH/CH2Cl2
as eluent) gave the title compound (0.629 g, 96%) as a yellow oil. The spectroscopic
data of this compound matched with those in the literature.60

Rf 0.18 (60:40 EtOAc/petrol).
60
[] 25
[] 24
D + 6.2 (c 0.14, CHCl3). [Lit.
D + 2.0 (c 1.00, CHCl3)].

IR max (cm-1): 3402, 2931, 2863, 1723, 1612, 1513, 1455, 1370, 1303, 1245, 1176,
1121, 1061, 1031, 950, 821, 741, 698.

H (500 MHz, CDCl3): 7.31 - 7.20 (5H, m, ArH), 6.85 - 6.84 (2H, m, ArH), 4.86 - 4.83
(1H, m, H1), 4.60 - 4.51 (3H, m, 2 x OCHHPh and OCHHPMP), 4.30 (1H, d, J = 10.7
Hz, OCHHPMP) 4.24 (1H, s (br), H7), 3.91 (1H, s (br), H6), 3.78 (3H, s, OCH3), 3.76 3.74 (1H, m, H5), 3.69 - 3.67 (1H, m, H2′), 3.65 - 3.63 (3H, m, H7a and H1″), 2.35
(1H, ddd, J = 10.5, 8.8, 3.4 Hz, H1′A), 1.92 (1H, td, J = 10.5, 4.4 Hz, H1′B), 1.22 (3H,
d, J = 4.9 Hz, H3′).

C (125 MHz, CDCl3): 163.0 (C3), 159.3 (ArC), 138.0 (ArC), 130.6 (ArC), 129.6 (2 x
ArCH), 128.5 (2 x ArCH), 127.8 (ArCH), 127.7 (2 x ArCH), 113.9 (2 x ArCH), 76.0
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(C7), 74.0 (C1), 73.5 (OCH2Ph), 72.3 (C6), 72.2 (C2′), 70.7 (OCH2PMP), 70.3 (1″),
65.2 (C7a), 62.5 (C5), 55.4 (OCH3), 37.5 (C1′), 20.0 (C3′).
ESIMS m/z 480 (100%) [M+Na]+, 458 (10%) [M+H]+.

(1R,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-1-((S)-2-(4methoxybenzyloxy)propyl)tetrahydropyrrolo[1,2-c]oxazol-3(1H)-one

(159)60:

Following the general method for the O-benzylation reaction, the diol 158 (0.671 g,
1.468 mmol) was treated with benzyl bromide (0.697 mL, 5.873 mmol),
tetrabutylammonium iodide (54 mg, 0.147 mmol) and sodium hydride (60% dispersion
in mineral oil, 0.176 g, 0.106 g NaH, 4.404 mmol) in anhydrous THF (60 mL) at 0 oC
for 15 min to rt (23 oC) for 1 d. Purification by flash column chromatography (0:100 to
30:70 EtOAc/petrol as eluent) gave the title compound (0.952 g, 92%) as a colorless
oil. The spectroscopic data of this compound matched with those in the literature.60

Rf 0.70 (60:40 EtOAc/petrol).
60
[] 25
[] 22
D + 29.1 (c 0.14, CHCl3). [Lit.
D + 9.3 (c 1.23, CHCl3)].

IR max (cm-1): 3031, 2929, 2862, 1750, 1611, 1513, 1455, 1390, 1359, 1303, 1246,
1228, 1065, 1031, 821, 736, 698.

H (500 MHz, CDCl3): 7.32 - 7.18 (17H, m, ArH), 6.84 (2H, d, J = 7.3 Hz, ArH), 4.99
(1H, d, J = 11.2 Hz, OCHHPh), 4.77 (1H, dt, J = 7.8, 6.6 Hz, H1), 4.58 - 4.48 (4H, m, 3
x OCHHPh and OCHHPMP), 4.40 (1H, d, J = 12.2 Hz, OCHHPh), 4.37 (1H, d, J =
12.2 Hz, OCHHPh), 4.22 (1H, d, J = 10.7 Hz, OCHHPMP), 4.15 (1H, dd, J = 7.8, 1.5
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Hz, H6), 3.97 (1H, dd, J = 7.8, 2.4 Hz, H5), 3.93 (1H, s (br), H7), 3.77 - 3.75 (1H, m,
H1″A), 3.73 (3H, s, OCH3), 3.66 - 3.61 (2H, m, H7a and H2′), 3.56 (1H, dd, J = 10.2,
2.0 Hz, H1″B), 2.09 (1H, dd, J = 14.2, 7.1 Hz, H1′A), 1.79 - 1.75 (1H, m, H1′B), 1.07
(3H, d, J = 5.9 Hz, H3′).

C (125 MHz, CDCl3): 162.1 (C3), 159.4 (ArC), 138.3 (ArC), 138.1 (ArC), 137.7
(ArC), 130.7 (ArC), 129.6 (2 x ArCH), 128.6 (2 x ArCH), 128.5 (2 x ArCH), 128.4 (2 x
ArCH), 128.1 (ArCH), 127.8 (5 x ArCH), 127.5 (ArCH), 127.3 (2 x ArCH), 114.0 (2 x
ArCH), 83.3 (C6), 77.2 (C7), 73.9 (C1), 73.4 (OCH2Ph), 73.3 (OCH2Ph), 73.0
(OCH2Ph), 72.3 (C2′), 70.8 (OCH2PMP), 69.3 (C1″), 64.4 (C7a), 61.1 (C5), 55.4
(OCH3), 37.4 (C1′), 19.9 (C3′).
ESIMS m/z 660 (70%) [M+Na]+, 638 (3%) [M+H]+.

(1R,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-1-((S)-2hydroxypropyl)tetrahydropyrrolo[1,2-c]oxazol-3(1H)-one (160)60: Dichloro-5,6dicyanobenzoquinone (DDQ) (0.333 g, 1.467 mmol) was added to a solution of 159
(0.904 g, 0.978 mmol) in 8:1 CH2Cl2/H2O (45 mL).60 The reaction mixture was stirred
at rt (26 oC) until TLC analysis (50:50 EtOAc/petrol) showed complete consumption of
32 (2.5 h). Purification by flash column chromatography (increasing polarity from
50:50 to 80:20 of EtOAc/petrol as eluent) gave the title compound (0.648 g, 84%) as a
yellow oil. The spectroscopic data of this compound matched with those in the
literature.60

Rf 0.23 (50:50 EtOAc/petrol).

Chapter 6 | 169

60
[] 25
[] 24
D + 19.7 (c 0.08, CHCl3). [Lit.
D + 19.8 (c 1.31, CHCl3)].

IR max (cm-1): 3452, 2972, 2864, 1742, 1511, 1397, 1361, 1231, 1206, 1127, 1071,

739, 699.

H (500 MHz, CDCl3): 7.33 - 7.23 (15H, m, ArH), 5.04 (1H, d, J = 11.7 Hz, OCHHPh),
4.79 (1H, ddd, J = 12.7, 8.3, 2.9 Hz, H1), 4.65 (1H, d, J = 11.7 Hz, OCHHPh), 4.57 4.50 (3H, m, 3 x OCHHPh), 4.40 (1H, d, J = 12.2 Hz, OCHHPh), 4.28 (1H, d, J = 7.8
Hz, H6), 4.03 (1H, s, H7), 3.99 - 3.98 (1H, m, H5), 3.92 - 3.88 (1H, m, H2′), 3.76 (1H,
dd, J = 10.2, 2.4 Hz, H1′′A), 3.73 (1H, d, J = 7.8 Hz, H7a), 3.60 (1H, dd, J = 10.2, 2.4
Hz, H1′′B), 2.09 (1H, ddd, J = 14.4, 8.3, 2.4 Hz, H1′A), 1.64 (1H, ddd, J = 14.4, 9.8, 4.4
Hz, H1′B), 1.07 (3H, d, J = 6.4 Hz, H3′).

C (125 MHz, CDCl3): 162.2 (C3), 138.2 (ArC), 138.1 (ArC), 137.7 (ArC), 128.6 (2 x
ArCH), 128.5 (2 x ArCH), 128.4 (2 x ArCH), 128.1 (ArCH), 127.8 (5 x ArCH), 127.6
(ArCH), 127.4 (2 x ArCH), 83.4 (C6), 76.9 (C7), 74.0 (C1), 73.4 (2 x OCH2Ph), 73.0
(OCH2Ph), 69.4 (C1′′), 65.2 (C2′), 64.4 (C7a), 61.1 (C5), 38.3 (C1′), 24.5 (C3′).
ESIMS m/z 540 (100%) [M+Na]+, 518 (48%) [M+H]+.

6.2.10 General method for the Mitsunobu reaction90

(R)-1-((1R,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3oxohexahydropyrrolo[1,2-c]oxazol-1-yl)propan-2-yl

4-nitrobenzoate

(196):

A

solution of 160 (0.455 g, 0.880 mmol), triphenylphosphine (1.038 g, 3.959 mmol) and
p-nitrobenzoic acid (0.662 g, 3.959 mmol) in toluene (9 mL) was cool to 0 oC and
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diisopropyl azodicarboxylate (0.780 mL, 3.959 mmol) was added.90 The reaction
mixture was allowed to warm to rt (27 oC) and stirred for 24 h. The volatiles were
removed in vacuo, extracted with CH2Cl2 (3 x 30 mL), dried (MgSO4) and concentrated
in vacuo to give a dark brown oil. Purification by flash column chromatography
(increasing polarity from 0:100 to 10:90 of MeOH/CH2Cl2 as eluent) gave the title
compound (0.498 g, 85%) as a yellow oil.

Rf 0.30 (30:70 EtOAc/petrol).

[] 25
D - 26.6 (c 0.64, CHCl3).

IR max (cm-1): 2934, 2864, 1752, 1719, 1525, 1346, 1274, 1100, 737.

H (500 MHz, CDCl3): 8.24 (2H, d, J = 8.8 Hz, ArH), 8.13 (2H, d, J = 8.8 Hz, ArH),
7.35 - 7.20 (15H, m, ArH), 5.27 - 5.21 (1H, m, H2′), 5.10 (1H, d, J = 11.7 Hz,
OCHHPh), 4.72 (1H, dt, J = 7.3, 6.6 Hz, H1), 4.66 (1H, d, J = 11.7 Hz, OCHHPh),
4.57 (1H, d, J = 11.7 Hz, OCHHPh), 4.52 (1H, d, J = 11.7 Hz, OCHHPh), 4.51 (1H, d,
J = 11.7 Hz, OCHHPh), 4.38 (1H, d, J = 11.7 Hz, OCHHPh), 4.32 (1H, dd, J = 7.8, 2.0
Hz, H6), 4.07 (1H, s, H7), 4.00 (1H, dt, J = 7.8, 2.9 Hz, H5), 3.76 (2H, d, J = 8.3 Hz,
H1′′A and H7a), 3.59 (1H, J = 10.3, 2.4 Hz, H1′′B), 2.42 (1H, dt, J = 14.6, 7.8 Hz, H1A′),
2.07 (1H, dt, J = 14.6, 4.4 Hz, H1′B), 1.31 (3H, d, J = 6.4 Hz, H3′).

C (125 MHz, CDCl3): 164.2 (C=O), 161.8 (C3), 150.6 (ArC), 138.1 (ArC), 137.8
(ArC), 137.4 (ArC), 135.7 (ArC), 130.8 (2 x ArCH), 128.6 (2 x ArCH), 128.5 (2 x
ArCH), 128.4 (2 x ArCH), 128.2 (ArCH), 127.8 (6 x ArCH), 127.7 (2 x ArCH), 127.4
(2 x ArCH), 123.6 (2 x ArCH), 83.3 (C6), 76.7 (C7), 73.4 (2 x OCH2Ph), 73.0
(OCH2Ph), 72.8 (C1), 70.3 (C2′), 69.2 (C1′′), 63.9 (C7a), 61.1 (C5), 35.5 (C1′), 22.1
(C3′).
ESIMS m/z 667 (100%) [M+H]+. HRASAPMS found 667.2671, calc for C38H39N2O9,
667.2656 [M+H]+.
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6.2.11 General method for hydrolysis of oxazolidinones60

(1R,3R)-1-((2R,3S,4R,5R)-3,4-Bis(benzyloxy)-5-(benzyloxymethyl)pyrrolidin-2yl)butane-1,3-diol (172)60: Sodium hydroxide (58 mg, 2.507 mmol) and 3 drops of
H2O were added to a solution of 196 (0.167 g, 0.251 mmol) in ethanol (3 mL).60 The
reaction mixture was stirred and irradiated in a CEM microwave reactor (the
temperature control was set at 110 oC and the maximum applied power at 200 W) for
1 h. After the reaction mixture had cooled to rt it was concentrated in vacuo to give a
yellow semi-solid. Purification by flash column chromatography (increasing polarity
from 0:100 to 8:92 of MeOH/CH2Cl2 as eluent) gave the title compound (0.120 g, 97%)
as a colorless oil. The spectroscopic data of this compound matched with those in the
literature.60

Rf 0.30 (5:95 MeOH/CH2Cl2).
60
[] 25
[] 24
D + 18.7 (c 0.83, CHCl3). [Lit.
D + 14.2 (c 1.00, CHCl3)].

IR max (cm-1): 3323, 3030, 2864, 1496, 1453, 1360, 1208, 1075, 915, 835, 736, 640.

H (500 MHz, CDCl3): 7.33 - 7.27 (15H, ArH), 4.88 (1H, d, J = 11.7 Hz, OCHHPh),
4.61 (1H, d, J = 11.7 Hz, OCHHPh), 4.56 (1H, d, J = 11.7 Hz, OCHHPh), 4.53 (1H, d,
J = 11.7 Hz, OCHHPh), 4.50 (1H, d, J = 12.2 Hz, OCHHPh), 4.44 (1H, d, J = 12.2 Hz,
OCHHPh), 4.17 (1H, t, J = 4.4 Hz, H1′), 4.08-4.05 (1H, m, H3), 4.03 - 4.01 (1H, m,
H3′), 3.89 (1H, dd, J = 5.8, 4.4 Hz, H4), 3.54 (1H, dd, J = 11.2, 5.4 Hz, H1′′A), 3.48 3.46 (2H, m, H5 and H1′′B), 3.02 (1H, dd, J = 7.3, 4.4 Hz, H2), 1.72 (1H, d, J = 14.2
Hz, H2′A), 1.44 (1H, dt, J = 14.2, 9.8 Hz, H2′B), 1.16 (3H, d, J = 5.8 Hz, H4′).
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C (125 MHz, CDCl3): 138.1 (ArC), 138.0 (ArC), 137.9 (ArC), 128.7 (2 x ArCH),
128.5 (2 x ArCH), 128.2 (2 x ArCH), 128.1 (3 x ArCH), 128.0 (3 x ArCH), 127.8 (3 x
ArCH), 81.3 (C4), 79.2 (C1′), 73.5 (OCH2Ph), 73.3 (OCH2Ph), 72.9 (C3), 72.8
(OCH2Ph), 70.2 (C1′′), 68.3 (C3′), 63.1 (C2), 60.4 (C5), 42.6 (C2′), 23.8 (C4′).
ESIMS m/z 492 (100%) [M+H]+.

6.2.12 General method for mesylation-cyclization60

(1R,3S,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3methylhexahydro-1H-pyrrolizin-1-ol (173)60

(1R,3S,5R,6R,7S,7aS)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3methylhexahydro-1H-pyrrolizin-1-yl methanesulfonate (198)

Triethylamine (73 L, 0.525 mmol) was slowly added to a solution of 172 (0.259 g,
0.525 mmol) in CH2Cl2 (28 mL) at 0 oC under a nitrogen atmosphere followed by a
0.13 M solution of methanesulfonyl chloride in anhydrous CH2Cl2 (4.040 mL, 0.525
mmol MeSO2Cl).60 The reaction mixture was stirred at 0 oC for 1.5 h and quenched
with sat. NaHCO3 solution (3.5 mL) and extracted with CH2Cl2 (3 x 15 mL). The
combined organic extracts were dried (MgSO4) and concentrated in vacuo to give a
yellow oil. Purification by flash column chromatography (increasing polarity from 2:98
to 10:90 of MeOH/CH2Cl2 as eluent) gave compound 173 (0.198 g, 77%) as a colorless
oil and compound 198 (39 mg, 13%) as a colorless oil. The spectroscopic data of
compound 173 matched with those in the literature.60
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173: Rf 0.30 (5:95 MeOH/CH2Cl2).
60
[] 25
[] 25
D + 21.7 (c 1.03, CHCl3). [Lit.
D + 7.2 (c 1.00, CHCl3)].

IR max (cm-1): 3360, 3030, 2922, 2862, 1469, 1452, 1359, 1310, 1208, 1094, 1048,
1027, 914, 735, 696.

H (500 MHz, CDCl3): 7.32 - 7.27 (15H, m, ArH), 4.74 (1H, J = 11.7 Hz, OCHHPh),
4.67 (1H, td, 7.8, 6.6, H7), 4.55 - 4.48 (5H, m, 5 x OCHHPh), 4.06 (1H, t, J = 4.6 Hz,
H1), 3.92 (1H, dd, J = 5.6, 4.4 Hz, H2), 3.45 - 3.41 (3H, m, H7a and H8), 3.09 (1H, dd,
J = 10.1, 5.6 Hz, H3), 3.06 - 3.02 (1H, m, H5), 2.27 (1H, dt, J = 11.9, 6.1 Hz, H6A),
1.59 (1H, td, J = 11.9, 9.8 Hz, H6B), 1.14 (3H, d, J = 6.1 Hz, H9).

C (75 MHz, CDCl3): 138.7 (ArC), 138.5 (ArC) 138.2 (ArC), 128.5 (4 x ArCH), 128.4
(2 x ArCH), 127.9 (4 x ArCH), 127.8 (2 x ArCH), 127.7 (3 x ArCH), 82.0 (C2), 77.6
(C1), 73.4 (OCH2Ph), 73.3 (C7a), 73.2 (OCH2Ph), 72.4 (OCH2Ph), 71.7 (C8), 71.0
(C7), 68.2 (C3), 62.4 (C5), 44.0 (C6), 22.0 (C9).
ESIMS m/z 474 (100%) [M+H]+.

198: Rf 0.31 (2:98 MeOH/CH2Cl2).

o
[] 25
(c 0.22, CHCl3).
D + 15.5

IR max (cm-1): 3027, 2929, 2856, 1497, 1454, 1355, 1175, 1098, 1027, 958, 735, 696.

H (500 MHz, CDCl3) 7.36 - 7.24 (15H, m, ArH), 5.36 - 5.40 (1H, m, H7), 4.78 (1H, d,
J = 11.2 Hz, OCHHPh), 4.59 - 4.47 (5H, m, 5 x OCHHPh), 4.13 (1H, t, J = 4.6 Hz,
H1), 3.96 (1H, dd, J = 6.7, 3.6 Hz, H2), 3.72 (1H, t, J = 4.9 Hz, H7a), 3.46 (2H, dd, J =
5.7, 3.9 Hz, H8), 3.10 - 3.04 (2H, m, H5 and H3), 2.81 (3H, s, OSO2CH3), 2.41 (1H, dt,
J = 14.9, 7.8 Hz, H6A), 1.91 - 1.81 (1H, m, H6B), 1.15 (3H, d, J = 6.3 Hz, H9).
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C (75 MHz, CDCl3) 138.4 (ArC), 138.3 (ArC), 137.9 (ArC), 128.7 (2 x ArCH), 128.5
(2 x ArCH), 128.4 (3 x ArCH), 128.1 (2 x ArCH), 127.9 (2 x ArCH), 127.8 (2 x
ArCH), 127.6 (2 x ArCH), 82.2 (C2), 79.3 (C7), 77.2 (C1), 73.5 (OCH2Ph), 73.4
(OCH2Ph), 72.7 (OCH2Ph), 71.5 (C8), 70.8 (C7a), 67.8 (C3), 62.0 (C5), 41.1 (C6), 37.9
(OSO2CH3), 21.6 (C9).
ESIMS m/z 552 (100%) [M+H]+. HRASAPMS found 552.2419, calc for C31H38NO6S,
552.2420 [M+H]+.

6.2.13 General method for Swern oxidation91

(3S,5R,6R,7S,7aS)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3-methylhexahydro1H-pyrrolizin-1-one (197): Oxalyl chloride (79 L, 0.920 mmol) was dropwise via
syringe in to a stirred solution of DMSO (130 L, 1.840 mmol) in CH2Cl2 (5 mL) at
-78 oC.91 The solution was stirred at -78 oC for 5 min and then a solution of 173 (43 mg,
0.092 mmol) in CH2Cl2 (2 mL) cooled to -78 oC was added dropwise via syringe,
followed by Et3N (0.513 mL, 3.680 mmol). The reaction mixture was stirred at -78 oC
for 1 h and then poured into H2O (40 mL) and extracted with Et2O (3 x 30 mL). The
combined organic extracts were washed with brine, dried (MgSO4), and concentrated in
vacuo to give a yellow oil. Purification by flash column chromatography (increasing
polarity from 0:100 to 10:90 of MeOH/CH2Cl2 as eluent) gave the title compound 197
(27 mg, 63%) as a colorless oil, and recovered 173 (13.2 mg, 30%).

Rf 0.61 (5:95 MeOH/CH2Cl2).

[] 25
D = + 28.2 (c 0.32, CHCl3).
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IR max (cm-1): 3030, 2864, 1750, 1698, 1452, 1361, 1270, 1207, 1098, 736, 661.

H (500 MHz, CDCl3): 7.32 - 7.23 (15H, m, ArH), 4.65 (1H, d, J = 11.7 Hz, OCHHPh),
4.60 (1H, d, J = 12.2 Hz, OCHHPh), 4.59 (1H, d, J = 11.7 Hz, OCHHPh), 4.51 (1H, d,
J = 12.2 Hz, OCHHPh), 4.50 (1H, d, J = 11.7 Hz, OCHHPh), 4.36 (1H, d, J = 11.7 Hz,
OCHHPh), 4.18 (1H, t, J = 3.4 Hz, H1), 3.91 (1H, dd, J = 8.8, 3.4 Hz, H2), 3.69 (1H, d,
J = 3.4 Hz, H7a), 3.63 (1H, dd, J = 9.8, 3.4 Hz, H8A), 3.56 (1H, dd, J = 9.8, 4.9 Hz,
H8B), 3.50 - 3.46 (1H, m, H5), 3.35 (1H, dt, J = 8.8, 4.4 Hz, H3), 2.61 (1H, dd, J =
17.6, 6.8 Hz, H6A), 2.10 (1H, dd, J = 17.6, 8.3 Hz, H6B), 1.21 (3H, d, J = 5.9 Hz, H9).

C (125 MHz, CDCl3): 214.7 (C7), 138.5 (ArC), 138.4 (ArC), 137.9 (ArC), 128.5 (2 x
ArCH), 128.4 (4 x ArCH), 128.0 (3 x ArCH), 127.9 (4 x ArCH), 127.8 (2 x ArCH),
83.4 (C2), 78.8 (C1), 73.8 (OCH2Ph), 73.5 (OCH2Ph), 73.1 (OCH2Ph), 72.0 (C8), 71.8
(C7a), 69.1 (C3), 60.7 (C5), 46.6 (C6), 22.5 (C9).
ESIMS m/z 472 (100%) [M+H]+. HRASAPMS found 472.2494, calc for C30H34NO4,
472.2488 [M+H]+.

6.2.14 General method for the reduction of a ketone to a secondary alcohol with
L-selectride® 92

(1S,3S,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3methylhexahydro-1H-pyrrolizin-1-ol (184): A solution of the cyclic ketone 173
(63 mg, 0.134 mmol) in THF (5 mL) was cooled to -78 oC and then L-selectride®
(1.0 M solution in THF, 0.536 mL, 0.536 mmol) was slowly added dropwise.92 The
reaction mixture was stirred at -78 oC for 1 h, warm to rt (22 oC) and stirred for 2 h.
Ammonia solution (1.0 M, 24 mL) was added and the resulting mixture was extracted
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with EtOAc (3 x 50 mL). The combined organic extracts was washed with brine, dried
(K2CO3) and concentrated in vacuo to give a light brown film. Purification by flash
column chromatography (increasing polarity from 0:100 to 10:90 of MeOH/CH2Cl2 as
eluent) gave the title compound (44 mg, 70%) as a colorless oil.

Rf 0.34 (5:95 MeOH/CH2Cl2).

[] 25
D + 36.2 (c 1.26, CHCl3).

IR max (cm-1): 3415, 3030, 2864, 1696, 1452, 1363, 1204, 1098, 1024, 736, 697.

H (500 MHz, CDCl3): 7.33 - 7.28 (15H, m, ArH), 4.74 (1H, d, J = 11.6 Hz, OCHHPh),
4.59 (2H, s, OCH2Ph), 4.53 (2H, s, OCH2Ph), 4.48 (1H, d, J = 11.6 Hz, OCHHPh),
4.37 - 4.33 (2H, m, H1 and H7), 4.02 (1H, dd, J = 5.4, 4.9 Hz, H2), 3.80 (1H, s (br),
H7a), 3.53 (1H, s (br), H8A), 3.47 - 3.41 (2H, m, H5 and H8B), 3.33 (1H, s (br), H3),
2.08 (1H, dd, J = 12.7, 5.4 Hz, H6A), 1.60-1.56 (1H, m, H6B), 1.20 (3H, d, J = 4.4 Hz,
H9).

C (125 MHz, CDCl3): 138.2 (ArC), 137.6 (ArC), 137.5 (ArC), 128.8 (2 x ArCH),
128.7 (2 x ArCH), 128.6 (2 x ArCH), 128.3 (2 x ArCH), 128.1 (4 x ArCH), 128.0
(ArCH), 127.8 (2 x ArCH), 80.6 (C2), 78.6 (C1, br), 73.6 (OCH2Ph), 73.5 (OCH2Ph),
73.2 (C7), 72.9 (OCH2Ph), 71.2 (C8, br), 70.1 (C7a), 69.3 (C3), 62.3 (C5, br), 45.0
(C6), 21.4 (C9, br).
ESIMS m/z 474 [M+H]+. HRASAPMS found 474.2642, calc for C30H36NO4, 474.2644
[M+H]+.
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6.2.15 General method for hydrogenolysis of benzyl ethers60

(1S,2R,3R,5S,7S,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine1,2,7-triol (174): PdCl2 (22 mg, 0.122 mmol) was added to a N2 flushed solution of the
cyclized product 184 (38 mg, 0.081 mmol) in MeOH (6 mL).60 The reaction mixture
was then stirred at rt (22 oC) under a H2 atmosphere (balloon) for 3 h and then filtered
through a pad of celite and washed with MeOH (10 mL). The combined filtrates were
concentrated in vacuo to give a colorless film which was dissolved in water (2 mL) and
held for 15 min in a column containing Amberlyst A-26 (OH-) ion-exchange resin
(1 g). Elution with water (3 x 5 mL) followed by evaporation in vacuo gave the title
compound (14 mg, 84%) as a colorless film.

[] 25
D + 18.5 (c 0.14, H2O).
IR max (cm-1): 3287, 2929, 1589, 1381, 1344, 1199, 1127, 1081.

H (500 MHz, D2O): 4.59 (1H, t, J = 4.9 Hz, H7), 4.41 (1H, dd, J = 5.4, 4.9 Hz, H1),
3.99 (1H, dd, J = 7.3, 4.9 Hz, H2), 3.71 (1H, dd, J = 11.7, 5.4 Hz, H8A), 3.67 (1H, dd, J
= 11.7, 5.8 Hz, H8B), 3.58 (1H, t, J = 5.4 Hz, H7a), 3.40 - 3.32 (1H, m, H5), 3.04 (1H,
app. dt, J = 6.3, 5.4 Hz, H3), 2.11 (1H, dd, J = 13.7, 5.8 Hz, H6), 1.71 (1H, ddd, J =
13.7, 10.2, 4.9 Hz, H6), 1.18 (3H, d, J = 5.9 Hz, H9).

C (125 MHz, D2O): 77.8 (C2), 75.7 (C7), 75.3 (C1), 73.3 (C3), 70.6 (C7a), 65.5 (C8),
64.2 (C5), 46.5 (C6), 22.8 (C9).
ESIMS m/z 204 [M+H]+. HRASAPMS found 204.1239, calc for [C9H18NO4]+,
204.1236 [M+H]+.
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6.3 Experimental for Chapter 3

(1R,3S)-1-((2R,3S,4R,5R)-3,4-Bis(benzyloxy)-5-(benzyloxymethyl)pyrrolidin-2yl)butane-1,3-diol (161)60: Following the general method for hydrolysis of an
oxazolidinone, compound 160 (171 mg, 0.331 mmol) was treated with sodium
hydroxide (38 mg, 1.655 mmol) in ethanol (3 mL) and 3 drops of H2O at 110 oC in a
CEM microwave reactor. Purification by flash column chromatography (0:100 to 5:95
MeOH/CH2Cl2 as eluent) gave the title compound (156 mg, 96%) as a colorless oil.
The spectroscopic data of this compound matched with those in the literature.60

Rf 0.32 (7.5:92.5 MeOH/CH2Cl2).
60
[] 25
[] 24
D + 31.3 (c 0.06, CHCl3). [Lit.
D + 13.6 (c 1.00, CHCl3)].

IR max (cm-1): 3355, 3029, 2894, 2858, 1494, 1451, 1405, 1344, 1208, 1145, 1084,

1051, 731, 694, 656.

H (500 MHz, CDCl3): 7.35 - 7.24 (15H, ArH), 4.85 (1H, d, J = 11.2 Hz, OCHHPh),
4.60 (1H, d, J = 12.2 Hz, OCHHPh), 4.55 (1H, d, J = 12.2 Hz, OCHHPh), 4.53 (1H, d,
J = 11.2 Hz, OCHHPh), 4.49 (1H, d, J = 11.7 Hz, OCHHPh), 4.43 (1H, d, J = 11.7 Hz,
OCHHPh), 4.15 - 4.12 (2H, m, J = 5.0 Hz, H3 and H1′), 3.99 - 3.96 (1H, m, H3′), 3.90
(1H, dd, J = 5.4, 5.0 Hz, H4), 3.53 - 3.47 (2H, m, H1′′), 3.46 - 3.44 (1H, m, H5), 3.10
(1H, dd, J = 8.3, 5.4 Hz, H2), 1.71 (1H, ddd, J = 14.4, 5.4, 2.4 Hz, H2′A), 1.65 (1H,
ddd, J = 14.4, 8.8, 5.8 Hz, H2′B), 1.18 (3H, d, J = 6.4 Hz, H4′).

C (75 MHz, CDCl3): 138.0 (ArC), 137.9 (ArC), 137.8 (ArC), 128.6 (2 x ArCH), 128.5
(4 x ArCH), 128.2 (3 x ArCH), 128.1 (3 x ArCH), 128.0 (ArCH), 127.9 (2 x ArCH),
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80.6 (C4), 79.8 (C3), 73.4 (OCH2Ph), 73.3 (OCH2Ph), 72.6 (OCH2Ph), 70.4 (C1′), 69.8
(C1′′), 65.3 (C3′), 63.1 (C2), 60.7 (C5), 44.6 (C2′), 23.9 (C4′).
ESIMS m/z 492 (100%) [M+H]+.

(1R,3R,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3methylhexahydro-1H-pyrrolizin-1-ol (162)60: Following the general method for
mesylation-cyclization, compound 161 (140 mg, 0.248 mmol) was treated with
triethylamine (40 L, 0.248 mmol), 0.13 M solution of methanesulfonyl chloride in
anhydrous CH2Cl2 (2.2 mL, 0.284 mmol MeSO2Cl) in CH2Cl2 (12.8 mL) at 0 oC for 1.5
h. Purification by flash column chromatography (0:100 to 10:90 MeOH/CH2Cl2 as
eluent) gave the title compound (134 mg, 100%) as a colorless oil. The spectroscopic
data of this compound matched with those in the literature.60

Rf 0.22 (5:95 MeOH/CH2Cl2).
60
[] 25
[] 25
D + 16.5 (c 0.26, CHCl3). [Lit.
D + 25.0 (c 1.00, CHCl3)].

IR max (cm-1): 3354, 2913, 2865, 1453, 1360, 1207, 1139, 1090, 1026, 732, 696.

H (500 MHz, CDCl3): 7.33 - 7.27 (15H, m, ArH), 4.71 (1H, d, J = 12.2 Hz, OCHHPh),
4.66 (1H, dd, J = 8.8, 4.4 Hz H7), 4.58 - 4.50 (5H, m, 5 x OCHHPh), 4.14 (1H, dd, J =
5.4, 4.9 Hz, H1), 3.90 (1H, dd, J = 5.0, 4.4 Hz, H2), 3.70 - 3.67 (1H, m, H5), 3.58 (1H,
dd, J = 4.9, 4.4 Hz, H7a), 3.45 - 3.43 (1H, m, H8A), 3.39 - 3.36 (2H, m, H3 and H8B),
1.85 (2H, dd, J = 7.3, 5.4 Hz, H6), 1.17 (3H, d, J = 6.8 Hz, H9).
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C (125 MHz, CDCl3): 138.4 (ArC), 138.3 (ArC) 138.2 (ArC), 128.5 (2 x ArCH), 128.4
(4 x ArCH), 127.9 (5 x ArCH), 127.8 (3 x ArCH), 127.7 (ArCH), 81.2 (C2), 76.6 (C1),
75.8 (C7a), 73.5 (OCH2Ph), 73.1 (OCH2Ph), 72.2 (OCH2Ph), 71.8 (C8), 71.3 (C7),
60.2 (C3), 56.9 (C5), 42.4 (C6), 16.2 (C9).
ESIMS m/z 474 (100%) [M+H]+.

(R)-3-((2R,3R,4R)-3,4-Bis(benzyloxy)-2-(benzyloxymethyl)-5-oxopyrrolidin-1yl)butanoic acid (201): Following the general method for the Swern oxidation using
162 (107 mg, 0.227 mmol), oxalyl chloride (0.195 mL, 2.270 mmol), DMSO (0.322
mL, 4.540 mmol) and Et3N (1.258 mL, 9.080 mmol) in CH2Cl2 (17 mL). Purification
by flash column chromatography (0:100 to 15:85 MeOH/CH2Cl2 as eluent) gave the
title compound 201 (17 mg, 16%), a mixture of 3 unknown ketones (16 mg, 15%) and
recovered 162 (41.4 mg, 39%), all as colorless oils.

Rf 0.50 (10:90 MeOH/CH2Cl2).

[] 25
D + 33.3 (c 0.33, CHCl3).

IR max (cm-1): 3062, 3030, 2931, 2867, 1696, 1495, 1452, 1354, 1307, 1102, 1026,
774, 657.

H (500 MHz, CDCl3): 7.36 - 7.26 (13H, m, ArH), 7.16 (2H, d, J = 7.5 Hz, ArH), 4.87
(1H, d, J = 12.2 Hz, OCHHPh), 4.71 (1H, d, J = 12.2 Hz, OCHHPh), 4.63 (1H, d, J =
12.2 Hz, OCHHPh), 4.54 (1H, d, J = 12.2 Hz, OCHHPh), 4.43 (1H, d, J = 11.7 Hz,
OCHHPh), 4.39 (1H, d, J = 11.7 Hz, OCHHPh), 4.22 (1H, d, J = 5.4 Hz, H3), 4.05 -
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3.98 (1H, m, H1′), 3.94 (1H, d, J = 5.4 Hz, H4), 3.63 (1H, s (br), H5), 3.48 (1H, dd, J =
10.2, 4.4 Hz, H1′′′A), 3.47 (1H, dd, J = 10.2, 3.4, H1′′′B), 2.96 (1H, dd, J = 16.1, 7.3 Hz,
H2′A), 2.76 (1H, dd, J = 16.1, 6.8 Hz, H2′B), 1.31 (3H, d, J = 2.9 Hz, H1′′).

C (75 MHz, CDCl3): 174.9 (C3′), 172.6 (C2), 137.8 (2 x ArC), 137.5 (ArC), 128.6 (2 x
ArCH), 128.5 (4 x ArCH), 128.3 (2 x ArCH), 128.1 (2 x ArCH), 128.0 (2 x ArCH),
127.9 (ArCH), 127.7 (2 x ArCH), 75.9 (C3), 75.7 (C4), 73.4 (OCH2Ph), 72.7
(OCH2Ph), 71.9 (OCH2Ph), 68.5 (C1′′′), 62.1 (C5), 47.4 (C1′), 38.3 (C2′), 18.2 (C1′′).
ESIMS m/z 526 (100%) [M+Na]+. HRASAPMS found 504.2407, calc for C30H34NO6,
504.2386 [M+H]+.

Swern oxidation of 162 followed by reduction of the resulting ketone to the
secondary alcohol with L-selectride®
(1S,3R,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3methylhexahydro-1H-pyrrolizin-1-ol (200):

(1R,3R,5R,6R,7S,7aS)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3methylhexahydro-1H-pyrrolizin-1-ol (202):

(3R,5R,6R,7R,7aS)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3-methylhexahydro1H-pyrrolizin-1-one (203):

(3R,4R,5R)-3,4-Bis(benzyloxy)-5-(benzyloxymethyl)-1-((R)-4-hydroxybutan-2yl)pyrrolidin-2-one (204):
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Following the general method for Swern oxidation using DMSO (0.778 mL, 10.960
mmol), oxalyl chloride (0.470 mL, 5.480 mmol), alcohol 162 (259 mg, 0.548 mmol),
anhydrous CH2Cl2 (30 mL) and Et3N (3.038 mL, 21.920 mmol) at -78 oC a yellow oil
was obtained which was used without further purification in the next reaction with
L-selectride®.

Following the general method for reduction of a ketone to a secondary alcohols with
L-selectride® using the above Swern oxidation crude product was treated with
L-selectride® (1.0 M solution in THF, 2.194 mL, 2.194 mmol) and THF (20 mL).
Purification by flash column chromatography (2:98 to 15:85 MeOH/CH2Cl2 as eluent)
gave compound 200 (11.7 mg, 4%), 202 (20.5 mg, 7%), 203 (18.0 mg, 7%), 204 (17.8
mg, 8%) and recovered 162 (18.1 mg, 7%).

200: Rf 0.44 (10:90 MeOH/CH2Cl2).

[] 25
D + 11.5 (c 0.33, CHCl3).

IR max (cm-1): 3350, 3030, 2919, 2868, 1690, 1452, 1363, 1097, 1026, 735, 644.

H (500 MHz, CDCl3): 7.34 - 7.26 (15H, m, ArH), 4.81 (1H, d, J = 11.7 Hz, OCHHPh),
4.61 (1H, d, J = 11.7 Hz, OCHHPh), 4.59 (1H, d, J = 11.7 Hz, OCHHPh), 4.55 (1H, d,
J = 11.7 Hz, OCHHPh), 4.54 (2H, s, OCH2Ph), 4.44 - 4.39 (1H, m, H7), 4.34 (1H, dd, J
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= 5.4, 4.9 Hz, H1), 4.04 (1H, dd, J = 5.8, 4.4 Hz, H2), 3.83 (1H, s (br), H7a), 3.68 3.66 (1H, m, H3), 3.60 - 3.55 (2H, m, H5 and H8A), 3.46 - 3.43 (1H, m, H8B), 2.17
(1H, dt, J = 12.2, 6.3 Hz, H6A), 1.69 - 1.78 (1H, m, H6B), 1.28 (3H, d, J = 6.8 Hz, H9).

C (75 MHz, CDCl3): 138.1 (ArC), 137.5 (ArC), 137.3 (ArC), 128.8 (4 x ArCH), 128.6
(2 x ArCH), 128.4 (2 x ArCH), 128.3 (2 x ArCH), 128.2 (2 x ArCH), 128.1 (2 x
ArCH), 128.0 (ArCH), 81.4 (C2), 78.3 (C1), 73.6 (2 x OCH2Ph), 73.0 (OCH2Ph), 71.4
(C7, absent), 70.8 (C8, absent), 68.3 (C7a), 61.2 (C3), 56.6 (C5, absent), 43.0 (C6),
16.8 (C9).
ESIMS m/z 474 (100%) [M+H]+. HRASAPMS found 474.2649, calc for C30H36NO4,
474.2644 [M+H]+.

202: Rf 0.69 (20:80 MeOH/CH2Cl2).

[] 25
D + 30.3 (c 0.12, CHCl3).

IR max (cm-1): 3271, 3030, 2919, 2861, 1454, 1364, 1206, 1102, 1035, 665, 645.

H (500 MHz, CDCl3): 7.35 - 7.18 (15H, m, ArH), 4.71 (1H, d, J = 12.7 Hz, OCHHPh),
4.68 (1H, d, J = 12.7 Hz, OCHHPh), 4.56 (2H, s, OCHHPh), 4.45 (1H, d, J = 11.7 Hz,
OCHHPh), 4.39(1H, d, J = 11.7 Hz, OCHHPh), 4.20 (1H, dd, J = 7.3, 4.9 Hz, H1), 4.07
- 4.04 (2H, m, H7 and H7a), 3.85 (1H, s (br), H2), 3.71 (1H, dd, J = 10.5, 2.9 Hz, H8A),
3.48 (1H, s (br), H3), 3.33 (1H, dd, J = 10.5, 2.0 Hz, H8B), 3.24 - 3.20 (1H, m, H5),
2.05 (1H, dd, J = 12.7, 5.4 Hz, H6A), 1.72 (1H, td, J = 12.7, 3.4 Hz, H6B), 1.30 (3H, d,
J = 5.8 Hz, H9).

C (125 MHz, CDCl3): 138.8 (ArC), 136.9 (2 x ArC), 128.7 (2 x ArCH), 128.5 (2 x
ArCH), 128.3 (2 x ArCH), 128.1 (2 x ArCH), 127.9 (2 x ArCH), 127.7 (2 x ArCH),
84.1 (C7*), 75.6 (C1, br), 73.7 (OCH2Ph), 73.3 (C2, br), 72.2 (OCH2Ph), 71.8
(OCH2Ph), 71.6 (C7a, br), 68.0 (C8*), 62.0 (C3), 50.2 (C5*), 46.6 (C6, br), 29.8 (C9).
* observed in gHMBC spectrum.
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ESIMS m/z 474 (100%) [M+H]+. HRASAPMS found 474.2635, calc for C30H36NO4,
474.2644 [M+H]+.

203: Rf 0.32 (5:95 MeOH/CH2Cl2).

[] 25
D - 62.5 (c 0.81, CHCl3).

IR max (cm-1): 3031, 2926, 2870, 1717, 1452, 1361, 1267, 1097, 737, 697.

H (500 MHz, CDCl3): 7.32 - 7.24 (13H, m, ArH), 7.20 (2H, d, J = 7.0 Hz, ArH), 4.55
(2H, d, J = 12.0 Hz, OCHHPh), 4.45 (1H, J = 12.0 Hz, OCHHPh), 4.43 (2H, d, J =
12.0 Hz, OCHHPh), 4.34 (1H, J = 12.0 Hz, OCHHPh), 4.15 (1H, s, H1), 3.99 (1H, s,
H2), 3.71 - 3.67 (2H, m, H5 and H7a), 3.54 - 3.48 (3H, m, H3 and H8), 2.25 - 2.13 (2H,
m, H6), 1.36 (3H, d, J = 6 .7 Hz, H9).

C (125 MHz, CDCl3): 218.0 (C7), 138.4 (ArC), 137.6 (2 x ArC), 128.7 (2 x ArCH),
128.6 (2 x ArCH), 128.5 (2 x ArCH), 128.0 (2 x ArCH), 127.8 (4 x ArCH), 127.6 (3 x
ArCH), 84.0 (C1), 83.0 (C2), 76.4 (C7a), 73.3 (OCH2Ph), 73.0 (C8), 71.6 (OCH2Ph),
70.9 (OCH2Ph), 62.7 (C3), 54.5 (C5), 43.1 (C6), 17.2 (C9).
ESIMS m/z 472 (100%) [M+H]+. HRASAPMS found 472.2469, calc for C30H34NO4,
472.2488 [M+H]+.

204: Rf 0.54 (5:95 MeOH/CH2Cl2).

[] 25
D + 77.2 (c 0.95, CHCl3).

IR max (cm-1): 3400, 2929, 2866, 1645, 1452, 1359, 1259, 1101, 1025, 697.
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H (500 MHz, CDCl3): 7.38 - 7.16 (15H, m, ArH), 4.93 (1H, d, J = 12.2 Hz, OCHHPh),
4.76 (1H, d, J = 12.2 Hz, OCHHPh), 4.70 (1H, d, J = 12.2 Hz, OCHHPh), 4.53 (1H, d,
J = 12.2 Hz, OCHHPh), 4.42 (2H, s, OCH2Ph), 4.36 (1H, d, J = 4.9 Hz, H3), 4.33 4.26 (1H, m, H1′), 4.01 (1H, d, J = 4.9 Hz, H4), 3.57 (2H, s (br), H3′A and H5), 3.52
(1H, s (br), H3′B), 3.48 (1H, dd, J = 10.2, 2.9 Hz, H1′′′A), 3.44 (1H, dd, J = 10.2, 4.9
Hz, H1′′′B), 1.74 - 1.70 (2H, m, H2′), 1.17 (1H, d, J = 7.3 Hz, H1′′).

C (125 MHz, CDCl3): 173.8 (C2), 137.9 (2 x ArC), 137.3 (ArC), 128.7 (2 x ArCH),
128.5 (2 x ArCH), 128.4 (2 x ArCH), 128.2 (2 x ArCH), 128.1 (ArCH), 128.0 (2 x
ArCH), 127.9 (ArCH), 127.8 (3 x ArCH), 76.9 (C4), 76.2 (C3), 73.6 (OCH2Ph), 72.7
(OCH2Ph), 72.3 (OCH2Ph), 69.1 (C1′′′), 59.9 (C5), 58.6 (C3′), 45.1 (C1′), 36.1 (C2′),
19.8 (C1′′).
ESIMS m/z 512 (100%) [M+Na]+. HRESIMS found 512.2413, calc for C30H35NO5Na,
512.2413 [M+Na]+.

(1S,3R,5R,6R,7R,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3methylhexahydro-1H-pyrrolizin-1-ol (206): Following the general method for the
reduction of a ketone to a secondary alcohol with L-selectride®, the ketone 203 (16 mg,
0.034 mmol) was treated with L-selectride® (1.0 M solution in THF, 0.136 mL, 0.136
mmol) in CH2Cl2 (6 mL). Purification by flash column chromatography (2:98 to 10:90
MeOH/CH2Cl2 as eluent) gave the title compound (9 mg, 58%) as a colorless oil.
Rf 0.54 (10:90 MeOH/CH2Cl2).

[] 25
D - 16.5 (c 0.47, CHCl3).
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IR max (cm-1): 3369, 3063, 3032, 2927, 2865, 1690, 1454, 1365, 1207, 1099, 1028,
740, 670.

H (500 MHz, CDCl3): 7.31 - 7.24 (15H, m, ArH), 4.61 (1H, d, J = 11.6 Hz, OCHHPh),
4.56 (1H, d, J = 11.7 Hz, OCHHPh), 4.55 (1H, d, J = 11.7 Hz, OCHHPh), 4.50 (1H, d,
J = 12.0 Hz, OCHHPh), 4.46 (1H, d, J = 11.6 Hz, OCHHPh), 4.44 (1H, d, J = 12.0 Hz,
OCHHPh), 4.28 (1H, s (br), H7), 4.18 (1H, s, H1), 4.09 (1H, s, H2), 3.70 (1H, br, H7a),
3.50 (1H, s (br), H8A), 3.45 (1H, dd, J = 9.1, 8.8 Hz, H8B), 3.38 (1H, s (br), H3), 3.20
(1H, br, H5), 2.24 (1H, dt, J = 12.5, 5.9 Hz, H6A), 1.37 (1H, dd, J =12.5, 10.5 Hz,
H6B), 1.24 (3H, d, J = 6.6 Hz).

C (125 MHz, CDCl3): 138.4 (ArC), 138.2 (ArC), 137.2 (ArC), 128.8 (2 x ArCH),
128.6 (4 x ArCH), 128.3 (3 x ArCH), 128.0 (2 x ArCH), 127.9 (3 x ArCH), 127.8
(ArCH), 85.6 (C2), 82.6 (C1, br), 73.7 (C7), 73.5 (C7a*), 73.4 (OCH2Ph), 72.8 (C8*),
71.8 (2 x OCH2Ph), 62.5 (C3, br), 54.6 (C5, br), 42.9 (C6, br), 17.0 (C9, br). * observed
in gHMBC spectrum.
ESIMS m/z 474 (100%) [M+H]+. HRASAPMS found 474.2652, calc for C30H36NO4,
474.2644 [M+H]+.

(1S,2R,3R,5R,7S,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine1,2,7-triol (hyacinthacine B5) (12): Following the general method for hydrogenolysis
of benzyl ethers, the alcohol 200 (11.7 mg, 0.025 mmol) was treated with PdCl2
(6.6 mg, 0.038 mmol) and MeOH (2 mL) at rt (19 oC) for 3 h. The title compound
(1.5 mg, 21%) was obtained as a colorless film.
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29
[] 25
[]D - 25.4 (c 0.26, H2O), temperature not reported].
D - 21.6 (c 0.08, H2O). [Lit.

IR max (cm-1): 3299, 2953, 1587, 1555, 1399, 1044, 839, 760, 692.

H (500 MHz, D2O): 4.55 (1H, td, J = 7.1, 6.8 Hz, H7), 4.34 (1H, dd, J = 4.4, 3.9 Hz,
H1), 4.04 (1H, dd, J = 7.3, 4.4 Hz, H2), 3.69 (1H, dd, J = 11.2, 4.4 Hz, H8A), 3.65 (1H,
dd, J = 11.2, 5.4 Hz, H8B), 3.52 (1H, dd, J = 6.9, 4.4 Hz, H7a), 3.39 (1H, td, J = 6.1,
5.3 Hz, H3), 3.34 - 3.30 (1H, m, H5), 2.19 (1H, dt, J = 12.7, 6.3 Hz, H6), 1.79 (1H, dt,
J = 12.7, 8.3 Hz, H6), 1.29 (3H, d, J = 6.8 Hz, H9).

C (75 MHz, D2O): 77.6 (C2), 75.6 (C7), 75.1 (C1), 69.7 (C7a), 66.0 (C8), 65.3 (C3),
57.7 (C5), 44.3 (C6), 18.1 (C9).
ESIMS m/z 204 (100%) [M+H]+. HRASAPMS found 204.1249, calc for C9H18NO4,
204.1236 [M+H]+.

(1R,2R,3R,5R,7S,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine1,2,7-triol (hyacinthacine B4) (11): Following the general method for hydrogenolysis
of benzyl ethers, the alcohol 206 (8.4 mg, 0.018 mmol) was treated with PdCl2 (4.8 mg,
0.027 mmol) and MeOH (1.4 mL) at rt (22 oC) for 3 h. The title compound (3.6 mg,
100%) was obtained as a colorless film.

29
[] 25
[]D - 6.7 (c 1.19, H2O), temperature not reported].
D - 7.7 (c 0.18, H2O). [Lit.

IR max (cm-1): 3291, 2930, 2882, 1637, 1592, 1384, 1343, 1137, 1064, 612.
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H (500 MHz, D2O): 4.44 (1H, td, J = 6.4, 5.7 Hz, H7), 4.16 (1H, dd, J = 7.8, 7.3 Hz,
H1), 3.97 (1H, dd, J = 7.8, 7.0 Hz, H2), 3.69 (2H, d, J = 5.4 Hz, H8), 3.30 (1H, dd, J =
7.3, 6.8 Hz, H7a), 3.28 - 3.24 (1H, m, H5), 3.14 (1H, dt, J = 7.8, 5.4 Hz, H3), 2.14 (1H,
dt, J = 13.2, 5.7 Hz, H6), 1.71 (1H, ddd, J = 13.2, 7.3, 6.4 Hz, H6), 1.26 (3H, d, J =
7.3 Hz, H9).

C (125 MHz, D2O): 82.0 (C2), 77.1 (C1), 73.1 (C7), 72.9 (C7a), 66.0 (C8), 64.5 (C3),
57.0 (C5), 42.7 (C6), 19.0 (C9).
ESIMS m/z 204 (100%) [M+H]+. HRASAPMS found 204.1246, calc for C9H18NO4,
204.1236 [M+H]+.

(1S,2R,3R,5R,7R,7aS)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine1,2,7-triol (7a-epi-hyacinthacine B3) (207): Following the general method for
hydrogenolysis of benzyl ethers, the alcohol 202 (2.3 mg, 0.005 mmol) was treated
with PdCl2 (1.3 mg, 0.008 mmol), and MeOH (0.5 mL) at rt (24 oC). The title
compound (1.0 mg, 100%) was obtained as a colorless film.

[] 25
D - 5.3 (c 0.11, H2O).
IR max (cm-1): 3294, 2967, 1649, 1552, 1405, 1083, 1044.

H (500 MHz, D2O): 4.38 (1H, t, J = 3.9 Hz, H7), 4.26 (1H, dd, J = 4.4, 3.9 Hz, H1),
4.08 (1H, dd, J = 7.3, 4.9 Hz, H2), 3.97 (1H, dd, J = 12.7, 6.8 Hz, H8A), 3.89 (1H, dd,
J = 12.7, 3.9 Hz, H8B), 3.59 (1H, dd, J = 4.4, 3.9 Hz, H7a), 3.51, (1H, ddd, J = 5.9, 4.4,
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3.9 Hz, H5), 3.23 (1H, ddd, J = 6.8, 4.9, 3.9 Hz, H3), 2.05 (1H, ddd, J = 13.2, 4.4, 3.9
Hz, H6), 1.71 (1H, ddd, J = 13.2, 11.2, 4.4 Hz, H6), 1.22 (3H, d, J = 5.9 Hz, H9).

C (125 MHz, D2O): 77.5 (C7a), 76.4 (C2), 72.1 (C7), 72.0 (C1), 66.8 (C3), 61.4 (C8),
55.2 (C5), 46.3 (C6), 22.0 (C9).
ESIMS m/z 204 (100%) [M+H]+. HRASAPMS found 204.1234, calc for C9H18NO4,
204.1236 [M+H]+.

(1R,3R,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3methylhexahydro-1H-pyrrolizin-1-yl 4-nitrobenzoate (209): Following the general
method for the Mitsunobu reaction, the alcohol 162 (0.144 g, 0.300 mmol) was treated
with triphenylphosphine (0.354 g, 1.350 mmol), p-nitrobenzoic acid (0.226 g, 1.350
mmol) and diisopropyl azodicarboxylate (0.266 mL, 3.959 mmol) in toluene (3 mL) at
80 oC for 2 d. Purification by flash column chromatography (20:70 to 50:50
EtOAc/petrol as eluent) gave the title compound (ca 70% pure) (40 mg) as a yellow
film and recovered 162 (45.5 mg, 32%) was also isolated.

Rf 0.60 (5:95 MeOH/CH2Cl2).
IR max (cm-1): 2921, 2854, 1722, 1527, 1347, 1273, 1103, 1027, 736, 697.

H (500 MHz, CDCl3): 8.28 (2H, d, J = 8.8 Hz, ArH), 8.16 (2H, d, J = 8.8 Hz, ArH),
7.37 - 7.22 (15H, m, ArH), 5.77 (1H, dt, J = 7.3, 4.1 Hz, H7), 4.75 (1H, d, J = 11.7 Hz,
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OCHHPh), 4.64 - 4.47 (5H, m, 5 x OCHHPh), 4.19 (1H, dd, J = 5.3, 4.1 Hz, H1), 3.93
(1H, s (br), H2), 3.78 (1H, dd, J = 5.3, 3.2 Hz, H7a), 3.68 - 3.60 (1H, m, H5), 3.42 (3H,
s (br), H3 and H8), 2.01 (2H, m, H6), 1.27 (3H, d, J = 6.2 Hz, H9).

C (125 MHz): 164.4 (C=O), 150.6 (ArC), 138.3 (2 x ArC), 138.2 (ArC), 135.7 (ArC),
130.8 (2 x ArCH), 128.7 (2 x ArCH), 128.5 (4 x ArCH), 127.9 (3 x ArCH), 127.8 (5 x
ArCH), 127.7 (2 x ArCH), 123.6 (ArCH), 81.4 (C2), 76.9 (C1), 76.1 (C7, br), 73.5
(OCH2Ph), 73.4 (OCH2Ph), 72.6 (OCH2Ph), 72.4 (C8), 60.1 (C3), 56.7 (C5), 39.8 (C6),
22.1 (C1).
ESIMS m/z 623 (100%) [M+H]+. HRESIMS found 623.2737, calc for C37H39N2O7,
623.2757 [M+H]+.

(1R,3R,5R,6R,7S,7aS)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3methylhexahydro-1H-pyrrolizin-1-yl methanesulfonate (210): Following the general
method for mesylation-cyclization, the alcohol 162 (16.8 mg, 0.034 mmol) was treated
with triethylamine (81 L, 0.578 mmol), methanesulfonyl chloride (0.184 mL, 2.380
mmol) and CH2Cl2 (1.5 mL) at rt for 1 d. Purification by flash column chromatography
(0:100 to 5:95 MeOH/CH2Cl2 as eluent) gave the title compound (16.5 mg, 87%) as a
colorless oil.

Rf 0.67 (5:95 MeOH/CH2Cl2).
[] 25
D - 10.5 (c 0.16, CHCl3).
IR max (cm-1): 3063, 3030, 2929, 2866, 1453, 1351, 1174, 1116, 1026, 935, 895, 697.

Chapter 6 | 191

H (500 MHz, CDCl3): 7.35 - 7.25 (15H, m, ArH), 5.50 - 5.49 (1H, m, H7), 4.59 - 4.44
(6H, m, 6 x OCHHPh), 4.22 (1H, dd, J = 5.9, 4.9 Hz, H1), 3.89 (1H, s (br), H2), 3.66 3.64 (1H, m, H7a), 3.56 - 3.49 (1H, m, H5), 3.33 (1H, dd, J = 8.5, 4.4 Hz, H8A), 3.28 3.25 (1H, m, H3), 3.20 (1H, dd, J = 8.5, 7.8 Hz, H8B), 2.81 (3H, s, OSO2CH3), 2.06
(1H, dd, J = 13.7, 4.9 Hz, H6A), 1.93 - 1.86 (1H, m, H6B), 1.19 (3H, d, J = 6.8 Hz,
H9).


C (75 MHz, CDCl3): 138.3 (ArC), 137.9 (2 x ArC), 132.2 (2 x ArCH), 128.5 (ArCH),
128.2 (4 x ArCH), 128.0 (2 x ArCH), 127.9 (4 x ArCH), 127.8 (2 x ArCH), 83.3 (C7),
79.2 (C2), 77.2 (C1), 73.6 (OCH2Ph), 73.4 (C7a), 72.9 (OCH2Ph), 72.4 (C8), 71.6
(OCH2Ph), 60.6 (C3), 56.8 (C5), 39.9 (C6), 37.7 (OSO2CH3), 15.5 (C9).
ESIMS m/z 552 (100%) [M+H]+. HRESIMS found 552.2418, calc for C31H38NO6S,
552.2420 [M+H]+.

(1R,3R,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3methylhexahydro-1H-pyrrolizin-1-yl benzoate (212): A solution of the mesylate 210
(31 mg, 0.056 mmol) in DMSO (6 mL) was stirred at rt for 5 min and then cesium
benzoate (26 mg, 0.106 mmol) was added.96 The reaction mixture was stirred at 70 oC
for 2 d. After the reaction mixture had cooled to rt, sat. sodium carbonate (5 mL) was
added and then extracted with Et2O (3 x 20 mL), dried (MgSO4) and concentrated in
vacuo to give a light brown film. Purification by flash column chromatography
(increasing polarity from 5:95 to 20:80 of EtOAc/CH2Cl2 as eluent) gave the title
compound (14 mg, 42%) as a colorless film.

Rf 0.20 (2:98 MeOH/CH2Cl2).
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[] 25
D - 18.7 (c 0.28, CHCl3).

IR max (cm-1): 3063, 3031, 2924, 2862, 1715, 1452, 1358, 1273, 1111, 1025, 736, 696.

H (500 MHz, CDCl3): 8.01 (2H, d, J = 7.8 Hz, ArH), 7.52 (1H, t, J = 7.3 Hz, ArH),
7.42 (2H, dd, J = 7.8, 7.3 Hz, ArH), 7.33 - 7.22 (15H, m, ArH), 5.75 - 5.72 (1H, m,
H7), 4.74 (1H, d, J = 11.7 Hz, OCHHPh), 4.67 (1H, d, J = 11.7 Hz, OCHHPh), 4.62
(1H, d, J = 11.7 Hz, OCHHPh), 4.56 (1H, d, J = 12.2 Hz, OCHHPh), 4.51 (1H, d, J =
11.7 Hz, OCHHPh), 4.49 (1H, d, J = 12.2 Hz, OCHHPh), 4.18 (1H, dd, J = 4.9, 3.9 Hz,
H1), 3.92 (1H, t, J = 3.9 Hz, H2), 3.78 (1H, s (br), H7a), 3.66 - 3.62 (1H, m, H5), 3.43
(3H, s (br), H3 and H8), 2.02 - 2.00 (2H, m, H6), 1.22 (3H, d, J = 6.8 Hz, H9).

C (125 MHz, CDCl3): 166.4 (C=O), 138.6 (2 x ArC), 138.4 (ArC), 133.0 (2 x ArCH),
130.7 (ArC), 129.7 (2 x ArCH), 128.4 (4 x ArCH), 127.9 (2 x ArCH), 127.8 (4 x
ArCH), 127.7 (2 x ArCH), 127.6 (2 x ArCH), 81.7 (C2), 76.9 (C1), 75.6 (C7), 73.5
(OCH2Ph), 73.3 (OCH2Ph), 72.5 (C7a and OCH2Ph), 72.2 (C8), 59.9 (C3), 56.4 (C5),
39.9 (C6), 16.2 (C9).
ESIMS m/z 578 [M+H]+. HRESIMS found 578.2902, calc for C37H40NO5, 578.2906
[M+H]+.

6.3.1 General method for the preparation of p-bromobenzoate derivatives97
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(1R,3S,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3methylhexahydro-1H-pyrrolizin-1-yl

4-bromobenzoate

(125):

Triethylamine

(17 L, 0.125 mmol) and DMAP (9 mg, 0.075 mmol) were added to the solution of
compound 173 (24 mg, 0.050 mmol) in CH2Cl2 (1 mL) under a nitrogen atmosphere
followed by p-nitrobenzoyl chloride (27 mg, 0.125 mmol).97 The reaction mixture was
stirred at rt (18 oC) for 2 d, water (5 mL) was then added and extracted with CH2Cl2
(3 x 25 mL). The combined organic extracts were washed with sat. sodium bicarbonate
solution, dried (MgSO4) and concentrated in vacuo to give a yellow oil. Purification by
flash column chromatography (increasing polarity from 0:100 to 1:99 of
MeOH/CH2Cl2 as eluent) gave the title compound (29 mg, 88%) as a colorless oil.
Rf 0.54 (2:98 MeOH/CH2Cl2).

[] 25
D + 5.1 (c 1.02, CHCl3).

IR max (cm-1): 3031, 2863, 1715, 1588, 1491, 1452, 1360, 1270, 1108, 1010, 849, 735,
697.

H (500 MHz, CDCl3) 7.87 (2H, d, J = 8.0 Hz, ArH), 7.57 (2H, d, J = 8.0 Hz, ArH),
7.37 (2H, d, J = 7.5 Hz, ArH), 7.30 - 7.24 (13H, m, ArH), 5.64 (1H, dt, J = 10.9, 5.7
Hz, H7), 4.92 (1H, d, J = 11.4 Hz, OCHHPh), 4.75 (1H, d, J = 11.5 Hz, OCHHPh),
4.58 (1 H, d, J = 12.2 Hz, OCHHPh), 4.57 (1H, d, J = 11.7 Hz, OCHHPh), 4.49 (1 H,
d, J = 12.2 Hz, OCHHPh), 4.42 (1H, d, J = 11.7 Hz, OCHHPh), 4.17 (1 H, s (br), H1),
3.97 (1H, dd, J = 8.8, 2.9 Hz, H2), 3.64 (1 H, s (br), H7a), 3.59 (1H, dd, J = 9.7, 3.2 Hz,
H8A), 3.52 (1H, dd, J = 9.7, 4.4 Hz, H8B), 3.19 - 3.10 (2H, m, H3 and H5), 2.45 (1H,
dt, J = 12.8, 6.5 Hz, H6A), 1.93 - 1.85 (1H, m, H6B), 1.19 (3H, d, J = 6.2 Hz, H9).

C (125 MHz, CDCl3) 166.0 (C=O), 139.0 (ArC), 138.6 (ArC), 138.1 (ArC), 131.8 (2 x
ArCH), 131.2 (2 x ArCH), 129.3 (ArC), 128.5 (2 x ArCH), 128.4 (4 x ArCH), 128.2
(ArC), 128.0 (2 x ArCH), 127.9 (2 x ArCH), 127.8 (ArCH), 127.7 (2 x ArCH), 127.5 (2
x ArCH), 83.5 (C2), 77.8 (C1), 74.6 (C7), 73.9 (OCH2Ph), 73.5 (OCH2Ph), 73.0
(OCH2Ph), 72.2 (C7a), 71.8 (C8), 67.4 (C3), 62.5 (C5), 40.7 (C6), 21.8 (C9).
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ESIMS m/z 656 [M(Br79)+H]+ (100%), 658 [M(Br81)+H]+ (95%). HRESIMS found
656.2045, calc for C37H39NO5Br79, 656.2012 [M+H]+.

(1R,3R,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3methylhexahydro-1H-pyrrolizin-1-yl 4-bromobenzoate (216): Following the general
method for the preparation of p-bromobenzoate derivatives, compound 162 (27 mg,
0.058 mmol) was treated with p-nitrobenzoyl chloride (32 mg, 0.145 mmol),
triethylamine (20 L, 0.145 mmol) and DMAP (11 mg, 0.087 mmol) in CH2Cl2 (2 mL)
rt (18 oC) for 2 d. Purification by flash column chromatography (0:100 to 1:99
MeOH/CH2Cl2 as eluent) gave the title compound (18 mg, 48%) as a colorless oil.
Rf 0.40 (2:98 MeOH/CH2Cl2).

[] 25
D - 23.0 (c 1.08, CHCl3).

IR max (cm-1): 3030, 2863, 1716, 1589, 1453, 1396, 1360, 1270, 1100, 1010, 847, 734,
635.

(500 MHz, CDCl3) 7.85 (2H, d, J = 8.4 Hz, ArH), 7.54 (2H, d, J = 8.4 Hz, ArH), 7.34 7.23 (15H, m, ArH), 5.73 - 5.71 (1H, m, H7), 4.74 (1H, d, J = 11.6 Hz, OCHHPh)),
4.64 (1H, d, J = 11.6 Hz, OCHHPh), 4.61 (1H, d, J = 12.0 Hz, OCHHPh), 4.56 (1H, d,
J = 12.0 Hz, OCHHPh), 4.52 - 4.47 (2H, m, 2 x OCHHPh), 4.17 (1H, t, J = 4.5 Hz,
H1), 3.92 (1H, t, J = 3.9 Hz, H2), 3.75 (1H, s (br), H7a), 3.62 (1H, td, J = 12.9, 6.1 Hz,
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H5), 3.41 (3H, s (br), H3 and H8), 2.02 - 1.96 (2H, m, H6,), 1.21 (3H, d, J = 6.8 Hz,
H9).

C (125 MHz, CDCl3) 165.6 (C=O), 138.5 (2 x ArC), 138.3 (ArC), 131.8 (2 x ArCH),
131.2 (2 x ArCH), 129.6 (ArC), 128.5 (2 x ArCH), 128.4 (2 x ArCH), 128.0 (ArC),
127.7 (5 x ArCH), 127.6 (2 x ArCH), 81.5 (C2), 76.9 (C1), 76.0 (C7), 73.5 (OCH2Ph),
73.3 (2 x OCH2Ph), 72.5 (C7a), 72.1 (C8), 59.9 (C3), 56.4 (C5), 39.9 (C6), 16.2 (C9).
ESIMS m/z 656 [M(Br79)+H]+ (100%), 658 [M(Br81)+H]+ (90%). HRESIMS found
656.2040, calc for C37H39NO5Br79, 656.2012 [M+H]+.

6.4 Experimental for Chapter 4

(2S,3S,4R,5R,E)-1,3-Bis(benzyloxy)-5-((R)-but-3-en-2-ylamino)-7-phenylhept-6ene-2,4-diol (219): Triethylamine (0.987 mL, 7.081 mmol) was added to the solution
of (R)--methylallyl amine hydrochloride salt 218 (0.504 g, 7.081 mmol) in ethanol
(100 mL) and then stirred at rt (25 oC) for 15 min.100 The 3,5-di-O-benzyl-,-Lxylofuranose 21798,99 (2.125 g, 6.437 mmol) and (E)-2-phenylvinylboronic acid (1.048
g, 0.081 mmol) were added to the reaction mixture. The reaction mixture was stirred at
rt (18 oC) for 3 d and concentrated in vacuo to give a brown oil. The crude oil was
dissolved in EtOAc (100 mL) and washed with 0.5 M NaOH solution (2 x 80 mL),
dried (MgSO4) and concentrated in vacuo to give a brown oil. Purification by flash
column chromatography (increasing polarity from 0:100 to 4:96 of MeOH/CH2Cl2 as
eluent) gave the title compound (2.102 g, 67%) as a yellow oil.

Rf 0.12 (5:95 MeOH/CH2Cl2).
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[] 25
D - 40.9 (c 0.66, CHCl3).

IR max (cm-1): 3389, 3298, 3061, 3029, 2921, 2863, 1497, 1451, 1366, 1073, 975, 916,
740, 641.

H (500 MHz, CDCl3) 7.35 - 7.21 (15H, m, ArH), 6.46 (1H, d, J = 16.0 Hz, H7), 6.09
(1H, dd, J = 16.0, 8.9 Hz, H6), 5.71 (1H, ddd, J = 17.2, 10.1, 7.4 Hz, H2′), 5.04 (1H, d,
J = 17.2 Hz, H3′trans), 4.98 (1 H, d, J = 10.1 Hz, H3′cis), 4.61 (2H, s, OCH2Ph), 4.47
(1H, d, J = 11.7 Hz, OCHHPh), 4.42 (1H, d, J = 11.7 Hz, OCHHPh), 4.03 (1H, s (br),
H2), 3.95 (1H, t, J = 4.8 Hz, H4), 3.65 (1H, s (br), H3), 3.62 - 3.58 (1H, m, H1A), 3.55
(1H, dd, J = 9.2, 5.7 Hz, H1B), 3.46 (1H, dd, J = 8.6, 4.8 Hz, H5), 3.29 – 3.25 (1H, m,
H1′), 1.09 (3H, d, J = 6.3 Hz, H1″).

C (125 MHz, CDCl3) 142.2 (C2′), 138.1 (ArC), 138.0 (ArC), 136.7 (ArC), 133.0 (C7),
128.6 (2 x ArCH), 128.4 (4 x ArCH), 128.2 (C6 + (2 x ArCH)), 127.8 (3 x ArCH),
127.7 (2 x ArCH), 126.5 (2 x ArCH), 114.3 (C3′), 79.9 (C3), 74.3 (OCH2Ph), 73.3
(OCH2Ph), 72.3 (C4), 71.3 (C1), 69.9 (C2), 60.2 (C5), 52.5 (C1′), 20.2 (C1″).
ESIMS m/z 488 [M+H]+. HRESIMS found 488.2813, calc for C31H38NO4, 488.2801
[M+H]+.

(2R,3R,4R,5R)-4-(Benzyloxy)-5-(benzyloxymethyl)-1-((R)-but-3-en-2-yl)-2styrylpyrrolidin-3-ol (230):

(2R,3R,4R,5R)-4-(Benzyloxy)-5-(benzyloxymethyl)-1-((R)-but-3-en-2-yl)-2styrylpyrrolidin-3-yl methanesulfonate (232)
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Following the general method for mesylation-cyclization, the alcohol 129 (0.127 g,
0.260 mmol) was treated with triethylamine (36 L, 0.260 mmol) and 0.13 M solution
of methanesulfonyl chloride in CH2Cl2 (2.00 mL, 0.260 mmol MeSO2Cl) in CH2Cl2
(3 mL) at 0 oC for 0.5 h. Triethylamine (36 L, 0.260 mmol) was then added and the
mixture was stirred and heated at reflux for 10 h. Purification by flash column
chromatography (0:100 to 10:90 EtOAc/CH2Cl2 as eluent) gave compound 230 (58 mg,
47%) and product 232 (21 mg, 15%), both as colorless oils.

230: Rf 0.26 (2:98 MeOH/CH2Cl2).

[] 25
D + 57.7 (c 0.53, CHCl3).

IR max (cm-1): 3417, 3063, 3029, 2970, 2917, 2863, 1499, 1451, 1363, 1082, 972, 918,
665, 604.

H (500 MHz, CDCl3) 7.38 - 7.20 (15H, m, ArH), 6.57 (1H, dd, J = 16.0, 9.6 Hz, H1‴),
6.48 (1H, d, J = 16.0 Hz, H2‴), 5.80 (1H, ddd, J = 17.3, 10.1, 7.8 Hz, H2′), 5.06 (1H, d,
J = 17.3 Hz, H3′trans), 4.94 (1 H, d, J = 10.1 Hz, H3′cis), 4.62 - 4.48 (4H, m, 4 x
OCHHPh), 3.98 - 3.96 (2H, m, H2 and H3), 3.93 (1H, s, H4), 3.57 (1H, dt, J = 8.7, 4.4
Hz, H1‴′A), 3.52 - 3.43 (2H, m, H1′ and H1‴′B), 3.33 (1H, s, H5), 1.15 (3H, d, J = 6.4
Hz, H1″).

C (125 MHz, CDCl3) 142.9 (C2′), 138.3 (ArC), 137.8 (ArC), 137.4 (ArC), 131.3
(C2‴), 130.3 (C1‴), 128.6 (4 x ArCH), 128.5 (2 x ArCH), 128.0 (ArCH), 127.9 (2 x
ArCH), 127.8 (2 x ArCH), 127.7 (ArCH), 127.3 (ArCH), 126.5 (2 x ArCH), 114.5
(C3′), 88.6 (C4), 77.9 (C3), 73.6 (OCH2Ph), 72.7 (C2), 71.6 (OCH2Ph), 71.5 (C1‴′),
66.2 (C5), 56.9 (C1′), 19.7 (C1″).
ESIMS m/z 470 [M+H]+. HRESIMS found 470.2691, calc for C31H36NO3, 470.2695
[M+H]+.
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232: Rf 0.73 (2:98 MeOH/CH2Cl2).

[] 25
D + 29.7 (c 0.24, CHCl3).

IR max (cm-1): 3028, 2933, 2865, 1495, 1452, 1359, 1175, 1077, 965, 843, 745, 624.

H (500 MHz, CDCl3) 7.34 - 7.21 (15H, m, ArH), 6.57 (1H, d, J = 15.9 Hz, H2‴), 6.38
(1H, dd, J = 15.9, 9.5 Hz, H1‴), 5.88 (1H, ddd, J = 17.4, 10.2, 7.6 Hz, H2′), 5.10 (1H,
d, J = 17.4 Hz, H3′trans), 5.02 (1H, d, J = 10.2 Hz, H3′cis), 4.88 (1H, s, H3), 4.64 (2H, s,
OCH2Ph), 4.52 - 4.49 (2H, m, OCH2Ph), 4.17 (1H, s, H4), 4.11 (1H, d, J = 9.5 Hz, H2),
3.57 (1H, dd, J = 8.9, 3.2 Hz, H1‴′A), 3.54 - 3.51 (1H, m, H1′), 3.42 (1H, s (br), H5),
3.40 - 3.34 (1H, m, H1‴′B), 2.87 (3H, s, OSO2CH3), 1.13 (3H, d, J = 6.4 Hz, H1″).

C (125 MHz, CDCl3) 141.6 (C2′), 138.4 (ArC), 137.9 (ArC), 136.6 (ArC), 133.6
(C2‴), 128.7 (4 x ArCH), 128.5 (4 x ArCH), 128.1 (2 x ArCH), 127.9 (ArCH), 127.8 (3
x ArCH), 127.5 (ArCH), 126.8 (C1‴), 126.7 (2 x ArCH), 115.3 (C3′), 87.1 (C3), 85.3
(C4), 73.3 (OCH2Ph), 71.8 (OCH2Ph), 71.0 (C1‴), 68.8 (C2), 65.2 (C5), 56.2 (C1′),
38.7 (OSO2CH3), 19.1 (C1″).
ESIMS m/z 548 [M+H]+. HRESIMS found 548.2461, calc for C32H38NO5S, 548.2471
[M+H]+.

(1R,2R,3R)-2-(Benzyloxy)-3-(benzyloxymethyl)-5-methyl-2,3-dihydro-1Hpyrrolizin-1-ol (233): Titanium tetraisopropoxide (4 L, 0.014 mmol) was added to a
solution of the compound 230 (33 mg, 0.070 mmol) in anhydrous CH2Cl2 (2 mL) under
a nitrogen atmosphere and stirred for 15 min.100 The reaction mixture was treated with
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Grubbs’ II ruthenium catalyst (6 mg, 0.007 mmol) and then heated at reflux for 24 h,
cooled to rt and then concentrated in vacuo to give a black semi-solid. Purification by
flash column chromatography with increasing polarity from 0:100 to 20:80 of
EtOAc/petrol as eluent gave the title compound (11 mg, 43%) as a colorless oil.

Rf 0.26 (2:98 EtOAc/petrol).

[] 25
D (unable to obtain a reliable result).

IR max (cm-1): 3422, 3062, 3030, 2924, 2863, 1685, 1496, 1453, 1360, 1092, 1071,
1026, 736, 696.

H (300 MHz, CDCl3) 7.37 - 7.23 (9H, m, ArH), 7.14 - 7.08 (1H, m, ArH), 6.04 (1H, d,
J = 2.9 Hz, H7), 5.97 (1H, s (br), H6), 4.90 (1H, d, J = 10.4 Hz, H1), 4.73 (1H, d, J =
11.9 Hz, OCHHPh), 4.61 (1H, d, J = 11.9 Hz, OCHHPh), 4.47 (1H, d, J = 12.1 Hz,
OCHHPh), 4.41 (1H, d, J =12.1 Hz, OCHHPh), 4.35 (1H, app. s, H2), 4.26 (1H, app. s,
H3), 3.71 (2H, app. s, H8), 3.22 (1H, d, J = 10.4 Hz, OH), 2.11 (3H, s, H9).

C (75 MHz, CDCl3) 137.7 (ArC), 136.8 (ArC), 136.7 (C7a, from gHMBC), 128.7 (2 x
ArCH), 128.6 (2 x ArCH), 128.2 (ArCH), 128.0 (ArCH), 127.9 (4 x ArCH), 123.5
(C5), 111.5 (C6), 101.6 (C7), 93.2 (C2), 73.6 (OCH2Ph), 71.8 (OCH2Ph), 71.0 (C1),
69.4 (C8), 62.7 (C3), 11.9 (C9).
ESIMS m/z 386 [M+Na]+. HRESIMS found 386.1731, calc for C23H25NO3Na,
386.1732 [M+Na]+.
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(4R,5R)-5-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-3-((R)-but-3-en-2-yl)-4styryloxazolidin-2-one (220):

(4R,5R,6S,7S)-6-(Benzyloxy)-7-(benzyloxymethyl)-3-((R)-but-3-en-2-yl)-5hydroxy-4-styryl-1,3-oxazepan-2-one (226)

Medthod A:
Following the general method for the synthesis of oxazolidinones, the alcohol 219 (56
mg, 0.115 mmol) was treated with triphosgene (17 mg, 0.058 mmol) and triethylamine
(17 L, 0.172 mmol) in anhydrous CH2Cl2 (4 mL) at 0 oC to rt (18 oC). Purification by
flash column chromatography (0:100 to 10:90 MeOH/CH2Cl2 as eluent) gave the title
compounds 220 (6 mg, 10%) and 226 (31 mg, 52%), both as colorless oils.

Medthod B:
Following the general method for the synthesis of oxazolidinones, the alcohol 219 (32
mg, 0.066 mmol) was treated with triphosgene (22 mg, 0.33 mmol) and triethylamine
(18 L, 0.132 mmol) in anhydrous THF (4 mL) at rt (18 oC). Purification by flash
column chromatography (0:100 to 10:90 MeOH/CH2Cl2 as eluent) gave the title
compounds 220 (18 mg, 53%) and 226 (6 mg, 19%), both as colorless oils.

220: Rf 0.49 (5:95 MeOH/CH2Cl2).

[] 25
D - 23.5 (c 1.73, CHCl3).
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IR max (cm-1): 3428, 3029, 2931, 2866, 1744, 1452, 1410, 1212, 1095, 1062, 1025,
921, 736, 624.

H (500 MHz, CDCl3) 7.34 - 7.22 (13H, m, ArH), 7.13 - 7.07 (2H, m, ArH), 6.56 (1 H,
d, J = 15.9 Hz, H2‴), 6.13 (1H, dd, J = 15.9, 9.7 Hz, H1‴), 5.99 - 5.91 (1H, m, H2′),
5.22 (1H, d, J = 10.4 Hz, H3′cis), 5.16 (1H, d, J = 17.3 Hz, H3′trans), 4.85 (1 H, t, J = 7.4
Hz, H5), 4.79 (1H, d, J = 11.2 Hz, OCHHPh), 4.56 (1H, d, J = 11.2 Hz, OCHHPh),
4.47 - 4.40 (2H, m, H4 and H1′), 4.32 (2H, s, OCH2Ph), 3.98 - 3.91 (1H, m, H2‴′), 3.78
(1H, dd, J = 7.0, 1.9 Hz, H1‴′), 3.50 - 3.42 (2H, m, H3‴′), 1.30 (3H, d, J = 7.0 Hz,
H1″).

C (125 MHz, CDCl3) 156.9 (C2), 137.9 (2 x ArC), 137.0 (C2′), 135.6 (ArC), 135.5
(C2‴), 128.9 (2 x ArCH), 128.7 (ArCH), 128.5 (4 x ArCH), 128.0 (2 x ArCH), 127.9
(ArCH), 127.8 (ArCH), 127.7 (2 x ArCH), 126.8 (2 x ArCH), 124.8 (C1‴), 117.2 (C3′),
77.9 (C5), 76.4 (C1‴′), 74.2 (OCH2Ph), 73.2 (OCH2Ph), 70.7 (C3‴′), 69.0 (C2‴′), 60.1
(C4), 51.8 (C1′), 18.6 (C1″).
ESIMS m/z 536 [M+Na]+. HRESIMS found 536.2433, calc for C32H35NO5Na,
536.2413 [M+Na]+.

226: Rf 0.56 (5:95 MeOH/CH2Cl2).

[] 25
D + 86.0 (c 0.54, CHCl3).

IR max (cm-1): 3388, 3029, 2934, 2870, 1664, 1451, 1249, 1103, 1052, 1001, 794, 624.

H (500 MHz, CDCl3) 7.35 - 7.16 (13H, m, ArH), 7.12 - 7.06 (2H, m, ArH), 6.69 (1H,
dd, J = 15.9, 9.0 Hz, H1‴), 6.43 (1H, d, J = 15.9 Hz, H2‴), 6.08 - 6.01 (1H, m, H2′),
5.34 (1H, d, J = 10.0 Hz, H3′cis), 5.31 (1 H, d, J = 16.2 Hz, H3′trans), 4.83 - 4.76 (1H, m,
H1′), 4.62 (1H, d, J = 11.8 Hz, OCHHPh), 4.53 - 4.50 (3H, m, H7 and 2 x OCHHPh),
4.40 (1 H, d, J = 11.2 Hz, OCHHPh), 4.07 - 4.04 (1H, m, H5), 4.01 (1 H, dd, J = 9.0,
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4.3 Hz, H4), 3.83 (1H, dd, J = 9.3, 6.0 Hz, H1‴′A), 3.78 (1H, d, J = 9.3 Hz, H1‴′B), 3.75
- 3.73 (1H, m, H6), 1.84 (1H, d, J = 5.8 Hz, OH), 1.28 (3H, d, J = 6.8 Hz, H1″).

C (125 MHz, CDCl3) 158.4 (C2), 139.2 (C2′), 138.0 (ArC), 137.6 (ArC), 136.5 (ArC),
131.6 (C2‴), 128.7 (2 x ArCH), 128.6 (2 x ArCH), 128.3 (2 x ArCH), 128.1 (2 x
ArCH), 128.0 (2 x ArCH), 127.9 (2 x ArCH), 127.8 (ArCH), 127.3 (C1‴), 126.8 (2 x
ArCH), 118.1 (C3′), 78.2 (C6), 74.8 (C7), 73.6 (OCH2Ph), 72.9 (OCH2Ph), 69.0 (C5),
68.4 (C1‴′), 61.6 (C4), 55.6 (C1′), 16.1 (C1″).
ESIMS m/z 536 [M+Na]+. HRESIMS found 536.2415, calc for C32H35NO5Na,
536.2413 [M+Na]+.

(3S,4S,5R,5aR,8R)-4-(Benzyloxy)-3-(benzyloxymethyl)-5-hydroxy-8-methyl3,4,5,5a-tetrahydropyrrolo[1,2-c][1,3]oxazepin-1(8H)-one (234): Following the
general method for the ring-closing metathesis, compound 226 (164 mg, 0.319 mmol)
was treated with Grubbs’ II ruthenium catalyst (14 mg, 0.016 mmol) in anhydrous
CH2Cl2 (10 mL) and heated at reflux for 1 d. Purification by flash column
chromatography (0:100 to 2:98 MeOH/CH2Cl2 as eluent) gave compound 234 (100 mg,
77%) as a colorless oil.

Rf 0.44 (5:95 MeOH/CH2Cl2).

[] 25
D - 49.3 (c 0.18, CHCl3).

IR max (cm-1): 3336, 2925, 2869, 1665, 1623, 1452, 1416, 1292, 1207, 1096, 1069,
1022, 946, 619.

Chapter 6 | 203

H (500 MHz, CDCl3) 7.37 - 7.26 (10H, m, ArH), 5.87 (1H, d, J = 6.3 Hz, H6), 5.79
(1H, d, J = 6.3 Hz, H7), 4.75 - 4.69 (3H, m, H3, H8 and OCHHPh), 4.58 - 4.55 (3H, m,
3 x OCHHPh), 4.30 (1 H, d, J = 9.1 Hz, H5a), 3.83 - 3.74 (2H, m, H1′), 3.68 (1H, dd, J
= 9.1, 5.0 Hz, H4), 3.42 (1H, t, J = 9.1 Hz, H5), 1.20 (3H, d, J = 6.4 Hz, H1″).

C (75 MHz, CDCl3) 153.8 (C1), 137.7 (ArC), 137.2 (ArC), 132.6 (C7), 128.9 (2 x
ArCH), 128.6 (2 x ArCH), 128.5 (ArCH), 128.2 (2 x ArCH), 128.1 (2 x ArCH), 127.9
(ArCH), 125.7 (C6), 81.9 (C4), 77.2 (C3), 73.6 (OCH2Ph), 73.4 (C5), 73.4 (OCH2Ph),
66.6 (C1′), 66.2 (C5a), 62.6 (C8), 20.1 (C1″).
ESIMS m/z 432 [M+Na]+. HRESIMS found 432.1797, calc for C24H27NO5Na,
432.1787 [M+Na]+.

6.4.3 General method for hydroboration followed by oxidation103

(3S,4S,5R,5aR,6R,8R)-4-(Benzyloxy)-3-(benzyloxymethyl)-5,6-dihydroxy-8methylhexahydropyrrolo[1,2-c][1,3]oxazepin-1(3H)-one (240)

(1R,2S,3S)-2,4-Bis(benzyloxy)-1-((2R,3R,5R)-3-hydroxy-1,5-dimethylpyrrolidin-2yl)butane-1,3-diol (241)

(1R,2S,3S)-2,4-Bis(benzyloxy)-1-((2R,4S,5R)-4-hydroxy-1,5-dimethylpyrrolidin-2yl)butane-1,3-diol (242)
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A 1.0 M solution of borane-tetrahydrofuran complex in THF (0.500 mL, 0.500 mmol
borane) was slowly added dropwise via syringe to the solution of compound 234
(19 mg, 0.047 mmol) in THF (2 mL) under a nitrogen atmosphere at 0 oC.103 The
reaction mixture was stirred for 15 min and allowed to warm to rt (20 oC) for 3 h.
Water (3 mL) was slowly added to the reaction mixture followed by the slow addition
of sodium perborate tetrahydrate (77 mg, 0.500 mmol) (the reaction temperature was
controlled by external cooling to not exceed 35 oC) and stirred at rt for 2 h. The
reaction mixture was poured into cold water in a separatory funnel and extracted with
Et2O (3 x 20 mL). The combined organic fractions were washed with water (2 x 30
mL), washed with sat. sodium chloride solution (2 x 30 mL), dried (MgSO4) and
concentrated in vacuo to afford a colorless oil. Purification by flash column
chromatography (increasing polarity from 0:100 to 20:80 of MeOH/CH2Cl2 as eluent)
gave compound 240 (1.5 mg, 8%), compound 241 (1.5 mg, 8%) and compound 242
(1.0 mg, 5%), all as colorless oils.

240: Rf 0.50 (5:95 MeOH/CH2Cl2).

[] 25
D - 22.3 (c 0.14, CHCl3).

IR max (cm-1): 3409, 3064, 3030, 2932, 2868, 1654, 1418, 1297, 1202, 1099, 1067,
1001, 731, 696.
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H (500 MHz, CDCl3) 7.41 - 7.24 (10H, m, ArH), 4.73 (1H, d, J = 11.5 Hz, OCHHPh),
4.64 - 4.60 (1H, m, H3), 4.53 - 4.50 (3H, m, 3 x OCHHPh), 4.45 - 4.42 (1H, m, H6),
4.23 - 4.20 (1H, m, H8), 3.81 (1H, dd, J = 11.0, 3.4 Hz, H1′A), 3.73 (1H, dd, J = 11.0,
6.9 Hz, H1′B), 3.69 - 3.65 (2H, m, H4 and H5), 3.30 - 3.23 (1H, m, H5a), 2.03 - 1.95
(1H, m, H7A), 1.90 (1H, dd, J = 11.7, 6.0 Hz, H7B), 1.10 (3H, d, J = 6.5 Hz, H1″).

C (125 MHz, CDCl3) 154.0 (C1), 137.6 (ArC), 137.3 (ArC), 129.0 (2 x ArCH), 128.6
(3 x ArCH), 128.2 (2 x ArCH), 128.1 (2 x ArCH), 128.0 (ArCH), 82.3 (C4), 76.9 (C3),
76.3 (C5), 74.6 (C6), 73.7 (OCH2Ph), 73.5 (OCH2Ph), 66.7 (C1′), 65.1 (C5a), 54.4
(C8), 37.6 (C7), 20.7 (C1″).
ESIMS m/z 450 [M+Na]+. HRESIMS found 450.1903, calc for C24H29NO6Na,
450.1893 [M+Na]+.

241: Rf 0.66 (5:95 MeOH/CH2Cl2).

[] 25
D + 15.7 (c 0.08, CHCl3).

IR max (cm-1): 3409, 3030, 2930, 2868, 1667, 1453, 1417, 1170, 1095, 1026, 977, 736,
698.

H (500 MHz, CDCl3) 7.39 - 7.23 (10H, m, ArH), 4.78 (1H, d, J = 11.0 Hz, OCHHPh),
4.67 (1H, d, J = 11.0 Hz, OCHHPh), 4.61 (1H, d, J = 11.7 Hz, OCHHPh), 4.58 - 4.51
(3H, m, H3, H3″ and OCHHPh), 4.23 (1H, s (br), H1″), 3.80 - 3.75 (2H, m, H2″ and
H4″A), 3.66 (1H, dt, J = 13.1, 6.5 Hz, H4″B), 3.61 - 3.51 (1H, m, H5), 3.26 (1H, d, J =
6.8 Hz, H2), 2.21 (3H, s, H1′), 1.98 - 1.92 (1H, m, H4A), 1.91 - 1.82 (1H, m, H4B), 1.30
(3H, d, J = 6.6 Hz, H1‴).

C (125 MHz, CDCl3) 137.5 (ArC), 137.0 (ArC), 128.9 (2 x ArCH), 128.8 (ArCH),
128.7 (2 x ArCH), 128.5 (2 x ArCH), 128.2 (2 x ArCH), 128.1 (ArCH), 81.2 (C2″),
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79.8 (C2), 74.6 (OCH2Ph), 73.9 (OCH2Ph), 70.8 (C4″), 70.4 (C1″), 66.9 (C3″), 66.8
(C3), 66.4 (C5), 38.6 (C4), 37.0 (C1′), 14.1 (C1‴).
ESIMS m/z 416 [M+H]+. HRESIMS found 416.2442, calc for C24H34NO5, 416.2437
[M+H]+.

242: Rf 0.56 (5:95 MeOH/CH2Cl2).

[] 25
D + 39.5 (c 0.06, CHCl3).

IR max (cm-1): 3452, 3031, 2926, 2862, 1453, 1172, 1094, 742, 700.

H (500 MHz, CDCl3) 7.36 - 7.26 (10H, m, ArH), 4.71 (1H, d, J = 11.1 Hz, OCHHPh),
4.64 - 4.56 (3H, m, H2″ and 2 x OCHHPh), 4.53 (1H, d, J = 11.6 Hz, OCHHPh), 4.07
(1H, s (br), H3″), 3.93 (1H, s (br), H4), 3.74 - 3.69 (1H, m, H4″A), 3.61 (1H, dd, J =
9.4, 5.8 Hz, H4″B), 3.55 - 3.51 (1H, m, H1″), 3.50 - 3.44 (1H, m, H2), 3.03 - 2.97 (1H,
m, H5), 2.86 (1H, d, J = 5.2 Hz, OH), 2.62 - 2.52 (1H, m, H3A), 2.21 (3H, s, H1′), 1.70
- 1.59 (1H, m, H3B), 1.38 (3H, d, J = 6.7 Hz, H1‴).

C (125 MHz, CDCl3) 137.5 (ArC), 136.9 (ArC), 128.8 (2 x ArCH), 128.7 (2 x ArCH),
128.6 (2 x ArCH), 128.4 (ArCH), 128.2 (3 x ArCH), 81.2 (C1″), 75.0 (C4″), 74.9
(OCH2Ph), 74.1 (C5), 73.8 (OCH2Ph), 72.3 (C2), 70.9 (C4), 70.7 (C3″), 66.8 (C2″),
37.7 (C1′), 30.3 (C3), 12.3 (C1‴).
ESIMS m/z 416 [M+H]+. HRESIMS found 416.2433, calc for C24H34NO5, 416.2437
[M+H]+.
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(3S,4S,5R,5aR,8R)-4,5-Bis(benzyloxy)-3-(benzyloxymethyl)-8-methyl-3,4,5,5atetrahydropyrrolo[1,2-c][1,3]oxazepin-1(8H)-one (235): Following the general
method for O-benzylation, compound 234 (95 mg, 0.232 mmol) was treated with
benzyl bromide (110 L, 0.928 mmol), tetrabutylammonium iodide (17 mg, 0.046
mmol), sodium hydride (60% dispersion in mineral oil, 28 mg, 16 mg NaH, 0.696
mmol) in anhydrous THF (15 mL) at 0 oC for 15 min to rt (20 oC) for 18 h. Purification
by flash column chromatography (0:100 to 20:80 EtOAc/petrol as eluent) gave the title
compound (38 mg, 33%) as a colorless oil.

Rf 0.24 (30:70 EtOAc/petrol).

[] 25
D + 7.1 (c 0.28, CHCl3).

IR max (cm-1): 3063, 3031, 2924, 2869, 1697, 1452, 1398, 1293, 1208, 1069, 1025,
735, 697.

H (500 MHz, CDCl3) 7.33 - 7.26 (15H, m, ArH), 5.78 (2H, s, H6 and H7), 4.76 - 4.66
(2H, m, H3 and H8), 4.62 - 4.35 (7H, m, H4 and 6 x OCHHPh), 3.96 (1H, s, H5a), 3.75
(2H, s, H1′), 3.36 (1H, dd, J = 9.6, 3.2 Hz, H5), 1.22 (3H, d, J = 6.4 H1″).

C (75 MHz, CDCl3) 153.4 (C1), 137.8 (ArC), 137.6 (ArC), 137.5 (ArC), 132.9 (C7),
128.6 (2 x ArCH), 128.5 (4 x ArCH), 128.2 (ArCH), 128.0 (5 x ArCH), 128.0 (2 x
ArCH), 127.9 (ArCH), 126.3 (C6), 81.4 (C5), 76.1 (C3 and C5a, br), 73.3 (2 x
OCH2Ph), 72.9 (OCH2Ph, br), 68.3 (C1′, br), 65.0 (C4, br), 62.3 (C8), 19.7 (C1″).
ESIMS m/z 522 [M+Na]+. HRESIMS found 522.2263, calc for C31H33NO5Na,
522.2256 [M+Na]+.
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